[go: up one dir, main page]

WO2000071107A2 - New pharmaceutical combinations for nos inhibitors - Google Patents

New pharmaceutical combinations for nos inhibitors Download PDF

Info

Publication number
WO2000071107A2
WO2000071107A2 PCT/IB2000/000295 IB0000295W WO0071107A2 WO 2000071107 A2 WO2000071107 A2 WO 2000071107A2 IB 0000295 W IB0000295 W IB 0000295W WO 0071107 A2 WO0071107 A2 WO 0071107A2
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
phenyl
ylamine
amino
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2000/000295
Other languages
French (fr)
Other versions
WO2000071107A8 (en
Inventor
Mario David Saltarelli
John Adams Lowe, Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200101110A priority Critical patent/EA200101110A1/en
Priority to APAP/P/2001/002326A priority patent/AP2001002326A0/en
Priority to MXPA01011978A priority patent/MXPA01011978A/en
Priority to PL00358538A priority patent/PL358538A1/en
Priority to KR1020017014884A priority patent/KR20020010916A/en
Priority to JP2000619414A priority patent/JP2003523941A/en
Priority to BR0010820-0A priority patent/BR0010820A/en
Priority to IL14595500A priority patent/IL145955A0/en
Priority to HU0301287A priority patent/HUP0301287A3/en
Priority to EEP200100611A priority patent/EE200100611A/en
Priority to EP00907891A priority patent/EP1178784A1/en
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Priority to AU29353/00A priority patent/AU2935300A/en
Priority to SK1660-2001A priority patent/SK16602001A3/en
Priority to CA002374668A priority patent/CA2374668A1/en
Priority to HR20010862A priority patent/HRP20010862A2/en
Publication of WO2000071107A2 publication Critical patent/WO2000071107A2/en
Priority to IS6126A priority patent/IS6126A/en
Priority to NO20015651A priority patent/NO20015651L/en
Anticipated expiration legal-status Critical
Priority to BG06208A priority patent/BG106208A/en
Publication of WO2000071107A8 publication Critical patent/WO2000071107A8/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms.
  • NOS inhibitors particularly selective neuronal NOS (nNOS) inhibitors
  • disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, REM sleep disorders, hypersomnia, parasomnias, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.
  • This invention also relates to the use of a NOS inhibitor in combination with an NK-1 receptor antagonist (e.g.. a substance P receptor antagonist), alone or in combination with one or more additional active agents, for the treatment of any of the foregoing disorders.
  • an NK-1 receptor antagonist e.g.. a substance P receptor antagonist
  • This invention also relates to the use of a NOS inhibitor in combination with a selective serotonin reuptake inhibitor (SSRI), optionally in combination with one or more additional active agents, for the treatment of any of the foregoing disorders.
  • SSRI selective serotonin reuptake inhibitor
  • This invention also relates to the use of a NOS inhibitor in combination with both an NK-1 receptor antagonist and an SSRI, alone or in combination with one or more additional active agents, for the treatment of any of the foregoing disorders.
  • NOS NOS - an inducible form
  • nNOS neuronal NOS
  • eNOS endothelial NOS
  • iNOS inhibitors can reverse this. It is also believed that iNOS plays a role in the pathology of diseases of the central nervous system such as ischemia. For example, inhibition of iNOS has been shown to ameliorate cerebral ischemic damage in rats, see Am. J. Phvsiol.. 268, p. R286 (1995)). Suppression of adjuvant induced arthritis by selective inhibition of iNOS is reported in Eur. J. Pharmacol.. 273, p. 15-24 (1995).
  • NO produced by nNOS is thought to play a role in diseases such as cerebral ischemia, pain, and opiate tolerance.
  • diseases such as cerebral ischemia, pain, and opiate tolerance.
  • inhibition of nNOS decreases infarct volume after proximal middle cerebral artery occlusion in the rat, see J. Cerebr. Blood Flow Metab., 14, p. 924- 929 (1994).
  • nNOS inhibition has also been shown to be effective in antinociception, as evidenced by activity in the late phase of the formalin-induced hindpaw licking and acetic acid-induced abdominal constriction assays, see Br. J. Pharmacol., 110, p. 219-224 (1993).
  • This invention relates to a method of treating a disorder or condition that can be treated by altering circadian rhythms in a mammal, including a human, comprising administering to said mammal:
  • This invention also relates to a pharmaceutical composition for treating a disorder or condition that can be treated by altering circadian rhythms in a mammal, including a human, comprising:
  • This invention also relates to a method of treating a condition or disorder that can be treated by altering circadian rhythms in a mammal, including a human, comprising administering to said mammal:
  • SSRI selective serotonin reuptake inhibitor
  • This invention also relates to a pharmaceutical composition for treating a disorder or condition that can be treated by altering circadian rhythms in a mammal, including a human, comprising: (a) a NOS inhibiting compound or pharmaceutically acceptable salt thereof;
  • This invention also relates to a method for treating a disorder or condition that can be treated by altering circadian rhythms in a mammal, including a human, comprising administering to said mammal: (a) a NOS inhibiting compound or pharmaceutically acceptable salt thereof; and
  • This invention also relates to a pharmaceutical composition for treating a disorder or condition that can be treated by altering circadian rhythms in a mammal, including a human, comprising:
  • This invention also relates to a method for treating a disorder or condition that can be treated by altering circadian rhythms in a mammal, including a human, comprising administering to said mammal an amount of a NOS inhibiting compound or pharmaceutically acceptable salt thereof that is effective in treating such disorder or condition.
  • This invention also relates to a pharmaceutical composition for treating a disorder or condition that can be treated by altering circadian rhythms in a mammal, including a human, comprising an amount of a NOS inhibiting compound or pharmaceutically acceptable salt thereof that is effective in treating such disorder condition, and a pharmaceutically acceptable carrier;
  • treating refers to reversing, alleviating, inhibiting or slowing the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • treatment refers to the act of treating, as “treating” is defined immediately above.
  • This invention also relates to a pharmaceutical composition for treating a disorder or condition selected from blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, REM sleep disorders, hypersomnia, parasomnias, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome in a mammal, including a human, comprising an amount of a NOS inhibiting compound or pharmaceutically acceptable salt thereof that is effective in treating such condition or disorder and a pharmaceutically acceptable carrier.
  • a disorder or condition selected from blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, REM sleep disorders, hypersomnia, parasomnias, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome in
  • This invention also relates to a method of treating a disorder or condition selected from blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, REM sleep disorders, hypersomnia, parasomnias, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome in a mammal, including a human, comprising administering to said mammal an amount of a NOS inhibiting compound or pharmaceutically acceptable salt thereof that is effective in treating or preventing such condition or disorder.
  • a disorder or condition selected from blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, REM sleep disorders, hypersomnia, parasomnias, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs
  • a more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is blindness.
  • Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is restless-legs syndrome. Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is jet lag.
  • Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is a parasomnia.
  • Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is nocturnal enuresis.
  • Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is a sleep-wake cycle disorder.
  • Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is hypersomnia. Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is seasonal affective disorder.
  • Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is a sleep disorder associated with shift work or irregular work schedules. Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is circadian sleep rhythms disorder.
  • Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is a REM sleep disorder.
  • Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is bipolar disorder.
  • Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is sleep deprivation. Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is narcolepsy.
  • Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is obesity.
  • This invention also relates to a method of treating a disorder or condition selected from dysthymia, major depressive disorder, bipolar disorder, seasonal affective disorder and other mood disorders; anxiety disorders (e.g..
  • sleep disorders such as circadian sleep rhythm disorders, narcolepsy, sleep apnea, REM sleep disorder, parasomnias, sleep-wake cycle disorders, sleep deprivation, insomnia, hypersomnia, and sleep disorders associated with advancing age, shift work or irregular work schedules; nocturnal enuresis, restless-legs syndrome and cognitive disorders such as dementias (e.g., age related dementia and senile dementia of the Alzheimer's type) and memory disorders in a mammal, including a human, comprising administering to said mammal:
  • This invention also relates to a pharmaceutical composition for treating a disorder or condition selected from dysthymia, major depressive disorder, bipolar disorder, seasonal affective disorder and other mood disorders; anxiety disorders (e.g., generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social phobias, agoraphobia and other phobias), blindness, obesity, stroke, jet lag, sleep disorders such as circadian sleep rhythm disorders, narcolepsy, sleep apnea, REM sleep disorder, parasomnias, sleep-wake cycle disorders, sleep deprivation, insomnia, hypersomnia, and sleep disorders associated with advancing age, shift work or irregular work schedules; nocturnal enuresis, restless-legs syndrome and cognitive disorders such as dementias (e.g.
  • This invention also relates to a method of treating a disorders or condition selected from dysthymia, major depressive disorder, bipolar disorder, seasonal affective disorder and other mood disorders; anxiety disorders (e.g., generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social phobias, agoraphobia and other phobias), blindness, obesity, stroke, jet lag, sleep disorders such as circadian sleep rhythm disorders, narcolepsy, sleep apnea, REM sleep disorder, parasomnias, sleep-wake cycle disorders, sleep deprivation, insomnia, hypersomnia, and sleep disorders associated with advancing age, shift work or irregular work schedules; nocturnal enuresis, restless-legs syndrome and cognitive disorders such as dementias (e.g., age related dementia and senile dementia of the Alzheimer's type) and memory disorders in a mammal, including a human, comprising administering to said mammal:
  • anxiety disorders e.g.
  • This invention also relates to a pharmaceutical composition for treating a disorder or condition selected from dysthymia, major depressive disorder, bipolar disorder, seasonal affective disorder and other mood disorders; anxiety disorders (e.g., generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social phobias, agoraphobia and other phobias), blindness, obesity, stroke, jet lag, sleep disorders such as circadian sleep rhythm disorders, narcolepsy, sleep apnea, REM sleep disorder, parasomnias, sleep-wake cycle disorders, sleep deprivation, insomnia, hypersomnia, and sleep disorders associated with advancing age, shift work or irregular work schedules; nocturnal enuresis, restless-legs syndrome and
  • This invention also relates to a method for treating a disorder or condition selected from dysthymia, major depressive disorder, bipolar disorder, seasonal affective disorder and other mood disorders; anxiety disorders (e.g., generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social phobias, agoraphobia and other phobias), blindness, obesity, stroke, jet lag, sleep disorders such as circadian sleep rhythm disorders, sleep apnea, narcolepsy, sleep apnea, REM sleep disorder, parasomnias, sleep-wake cycle disorders, sleep deprivation, insomnia, hypersomnia, and sleep disorders associated with advancing age, shift work or irregular work schedules; nocturnal enuresis, restless-legs syndrome and cognitive disorders such as dementias (e.g., age related dementia and senile dementia of the Alzheimer's type) and memory disorders in a mammal, including a human, comprising administering to said mammal: (
  • This invention also relates to a pharmaceutical composition for treating a disorder or condition selected from dysthymia, major depressive disorder, bipolar disorder, seasonal affective disorder and other mood disorders; anxiety disorders (e.g., generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social phobias, agoraphobia and other phobias), blindness, obesity, stroke, jet lag, sleep disorders such as circadian sleep rhythm disorders, sleep apnea, narcolepsy, sleep apnea, REM sleep disorder, parasomnias, sleep-wake cycle disorders, sleep deprivation, insomnia, hypersomnia, and sleep disorders associated with advancing age, shift work or irregular work schedules; nocturnal enuresis, restless-legs syndrome and cognitive disorders such as dementias (e.g., age related dementia and senile dementia of the Alzheimer's type) and memory disorders in a mammal, including a human, comprising: (a) a NOS
  • a pharmaceutically acceptable carrier wherein the active agents "a” and "b” are present in such composition in amounts that render the combination of the two agents effective in treating such disorder or condition.
  • This invention also relates to any of the above methods and pharmaceutical compositions wherein the disorder or condition is selected from hypersomnias, parasomnias, restless-legs syndrome, sleep-wake cycle disorders and sleep disorders associated with shift work or irregular work schedules.
  • This invention also relates to any of the above methods and pharmaceutical compositions wherein the NOS inhibiting compound is a compound of the formula I, II, III, IV, V or VI, as defined below.
  • NOS inhibiting compounds that can be used in the methods and pharmaceutical compositions of the present invention are compounds of the formula
  • ring A is a fused 5-7 membered saturated or unsaturated ring wherein from zero to two of the ring members are heteroatoms selected, independently, from nitrogen, oxygen and sulfur, with the proviso that no two adjacent ring members can both be heteroatoms;
  • X is oxygen or a bond
  • n is an integer from two to six
  • R 1 and R 2 are selected, independently, from (Ci-Ce) alkyl, aryl, tetrahydronaphthalene and aralkyl, wherein said aryl and the aryl moiety of said aralkyl is phenyl or naphthyl and the alkyl moiety is straight or branched and contains from 1 to 6 carbon atoms, and wherein said alkyl, said aryl, said tetrahydronaphthalene and the aryl moiety of said aralkyl may optionally be substituted with from one to three substituents, preferably from zero to two substituents, that are selected, independently, from halo (e.g., chloro, fluoro, bromo, iodo), nitro, hydroxy, cyano, amino, (C C 4 ) alkoxy, and (C ⁇ -C 4 ) alkylamino; or R 1 and R 2 form, together with the nitrogen to which they are attached, a piperazine
  • R 5 is selected from hydrogen, (C C ⁇ Jalkyl, phenyl, naphthyl, phenyl-(C 1 -C 6 )alkyl- and naphthyl(C 1 -C 6 )alkyl-; and wherein said piperazine, azetidine, piperidine and pyrrolidine rings may optionally be substituted with one or more substituents, preferably with from zero to two substituents that are selected, independently, from (C 1 -C 6 )alkyl, amino, (C- ⁇ -C 6 ) alkylamino, [di ⁇ C ⁇ CeJalkyljamino, phenyl substituted 5 to 6 membered heterocyclic rings containing from 1 to 4 rings nitrogen atoms, benzoyl, benzoylmethyl, benzylcarbonyl, phenylaminocarbonyl, phenylethyl and phenoxycarbonyl, and wherein the phenyl moieties of any of the fore
  • NOS inhibitors of the formula I 6-[4-(3-Amino-cyclohexyloxy)-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(3-Amino-cyclopentyloxy)-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(3-Amino-cyclobutyloxy)-naphthalen-1-yl]-pyridin-2-yiamine;
  • NOS inhibiting compounds that can be used in the methods and pharmaceutical compositions of this invention are compounds of the formula
  • each ( ) n represents (CH 2 ) n ;
  • R 1 and R 2 are selected, independently, from hydrogen, (C r C 6 ) alkyl, tetrahydronaphthalene and aralkyl, wherein the aryl moiety of said aralkyl is phenyl or naphthyl and the alkyl moiety is straight or branched and contains from 1 to 6 carbon atoms, and wherein said (d-C 6 ) alkyl and said tetrahydronaphthalene and the aryl moiety of said aralkyl may optionally be substituted with from one to three substituents, preferably from zero to two substituents, that are selected, independently, from halo (e.g., chloro, fluoro, bromo, iodo), nitro, hydroxy, cyano, amino, (C1-C 4 ) alkoxy, and (C ⁇ -C 4 ) alkylamino
  • halo e.
  • R 5 is selected from hydrogen, (d-C ⁇ alkyl, phenyl, naphthyl, phenyl-(C C 6 )alkyl- and naphthyl(C C 6 )alkyl-; and wherein said piperazine, piperidine and pyrrolidine rings may optionally be substituted with one or more substituents, preferably with from zero to two substituents that are selected, independently, from (C ⁇ -C 6 )alkyl, amino, (C f C 6 ) alkylamino, [di-(C 1 -C 6 )alkyl]amino, cyclohexyl, methanesulfonyl, phenoxyacetyl, furanylcarbonyl, trifluoromethylphenyl, phenoxyacetyl, benzenesulfonyl, isoquinolinyl, quinolinyl, hydroxyphenylethyl, aminophenylethyl, phenyl substituted
  • X and Y are selected, independently, from methyl, methoxy, hydroxy and hydrogen;
  • R 10 is hydrogen or (d-C 6 ) alkyl; with the proviso that R 8 is absent when N is zero and R 9 is absent when m is zero.
  • Examples of preferred compounds of the formula II are those wherein NR 1 R 2 is:
  • NR 3 R 4 is NH 2 .
  • R 5 is aralkyl, exj., benzyl, and R 6 is (4-fluoro)phenylacetyl.
  • NOS inhibiting compounds that can be used in the methods and pharmaceutical compositions of this invention are compounds of the formula
  • X is CHOH, CH 2 , or CHR 10 wherein R 10 , together with X, the CH 2 group adjacent to X and the nitrogen of NR 1 R 2 , forms a five or six membered saturated ring;
  • R 1 , R 2 , R 3 and R 4 are selected, independently, from hydrogen (d-C 6 ) alkyl, tetrahydronaphthalene, aryl and aralkyl, wherein said aryl and the aryl moiety of said aralkyl is phenyl or naphthyl and the alkyl moiety is straight or branched and contains from 1 to 6 carbon atoms, and wherein said (d-d.) alkyl and said tetrahydronaphthalene and the aryl moiety of said aralkyl may optionally be substituted with from one to three substituents, preferably from zero to two substituents, that are selected, independently, from halo (e.g., chloro, fluoro, bromo, iodo), nitro, hydroxy, cyano, amino, (d-C 4 ) alkoxy, and (d-d) alkylamino; or R 1 and R 2 , together with the nitrogen to which they
  • R 7 is selected from hydrogen, (C 1 -C 6 )alkyl, phenyl, naphthyl, phenyl-(d-C 6 )alkyl- and naphthyl(d-C 6 )alkyl-; and wherein said piperazine, piperidine and pyrrolidine rings may optionally be substituted with one or more substituents, preferably with from zero to two substituents that are selected, independently, from (C 1 -C 6 )alkyl, amino, (C C 6 ) alkylamino, [di-(d-C 6 )alkyl]amino, phenyl substituted 5 to 6 membered heterocyclic rings containing from 1 to 4 rings nitrogen atoms, benzoyl, benzoylmethyl, benzylcarbonyl, phenylaminocarbonyl, phenylethyl and phenoxycarbonyl, and wherein the phenyl moieties of any of the foregoing substituents may optional
  • compounds of the formula III include: (a) compounds of the formula III wherein R 1 , R 2 , R 3 and R 4 are selected, independently, from (d-C 6 )alkyl; (b) compounds of the formula III wherein R 3 and R 4 are selected, independently, from (C ⁇ -C 6 )alkyl, and R 1 and R 2 , together with the nitrogen to which they are attached, form a ring;
  • NOS inhibiting compounds that can be used in the methods and pharmaceutical compositions of this invention are compounds of the formula
  • R 1 and R 2 are selected, independently, from hydrogen, halo, hydroxy, ( d-C 6 )alkoxy, (d-C 7 )alkyl, (C 2 -C 6 )alkenyl, and (C 2 - C 10 )alkoxyalkyl; and G is selected from hydrogen, (d-C 6 )alkyl, (d-C 6 )alkoxy-(C--C 3 )alkyl, aminocarbonyl-(C ⁇ -
  • R 3 and R 4 are selected, independently, from hydrogen, (d-C ) alkyl, tetrahydronaphthalene and aralkyl, wherein the aryl moiety of said aralkyl is phenyl or naphthyl and the alkyl moiety is straight or branched and contains from 1 to 6 carbon atoms, and wherein said (d-C 7 ) alkyl and said tetrahydronaphthalene and the aryl moiety of said aralkyl may optionally be substituted with from one to three substituents, preferably from zero to two substituents, that are selected, independently, from hal
  • C )alkyl-0- is the oxygen atom depicted in structural formula I) at a nitrogen atom of the NR R ' ring or at any other atom of such ring having an available bonding site; or G is a group of the formula A
  • Z is nitrogen or CH, n is zero or one, q is zero, one, two or three and p is zero, one or two; and wherein the 2-amino piperidine ring depicted in structure I above may optionally be replaced with
  • Examples of compounds of the formula IV are those wherein G is N(R 3 )(R )(C 0 -C 4 ) alkyl and N(R 3 )(R 4 ) is amino, dimethylamino, methylbenzylamino, (d-C 4 )alkylamino, di-[(d- C 4 )alkyl]amino or one of the following groups:
  • Preferred compounds of the formula IV include those wherein R 2 is hydrogen and R is (d - C 3 )alkoxy and is in the ortho position relative to the pyridine ring of formula IV.
  • R 1 and R 2 are selected, independently, from (d-C 2 )alkoxy.
  • NOS inhibitors that can be used in the methods and pharmaceutical compositions of this invention are compounds of the formula wherein R 1 and R 2 are selected, independently, from hydrogen, hydroxy, methyl and methoxy; and G is a group of the formula
  • Y is NR 3 R 4 , (d-C 6 )alkyl or aralkyl, wherein the aryl moiety of said aralkyl is phenyl or naphthyl and the alkyl moiety is straight or branched and contains from 1 to 6 carbon atoms, and wherein said (C C 6 )alkyl and the aryl moiety of said aralkyl may be substituted with from one to three substituents, preferably from zero to two substituents, that are selected, independently, from halo (e.g., chloro, fluoro, bromo or iodo), nitro, hydroxy, cyano, amino, (d-C 4 )alkoxy and (d-C 4 ) alkylamino;
  • halo e.g., chloro, fluoro, bromo or iodo
  • X is N when Y is (d-C 6 ) alkyl, aralkyl, or substituted (d-C 6 )alkyl, and X is CH when Y is NR 3 R 4 ; q is zero, one or two; m is zero, one or two; and
  • R 3 and R 4 are selected, independently, from (C C 6 ) alkyl, tetrahydronaphthalene and aralkyl, wherein the aryl moiety of said aralkyl is phenyl or naphthyl and the alkyl moiety is straight or branched and contains from 1 to 6 carbon atoms, and wherein said (d-C 6 ) alkyl and said tetrahydronaphthalene and the aryl moiety of said aralkyl may optionally be substituted with from one to three substituents, preferably from zero to two substituents, that are selected, independently, from halo (e.g., chloro, fluoro, bromo or iodo), nitro, hydroxy, cyano, amino, (d-C ) alkoxy, and (d-C ) alkylamino; or R 3 and R 4 form, together with the nitrogen to which they are attached, a piperazine, piperidine or pyrrolidine
  • piperazine, piperidine and pyrrolidine rings may optionally be substituted with one or more substituents, preferably with from zero to two substituents, that are selected, independently, from amino, (C C 6 ) alkylamino, [di-(d-C 6 )alkyl]amino, phenyl substituted 5 to 6 membered heterocyclic rings containing from 1 to 4 rings nitrogen atoms, benzoyl, benzoylmethyl, benzylcarbonyl, phenylaminocarbonyl, phenylethyl and phenoxycarbonyl, and wherein the phenyl moieties of any of the foregoing substituents may optionally be substituted with one or more substituents, preferably with from zero to two substituents, that are selected, independently, from halo, (d-C 3 )alkyl, (d-C 3 )alkoxy, nitro, amino, cyano, CF 3 and OCF 3 ; and the pharmaceutically
  • NR 5 R 6 is NH
  • Specific preferred compounds of formula V include: 3- ⁇ 2-[4'-(6-Amino-pyridin-2-yl)-biphenyl-4-yl]-ethyl ⁇ -3-aza-bicyclo[3.1.0]hex-6-ylamine;
  • NOS inhibitors that can be employed in the methods and pharmaceutical composition of this invention are compounds of the formula
  • n and m in the bridging rings are independently 1 , 2 or 3, and a carbon in one of said bridging rings may be substituted by a heteroatom selected from O, S and N, with the proviso that a bridgehead carbon can only be substituted by nitrogen
  • R 1 and R 2 are independently selected from Ci to C 6 alkyl, which may be linear, branched or cyclic or contain both linear and cyclic or branched and cyclic moieties, wherein each of R 1 and R 2 may be independently optionally substituted with from one to three substituents, preferably from zero to two substituents, that are selected, independently, from halo (e.g., chloro, fluoro, bromo, iodo), nitro, hydroxy, cyano, amino, (d-d) alkoxy, and (d-C ) alkylamino; or R 1 and R 2 form, together with the nitrogen to which they are attached, a piperazine, azetidine, piperidine or
  • R 5 is selected from hydrogen, d to C 6 alkyl, phenyl, naphthyl, phenyl-d to C 6 alkyl- and naphthyl d to C 6 alkyl-.
  • Preferred compounds of the formula IV include those wherein NR 1 R 2 is an optionally substituted piperidine, azetidine, piperazine or pyrrolidine ring or a 3-aza-bicyclo[3.1.0]hex-6- ylamine ring; and wherein said piperazine, azetidine, piperidine, pyrrolidine and 3-aza-bicyclo[3.1.0]hex- 6-ylamine rings may optionally be substituted with one or more substituents, preferably with from zero to two substituents that are selected, independently, from d to C 6 alkyl, amino, d to C 6 alkylamino, [di-d to C 6 alkyljamino, phenyl, substituted 5 to 6 membered heterocyclic rings containing from 1 to 4 rings nitrogen atoms, benzoyl, benzoylmethyl, benzylcarbonyl, phenylaminocarbonyl, phenylethyl and phenoxycarbonyl, and wherein the phen
  • one or more substituents refers to a number of substituents that equals from one to the maximum number of substituents possible based on the number of available bonding sites.
  • halo and halogen, as used herein, unless otherwise indicated, include chloro, fluoro, bromo and iodo.
  • Formulas I - VI above include compounds identical to those depicted but for the fact that one or more hydrogen, carbon or other atoms are replaced by isotopes thereof. Such compounds may be useful as research and diagnostic tools in metabolism pharmacokinetic studies and in binding assays.
  • SSRI's that can be used in the methods and pharmaceutical compositions of this invention are sertraline, fluoxetine, paroxetine, citalopram and fluvoxamine.
  • NK-1 receptor antagonists that can be used in the methods and pharmaceutical compositions of this invention are the following compounds and their pharmaceutically acceptable salts:
  • NK-1 receptor antagonists that can be used in the methods and pharmaceutical composition of this invention are those referred to in the following references, all of which are incorporated herein by reference in their entireties: United States Patent 5,162,339, which issued on November 11, 1992; United States Patent 5,232,929, which issued on August 3, 1993; World Patent Application WO 92/20676, published November 26, 1992; World Patent Application WO 93/00331, published January 7, 1993; U.S. Patent No.
  • Preferred embodiments of this invention relate to the above methods and pharmaceutical compositions that employ an SSRI wherein said SSRI is sertraline.
  • Other preferred embodiments of this invention are the method and pharmaceutically compositions referred to above that employ sertraline in combination with a NOS inhibiting composition of the formula I, II, III, IV, V or VI.
  • compositions and methods referred to above that employ sertraline in combination with an NK-1 receptor antagonist, wherein said NK-1 receptor antagonist is selected from one of the following compounds in the pharmaceutically acceptable salts:
  • Scheme 1 illustrates a method of preparing compounds of the formula I wherein X is a bond and ring A is benzo.
  • Schemes 2 and 3 illustrate methods of preparing compounds of the formula I wherein X is oxygen and ring A is benzo.
  • the starting materials used in the procedures of Schemes 1 and 2 are either commercially available, known in the art or readily obtainable from known compounds by methods that will be apparent to those skilled in the art.
  • the compound of formula (2) is cooled to about -70°C in dry tetrahydrofuran (THF), and then a solution of n-butyl lithium is added to it. The resulting solution is then treated with triethyl borate and allowed to warm to room temperature to form the compound of formula (3).
  • the compound of formula (3) is reacted with the compound of formula (4) to form the compound of formula (5).
  • This reaction is generally carried out in an aqueous ethanol solvent, in the presence of sodium carbonate and tetrakistriphenylphoshine palladium, at about the reflux temperature.
  • the compound of the formula (6) can be formed in the following manner. First, the compound of formula (5) is reacted with N-bromosuccinimide (NBS) and bis-(1-cyano-1-aza)- cyclohexane in carbon tetrachloride and refluxed for about 8 hours, with additional portions of the initiator being added at about 1 , 2 and 4 hours. After evaporation of the solvent, the product of this reaction is reacted with triethylammonium cyanide in methylene chloride at about room temperature to form the compound of formula (6). Saturation of a solution of the compound of formula (6) in ethanol with hydrogen chloride, followed by refluxing the mixture and then heating in aqueous hydrochloric acid, yields the compound of formula (7).
  • NBS N-bromosuccinimide
  • bis-(1-cyano-1-aza)- cyclohexane in carbon tetrachloride
  • triethylammonium cyanide in
  • the compound of the formula (7) that is formed in the preceding step can be converted into the compound of formula IA in the following manner.
  • the compound of formula (7) is reacted with the appropriate compound of the formula R 2 R 1 NH and N-ethyl-N-dimethylaminopropyl carbodiimide (EDAC) in the presence of a base.
  • suitable bases are those selected from trialkylamines, alkali metal carbonates and alkaline earth metal carbonates.
  • This reaction is typically conducted in a solvent such as acetonitrile, methylene chloride or N,N-dimethylformamide (DMF), at a temperature from about room temperature to about 100°C, preferably at about room temperature.
  • a catalytic additive such as N-hydroxysuccinamide or hydroxybenzotriazole.
  • the product of the foregoing reaction is then reduced using methods well known to those of skill in the art.
  • the reduction can be carried out using lithium aluminum hydride in tetrahydrofuran, with or without aluminum chloride, or using borane methyl sulfide in tetrahydrofuran, at a temperature of about -78°C to about 0°C, preferably at about -70°C, to yield the desired compound of formula IA.
  • the compound of formula (8) is reacted with tetrabutylammonium tribromide in 1 ,2-dichloroethane at about room temperature.
  • the product of this reaction is then treated with benzyl bromide and potassium carbonate in a solvent such as acetonitrile, at about the reflux temperature of the reaction mixture, to form the compound of formula (9).
  • the compound of formula (9) is then converted into 1-benzyloxy-naphthalene-4-boronic acid by the procedure described above for preparing the boronic acid derivative of formula (3) in Scheme 1.
  • the compound of formula (11) can be converted into the compound of formula (13) using the following two step process.
  • the compound of formula (11) is reacted with ammonium formate and ten percent palladium on carbon, in an ethanol solvent, at about the reflux temperature of the reaction mixture, to yield the analogous compound to that having formula (11), wherein the benzyloxy group of formula (11) is replaced with a hydroxy group.
  • the compound of formula (12) is then formed by reacting the above hydroxy derivative with 2-bromoethylacetate and potassium carbonate in acetonitrile at about the reflux temperature of the reaction mixture.
  • the compound of formula (13) is reduced to form the corresponding compound wherein the carbonyl group is replaced by a methylene group, after which the 2,5-dimethylpyrrolyl protecting group is removed.
  • the reduction can be earned out using methods well known to those of skill in the art, for example, using lithium aluminum hydride in tetrahydrofuran, with or without aluminum chloride, or using borane methyl sulfide in tetrahydrofuran, at a temperature of about -78°C to about 0°C, preferably at about -70°C.
  • Removal of the 2,5-dimethylpyr ⁇ olyl protecting group can be accomplished by reaction with hydroxylamine hydrochloride. This reaction is generally carried out in an alcoholic or aqueous alcoholic solvent, at a temperature from about room temperature to about the reflux temperature of the reaction mixture, preferably at about the reflux temperature, for about 8 to about 72 hours.
  • the known 1-fluoronaphthalene (14) is brominated with bromine in acetic acid at a temperature from about room temperature to about the reflux temperature of the reaction mixture for about 1 to about 48 hours, and the bromide cooled to about -70°C in dry tetrahydrofuran (THF), and then a solution of n-butyl lithium is added to it. The resulting solution is then treated with triethyl borate and allowed to warm to room temperature to form the compound of formula (15). The compound of formula (15) is reacted with the compound of formula (4) to form the compound of formula (16).
  • THF dry tetrahydrofuran
  • This reaction is generally carried out in an aqueous ethanol solvent, in the presence of sodium carbonate and tetrakistriphenylphoshine palladium, at about the reflux temperature.
  • the compound of formula (16) is then treated with an alkali metal alkoxide prepared from a compound of the formula HO(CH 2 ) n NR 1 R 2 and sodium hydride in a polar solvent such as dimethylformamide, at a temperature from room temperature to 140°C for about 1 to about 48 hours.
  • This reaction produces the corresponding compound of formula (17), which is then deblocked to remove the 2,5-dimethylpyrrolyl protecting group by reaction with hydroxylamine hydrochloride.
  • This reaction is generally carried out in an alcoholic or aqueous alcoholic solvent, at a temperature from about room temperature to about the reflux temperature of the reaction mixture, preferably at about the reflux temperature, for about 8 to about 72 hours.
  • pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, Le., about 1 atmosphere, is preferred as a matter of convenience.
  • the compound of formula (18) is reacted with a compound of the formula CHR 3 R 4 Br or CHR 2 R 4 i and potassium carbonate, in a solvent such as acetonitrile, at about the reflux temperature of the reaction mixture, to convert the hydroxy group of formula (18) into a group having the formula -OCHR 3 R 4 .
  • the resulting compound is then reduced, at about room temperature, using hydrogen gas in the presence of 10% palladium on carbon, in an ethanol solvent, to form 3-OCHR 3 R 4 -4-aminotoluene, which is then reacted with sodium nitrite and cuprous bromide in concentrated sulfuric acid to form 3-OCHR 3 R 4 -4-bromotoluene.
  • the 3-OCHR 3 R -4-bromotoluene produced in the foregoing reaction is then cooled to about -70°C in dry tetrahydrofuran (THF), and a solution of n-butyl lithium is added to it.
  • THF dry tetrahydrofuran
  • the resulting solution is then treated with triethyl borate and allowed to warm to room temperature to form the compound of formula (19).
  • the compound of formula (19) is reacted with the compound of formula (20) to form the compound of formula (21).
  • This reaction is generally carried out in an aqueous ethanol solvent, in the presence of sodium carbonate and tetrakistriphenylphosphine palladium, at about the reflux temperature of the reaction mixture.
  • the compound of the formula (23) can be formed in the following manner. First, the compound of formula (21) is reacted with N-bromosuccinimide (NBS) and bis-(1-cyano-1-aza)- cyclohexane (formula (22)) in carbon tetrachloride and refluxed for about 8 hours, with additional portions of the initiator being added at about 1 , 2 and 4 hours. After evaporation of the solvent, the product of this reaction is reacted with triethylammonium cyanide in methylene chloride at about room temperature to form the compound of formula (23).
  • NBS N-bromosuccinimide
  • formula (22) bis-(1-cyano-1-aza)- cyclohexane
  • the compound of the formula (25) that is formed in the preceding step can be converted into the compound of formula III (wherein X is CH 2 ) in the following manner.
  • the compound of formula (25) is reacted with the appropriate compound of the formula R 2 R 1 NH and N-ethyl-N- dimethylaminopropyl carbodiimide (EDAC) in the presence of a base.
  • suitable bases are those selected from trialkylamines, alkali metal carbonates and alkaline earth metal carbonates.
  • This reaction is typically conducted in a solvent such as acetonitrile, methylene chloride or N,N-dimethylformamide (DMF), at a temperature from about room temperature to about 100°C, preferably at about room temperature.
  • the reaction is conducted in the presence of a catalytic additive such as N-hydroxysuccinamide or hydroxybenzotriazole.
  • a catalytic additive such as N-hydroxysuccinamide or hydroxybenzotriazole.
  • the product of the foregoing reaction is then reduced using methods well known to those of skill in the art.
  • the reduction can be carried out using lithium aluminum hydride in tetrahydrofuran, with or without aluminum chloride, or using borane methyl sulfide in tetrahydrofuran, at a temperature of about -78°C to about 0°C, preferably at about -70°C, to yield the desired compound of formula III (wherein X is CH 2 ).
  • a halogen-metal exchange reaction is carried out on 3-fluoro-4-bromotoluene in tetrahydrofuran, ether, dimethoxyethane, hexane or another suitable ethereal or hydrocarbon solvent, at a temperature from -100°C to about room temperature, using butyl lithium or another suitable alkyl lithium reagent, followed by reaction with a borate triester such as triethyl or triisopropyl borate, for about 1 to about 48 hours at a temperature from about -100°C to about the reflux temperature.
  • a borate triester such as triethyl or triisopropyl borate
  • the intermediate boronic acid derivative is then converted into the compound of formula (26) in an aqueous ethanol solvent, in the presence of sodium carbonate and tetrakistriphenylphosphine palladium, at about the reflux temperature of the reaction mixture, using 6-bromo-2-(t-butylcarbonylamino)pyridine as the coupling partner.
  • the compound of formula (26) is then converted into a compound of the formula (27) by displacement of the fluoro group from the alcohol with a suitable alkoxide, which is formed in a solvent such as dimethylformamide, tetrahydrofuran or dioxane, and a metal hydride such as sodium hydride, at a temperature from about room temperature to about the reflux temperature, for a period of about 5 minutes to about 5 hours.
  • a suitable alkoxide which is formed in a solvent such as dimethylformamide, tetrahydrofuran or dioxane, and a metal hydride such as sodium hydride
  • the compound of formula (27) is then converted into the corresponding compound of the formula (25) in the following manner.
  • the compound of formula (27) is reacted with N- bromosuccinimide (NBS) and bis-(1-cyano-1-aza)-cyclohexane (formula (22) in Scheme 4) in carbon tetrachloride and refluxed for about 8 hours, with additional portions of the initiator being added after about 1, 2 and 4 hours, to brominate the methyl group of such compound.
  • N- bromosuccinimide N- bromosuccinimide
  • bis-(1-cyano-1-aza)-cyclohexane formula (22) in Scheme 4
  • the product of this reaction is reacted with triethylammonium cyanide in methylene chloride at about room temperature to form the corresponding compound wherein the bromo substituent is replaced by cyano.
  • the resulting cyano derivative is then hydrolyzed to form the corresponding compound of formula (25).
  • the base hydrolysis is typically carried out using an alkali metal or alkaline earth metal hydroxide in a mixture of ethanol and water at a temperature from about room temperature to about the reflux temperature of the solvent.
  • the compound of the formula (25) that is formed in the preceding step can be converted into the compound of formula I in the following manner.
  • the compound of formula (25) is reacted with the appropriate compound of the formula R 2 R 1 NH and N-ethyl-N-dimethylaminopropyl carbodiimide (EDAC) in the presence of a base.
  • suitable bases are those selected from trialkylamines, alkali metal carbonates and alkaline earth metal carbonates.
  • This reaction is typically conducted in a solvent such as acetonitrile, methylene chloride or N,N-dimethylformamide (DMF), at a temperature from about room temperature to about 100°C, preferably at about room temperature.
  • a catalytic additive such as N-hydroxysuccinamide or hydroxybenzotriazole.
  • the product of the foregoing reaction is then reduced using methods well known to those of skill in the art to yield the desired compound of formula III (wherein X is CH 2 ).
  • the reduction can be carried out using lithium aluminum hydride in tetrahydrofuran, with or without aluminum chloride, or using borane methyl sulfide in tetrahydrofuran, at a temperature of about -
  • pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, Le., about 1 atmosphere, is preferred as a matter of convenience.
  • IVA Scheme 6 illustrates a method for preparing compounds of the formula I wherein G is hydrogen, R 1 is -OR wherein R is (d-C 6 )alkyl and R 2 is hydrogen. These compounds are referred to in Scheme I as compounds of the formula "IA".
  • the compound of formula (28) is reacted with excess potassium carbonate and one equivalent of tosyl chloride in acetone, at a temperature from about 0°C to about 80 C C, preferably at the reflux temperature of the reaction mixture.
  • a compound of the formula RX wherein R is (d-C 6 )alkyl and X is iodo, chloro or bromo, is then added to the reaction mixture and the mixture is allowed to react at a temperature ranging from about 0°C to about 80°C, preferably at the reflux temperature of the mixture. This reaction yields a compound of the formula (29).
  • the compound of formula (29) is then converted into the corresponding compound of formula (30) by reacting it with potassium hydroxide in ethanol, using water as the solvent.
  • This reaction can be carried out at a temperature from about room temperature to about the reflux temperature of the reaction mixture.
  • the reaction mixture is heated to reflux and allowed to react at that temperature.
  • the compound of formula (30) is then reacted with potassium carbonate and benzyl bromide in acetone, at a temperature from about room temperature to about 80°C, to form the corresponding compound of formula (31).
  • the reaction is conducted at about the reflux temperature.
  • Such protecting groups are well known to those of skill in the art.
  • the above compounds of the formula (33A) are either commercially available, known in the scientific literature or easily obtaining using well known methods and reagents.
  • the benzyl substituent can be removed from the compound of formula (34) by reacting such compound with ammonium formate in water or a lower alcohol solvent, or in a mixture of one or more of these solvents, at a temperature from about room temperature to about the reflux temperature of the reaction mixture. This reaction is preferably carried out at the reflux temperature in the presence of about 20% palladium hydroxide on carbon.
  • the resulting compound of formula (35) is then converted into the desired compound of formula IVA by reacting it with hydroxylamine in a solvent selected from water, lower alcohols and mixtures of these solvents, at a temperature from about room temperature to about the reflux temperature of the solvent, preferably at about the reflux temperature.
  • Scheme 7 illustrates a method for preparing compounds of the formula IV wherein G is hydrogen into the corresponding compounds of formula IV wherein G is other than hydrogen.
  • a compound of the formula IVA can be converted into the corresponding compound of formula IVC by reacting it with the compound of the formula GX, wherein X is iodo, chloro, or bromo, and G is CH 2 CH 2 NR R 4 , and potassium carbonate in either dimethylformamide (DMF) or acetone at a temperature from about room temperature to about the reflux temperature of the mixture, preferably at about the reflux temperature.
  • DMF dimethylformamide
  • Compounds of the formula IVC can also be formed, as illustrated in Scheme 7, as by first preparing the corresponding compounds of formula IVB and then converting them, if so desired, into the corresponding compounds of formula IVC.
  • the resulting compounds of formula of IVB can be converted into the corresponding compounds of formula IVC by reacting them with lithium aluminum hydride and aluminum chloride in a THF solvent, or with borane in THF.
  • Other aluminum hydride reducing agents can also be _ -
  • reaction is generally carried out at temperatures ranging from room temperature to about the reflux temperature of the reaction mixture, and is preferably carried out at the reflux temperature.
  • Other appropriate solvents include other organic ethers such as ethyl ether, dioxane and glyme, THF is preferred solvent.
  • Scheme 8 illustrates how certain compounds of the formula IV having different substituents R 1 and R 2 than are depicted in the processes of Scheme 6 can be prepared.
  • Such compounds are prepared by a process similar to that depicted in Scheme 6, with the exception that the processes of Scheme 6 involved in the synthesis of compound (32) are replaced with those depicted in Scheme 8.
  • the compound of formula (36) when R 2 is hydrogen and R 1 is fluoro at the ortho position, the compound of formula (36) is converted to the corresponding phenylboronic acid in a manner analogous to the conversion of compounds of the formula (31 ) into those of the formula (32) in Scheme (6).
  • the resulting phenylboronic acid derivative is referred to in Scheme 8 as compound (32A).
  • compounds of the formula IV wherein R and R 2 are both methyl and are both at an ortho position relative to the pyridine ring may be prepared by converting the compound of formula (37), as shown in Scheme 8, into the corresponding phenylboronic acid derivative designated as compound (32B), in a matter analogous to the conversion of compounds of formula (31) into those of the formula (32) in Scheme 6.
  • the compounds of formulas (32A) and (32B) can then be transformed into the desired corresponding compounds of the formula IV using procedures analogous to those shown in Scheme 6.
  • Scheme 9 exemplifies methods of preparing compounds of the formula IV wherein G is NR 3 R 4 and NR 3 R 4 forms an N-methylpyrrolin-2-yl ring.
  • Compounds of the formula IV wherein G is NR 3 R 4 and NR R 4 forms other nitrogen containing rings can be prepared in an analogous fashion.
  • the compound of formula IVD is allowed to react with 3- methanesulfonyloxy-pyrrolidine-1 -carboxylic acid tert-butyl ester to form the compound of formula (38).
  • the mesylate leaving group can be replaced with another appropriate leaving group.
  • a catalytic amount of tetrabutylammonium iodide (TBAI) is added to the reaction mixture.
  • TBAI tetrabutylammonium iodide
  • This alkylation reaction is typically carried out in the presence of an alkali metal alkoxide, preferable potassium tert-butoxide, in a high boiling polar organic solvent such as dimethylsulfoxide (DMSO) or DMF, preferably DMSO.
  • the reaction temperature can range from about 50°C to about 100°C, and is preferably about 100°C.
  • Reduction of the compound of formula XII yields the compound of formula IVF.
  • This reduction is preferably accomplished using lithium aluminum hydride as the reducing agent and tetrahydrofuran (THF) or another organic ether (e.g., ethyl ether or glyme) as the solvent.
  • THF tetrahydrofuran
  • Other aluminum hydride reducing agents can also be used, such as diisobutyl aluminum hydride.
  • Diborane can also be used.
  • the foregoing reaction is generally conducted at a temperature from about room temperature to about the reflux temperature of the reaction mixture, preferably at about the reflux temperature.
  • alkylation of the compound of formula IVD with 1-(2- chloroethyl)-pyrrolidine yields the compound of formula IVE.
  • This reaction is generally conducted in the present of a base such as cesium carbonate, potassium carbonate, or sodium carbonate, preferably cesium carbonate, in a solvent such as acetone, DMSO or acetonitrile, preferably acetone, at a temperature from about room temperature to about the reflux temperature, preferably at about the reflux temperature.
  • Scheme 11 illustrates a method of preparing the benzeneboronic acid intermediates use in the syntheses described in Schemes 6 and 8 above wherein the benzene ring of the benzeneboronic acid contains a cycloalkyl substituent.
  • Such intermediates can be used in the processes of Schemes 6 and 8 to form compounds of the formula IV wherein one or both of R 1 and R 2 are cycloalkyl groups.
  • the compound of formula (39) is allowed to reflux, in the presence of magnesium metal, in THF or ethyl ether for about 8 hours, after which cyclobutanone is added to the reaction mixture. This reaction yields the compound of formula (40).
  • the compound of formula (42) that was formed in the above step is then brominated by reaction with N-bromosuccinimide (NBS) and silica gel in a chlorinated hydrocarbon solvent such as carbon tetrachloride, methylene chloride or chloroform. This reaction is typically carried out at room temperature.
  • the compound of formula (43) that is produced in this reaction can then be converted into the benzeneboronic acid derivative of formula (44) in the following manner.
  • the compound of formula (43) in a solvent such as THF, is cooled to a temperature of about -78°C to about -70°C, after which n-butyl lithium is added. After stirring the reaction mixture for about 1 hour, triethyl borate is added and the mixture is allowed to stir for an additional 1-3 hours.
  • the benzeneboronic acid intermediate can then be isolated by methods well known to of those skilled _ 74 _
  • Scheme 12 exemplifies a process for making compounds of the formula IV wherein G is alkenyl, as well as compounds of the formula IV wherein G is hydrogen and R 2 is an alkyl or alkenyl group.
  • the compound of formula IVA is converted into the corresponding compound having the formula IVH using an alkylation reaction analogous to that used to convert the compound of formula IVD into that of formula IVG in Scheme 11. Heating the resulting compound of formula IVH to about 230°C yields the corresponding compounds of formulas IVJ and IVK.
  • Scheme 13 illustrates an alternate method of preparing compounds of the formula IV wherein G is NR 3 R 4 (C 0 -C ) alkyl.
  • G is NR 3 R 4 (C 0 -C ) alkyl.
  • a compound of the formula (45) is reacted with bromine in acetic acid at a temperature from about 0°C to about 60°C, preferably at about room temperature. This reaction produces the corresponding compound having a bromine substituent para to the fluoro substituent, which can then be converted into the corresponding boronic acid derivative of formula (46) as described above for the synthesis of compounds of the formula (32) (in Scheme 6) and (44) (in Scheme 11).
  • Scheme 14 illustrates a method of synthesizing compounds of the formula I wherein G is an optionally substituted pyrrolidin-2-yl or pyrrolidin-3-yl group.
  • G is an optionally substituted pyrrolidin-2-yl or pyrrolidin-3-yl group.
  • a compound of the formula IVA is reacted with a compound of the formula triphenylphosphine and diethylazodicarboxylate or another water soluble azodicarboxylate in THF under standard Mitsunobo reaction conditions. Typically, the reactants are combined at about 0°C and then allowed to warm to room temperature.
  • the compound of formula (48) that is formed in the above reaction can be converted into the desired product having formula IVP (or a similar compound wherein the methyl substituent depicted in structure IVP is replaced with another alkyl group) by reducing it.
  • This reduction can be accomplished by reacting the product from the preceding reaction with lithium aluminum hydride and aluminum chloride in THF or borane in THF as described above for the formation of compounds of the formula IVC.
  • the corresponding compound of formula IV wherein the alkyl substituent on the pyrrolidine nitrogen formula IVP is replaced with hydrogen can be obtained by reacting the compound of formula (48), or an alkyl analogue of (48), as referred to above, with trifluoroacetic acid or hydrochloric acid in a solvent such as dioxane, or ether, preferably dioxane, at a temperature from about 0°C to about reflux temperature of the reaction mixture, preferably at about the reflux temperature.
  • a solvent such as dioxane, or ether, preferably dioxane
  • compound (50) is prepared by reaction of 1 ,4-dibromobenzene with an organolithium reagent, preferably butyl lithium, at a temperature from -100°C to about 0°C, followed by addition to 2-(2,5-dimethylpyrrolyl)-pyridine at a temperature from about 0°C to about 50°C in an ethereal solvent, preferably diethyl ether, for about 1 to 24 hours.
  • organolithium reagent preferably butyl lithium
  • Compound (51) is prepared by reacting (50) with a boronic acid derivative of the formula p-OHC(CH 2 ) m - 2 (C 6 H 3 R 1 R 2 )B(OH) 2 in a solvent consisting of an alcohol, preferably ethanol, optionally mixed with water and a halogenated hydrocarbon, at a temperature from about 25°C to about 150°C, for about 1 to 24 hours, using a palladium-based catalyst, either palladium-zero or palladium-two oxidation state, typically with phosphine ligands, preferably tetrakis-triphenylphosphine palladium.
  • a solvent consisting of an alcohol, preferably ethanol, optionally mixed with water and a halogenated hydrocarbon
  • Compound (52) is prepared by reacting (51) with tosylmethylisocyanide in the presence of potassium t-butoxide and ethanol, in an ethereal solvent such as 1,2-dimethoxyethane, at a temperature from about -100°C to about 100°C, for about 1 to 24 hours.
  • Compound (53) is prepared from (52) by basic hydrolysis of the nitrite using an alkali metal hydroxide in an aqueous alcohol-based solvent, such as aqueous ethanol, at a temperature from about 25°C to about 125°C, for about 30 minutes to 48 hours.
  • Compound (54) is prepared from (53) by dehydrative coupling with ammonia, a primary or secondary amine of the fomnula R 3 R NH effected by a dehydrating agent such as a carbodiimide, for example, N-ethyl-N-(dimethylaminopropyl)- carbodiimide, in a solvent that is a halogenated hydrocarbon or a N.N-dialkylamide, such as dimethylformamide, at a temperature from about 0°C to about 100°C, for about 1 to 48 hours.
  • a dehydrating agent such as a carbodiimide, for example, N-ethyl-N-(dimethylaminopropyl)- carbodiimide
  • a solvent that is a halogenated hydrocarbon or a N.N-dialkylamide, such as dimethylformamide at a temperature from about 0°C to about 100°C, for about 1 to 48 hours.
  • Compound (55) is prepared from (54) by deblocking using hydroxylamine hydrochloride in an aqueous or alcoholic solvent, preferably aqueous ethanol, at a temperature from about 25°C to about 100°C, for about 1 to 48 hours, and may include deblocking a protecting group such a the t- butoxycarbonyl group by reaction with trifluoroacetic acid or a related polyhalogenated acetic acid or a gaseous hydrogen halide such as HCI, in a halogenated hydrocarbon, ethereal solvent or ethyl acetate, at a temperature from about -70°C to about 100°C, for about 10 minutes to 24 hours.
  • an aqueous or alcoholic solvent preferably aqueous ethanol
  • an ethereal solvent such as ethyl ether or tetrahydrofuran
  • compound (56) is prepared from (50) by reaction with 3-pyridyl boronic acid and a palladium catalyst, in either the palladium-zero or palladium-two oxidation state, with ligands typically comprised of trialkyl or triaryl phosphines, such as tetrakis-triphenylphosphine palladium, in an aqueous alcoholic solvent at a temperature from about 25°C to about 125°C for about 1 to 48 hours.
  • ligands typically comprised of trialkyl or triaryl phosphines, such as tetrakis-triphenylphosphine palladium
  • Compound (57) is prepared from (56) by alkylation with an alkyl or aralkyl halide or sulfonate, in an ethereal, alcoholic , aqueous alcoholic, or dialkylamine-based solvent, such as dimethylformamide, at a temperature from about 0°C to about 125°C for about 30 minutes to 72 hours, followed by reduction with a borohydride- or aluminum hydride-based reagent, such as sodium borohydride, in an ethereal, alcoholic, or aqueous-alcoholic solvent, typically methanol, at a temperature from about 0°C to about 125°C for about 1 to 72 hours.
  • a borohydride- or aluminum hydride-based reagent such as sodium borohydride
  • Y in formulas (57) and VA-a is benzyl.
  • Compounds of the formula VA-a wherein Y is benzyl can be converted into the corresponding compounds wherein Y is other than benzyl by debenzylation using hydrogen or ammonium formate in the presence of a noble metal catalyst, such as palladium, in an ethereal, halogenated hydrocarbon, alcoholic, or aqueous alcoholic solvent, at a temperature from 0 C C to 100°C for a time from 30 minutes to 24 hours, followed by reductive amination with an alkyl or aralkyl aldehyde in the presence of a borohydride-based reagent such as sodium cyanoborohydride or sodium triacetoxyborohydride, in an ethereal, halogenated hydrocarbon, alcoholic, or aqueous-alcoholic solvent, at a temperature from 0°C to 100°C for a time from 1 to 72 hours.
  • a noble metal catalyst such as palla
  • compound (58) is prepared by reductive amination of 2-(4- bromophenylmethyl)-piperidine with benzaldehyde and a borohydride-based reagent such as sodium cyanoborohydride or sodium triacetoxyborohydride, in an ethereal, halogenated hydrocarbon, alcoholic, or aqueous-alcoholic solvent, at a temperature from about 0°C to about 100°C for about 1 to 72 hours.
  • a borohydride-based reagent such as sodium cyanoborohydride or sodium triacetoxyborohydride
  • Compound (59) is prepared from compound (58) by reaction of compound (58) with an organolithium reagent, typically butyl lithium, followed by addition of the resulting organolithium reagent to 2-(2,5-dimethylpyrrolyl)-pyridine, in an ethereal solvent such as ethyl ether, at a temperature from about -70°C to about 100°C for about 30 minutes to 48 hours.
  • organolithium reagent typically butyl lithium
  • 2-(2,5-dimethylpyrrolyl)-pyridine in an ethereal solvent such as ethyl ether
  • compound (60) is prepared from 6-bromo-2-(2,5- dimethylpyrrolyl)-pyridine and 4-formylphenylboronic acid in the presence of a palladium catalyst, . -
  • ligands typically comprised of trialkyl or triaryl phosphines, such as tetrakis-triphenylphosphine palladium, in an aqueous alcoholic solvent, at a temperature from about 25°C to about 125°C for about 1 to 48 hours.
  • Compound (61) is then prepared from (60) by reaction of (60) with the enamine of a ketone or aldehyde, typically the mo ⁇ holine or pyrrolidine enamine, in a aromatic hydrocarbon, hydrocarbon, or halogenated hydrocarbon solvent, preferably toluene, at a temperature from about 25°C to about 150°C for about 1 to 72 hours, followed by an aqueous hydrolysis step, typically with aqueous hydrochloric acid, and then reduction with hydrogen or ammonium formate in the presence of a noble metal catalyst, such as palladium, in an ethereal, halogenated hydrocarbon, alcoholic, or aqueous alcoholic solvent, at a temperature from about 0°C to about 100°C for about 30 minutes to 24 hours.
  • a noble metal catalyst such as palladium
  • the final compound in Scheme 18, VA is prepared by reductive amination of compound (61) with ammonia, a primary amine, or a secondary amine in the presence of a borohydride-based reagent such as sodium cyanoborohydride or sodium triacetoxyborohydride, in an ethereal, halogenated hydrocarbon, alcoholic, or aqueous-alcoholic solvent, at a temperature from about 0°C to about 100°C for about 1 to 72 hours, followed by deblocking with hydroxylamine hydrochloride in an alcoholic or aqueous- alcoholic solvent, typically aqueous ethanol, at a temperature from about 25 C C to about 125°C for about 1 to 72 hours.
  • a borohydride-based reagent such as sodium cyanoborohydride or sodium triacetoxyborohydride
  • compound (62) is prepared from 3-(4-bromophenyl)-glutaric acid by dehydration with acetic anhydride or a similar dehydrating reagent, followed by reaction with benzylamine in a hydrocarbon, aromatic hydrocarbon, or halogenated hydrocarbon solvent, at a temperature from about 25°C to about 180°C for about 1 to 48 hours, followed by dehydration with acetic anhydride, or a similar dehydrating reagent, at a temperature from about 25 C C to about reflux for about 1 to 48 hours.
  • Compound (63) is prepared by reduction of (64) with borane, borane methyl sulfide, alane, or lithium aluminum hydride in an ethereal or hydrocarbon solvent, at a temperature from about 0°C to about 100°C for about 30 minutes to 48 hours.
  • Compound (64) is prepared from compound (63) by reaction of compound (63) with an organolithium reagent, typically butyl lithium, followed by addition of the resulting organolithium reagent to 2-(2,5- dimethylpyrrolyl)-pyridine, in an ethereal solvent, such as ethyl ether, at a temperature from about - 70°C to about 100°C for about 30 minutes to 48 hours.
  • an organolithium reagent typically butyl lithium
  • 2-(2,5- dimethylpyrrolyl)-pyridine in an ethereal solvent, such as ethyl ether
  • the compound of formula (65) is prepared by reaction of norbornylene and 2-hydroxypyrone followed by aromatization with palladium oxide, according to the procedure described in Syn. Commun., 5, 461, (1975). It is then reacted with tetrabutylammonium tribromide in 1 ,2-dichloroethane at about room temperature for about 10 minutes to about 10 hours. The product of this reaction is then treated with benzyl bromide and potassium carbonate in a solvent such as acetonitrile, at about the reflux temperature of the reaction mixture for about 1 to 48 hours, to form the compound of formula (66).
  • the compound of formula (66) is then converted into 5-benzyloxy-1 ,2,3,4-tetrahydro-1 ,4- methano-naphthalene-8-boronic acid by cooling the compound of formula III to about -70°C in dry tetrahydrofuran (THF), and adding a solution of n-butyl lithium to it. The resulting solution is then treated with triethyl borate and allowed to warm to room temperature for about 1 to 48 hours to form 5-benzyloxy-1,2,3,4-tetrahydro-1,4-methano-naphthalene-8-boronic acid.
  • THF dry tetrahydrofuran
  • the compound of fomnula (67) can be converted into the compound of formula V using the following two step process.
  • the compound of formula (67) is reacted with ammonium formate and ten percent palladium on carbon, in an ethanol solvent, at about the reflux temperature of the reaction mixture, for about 10 minutes to about 10 hours to yield the analogous compound to that having formula (67), wherein the benzyloxy group of formula (67) is replaced with a hydroxy group.
  • the compound of formula (68) is then formed by reacting the above hydroxy derivative with 2- bromoethylacetate and potassium carbonate in acetonitrile at about the reflux temperature of the reaction mixture for about 1 to 48 hours.
  • Suitable bases are those selected from trialkylamines, alkali metal carbonates and alkaline earth metal carbonates.
  • This reaction is typically conducted in a solvent such as acetonitrile, methylene chloride or N,N-dimethylformamide (DMF), at a temperature from about room temperature to about 100°C, preferably at about room temperature for about 1 to 48 hours.
  • a catalytic additive such as N-hydroxysuccinamide or hydroxybenzotriazole.
  • the compound of formula (69) can be converted into the desired compound of formula I as follows.
  • the compound of formula (69) is reduced to form the corresponding compound wherein the carbonyl group is replaced by a methylene group, after which the 2,5-dimethylpyrrolyl protecting group is removed.
  • the reduction can be carried out using methods well known to those of skill in the art, for example, using lithium aluminum hydride in tetrahydrofuran, with or without aluminum chloride, or using borane methyl sulfide in tetrahydrofuran, at a temperature of about -78°C to about reflux, preferably at about -70°C to room temperature for about 1 to about 24 hours.
  • Removal of the 2,5-dimethylpyrrolyl protecting group can be accomplished by reaction with hydroxylamine hydrochloride. This reaction is generally carried out in an alcoholic or aqueous alcoholic solvent (preferably, using ethanol as the alcohol), at a temperature from about room temperature to about the reflux temperature of the reaction mixture, preferably at about the reflux temperature, for about 8 to about 72 hours.
  • an alcoholic or aqueous alcoholic solvent preferably, using ethanol as the alcohol
  • pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, e., about 1 atmosphere, is preferred as a matter of convenience.
  • the compounds of formulas l-VI that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I, II, III, IV, V or VI from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt.
  • the acid addition salts of the active base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.
  • the compounds of formulas I, II, III, IV, V and VI, and their pharmaceutically acceptable salts, are useful as NOS inhibitors Le., they possess the ability to inhibit the NOS enzyme in mammals, and therefore they are able to function as therapeutic agents in the treatment of the aforementioned disorders and diseases in an afflicted mammal.
  • the ability of compounds of formulas l-VI to inhibit NOS may be determined using procedures described in the literature.
  • the ability of compounds of the formulae I to inhibit endothelial NOS may be determined by using the procedures described by Schmidt et aL in Proc. Natl. Acad. Sci. U.S.A., 88, pp. 365-369 (1991) and by Pollock et a]., in Proc. Natl. Acad. Sci. U.S.A., 88, pp. 10480-10484 (1991).
  • the ability of compounds of the formulae I to inhibit inducible NOS may be determined using the procedures described by Schmidt et aL, in Proc. Natl. Acad, Sci.
  • the compounds of formula l-VI and their pharmaceutically acceptable salts can be administered via either the oral, parenteral or topical routes.
  • these compounds are most desirably administered, when used as the single active agent for the treatment of disorders or conditions that can be treated by altering circadian rhythms, in dosages ranging from about 0.01 to about 250 mg per day, in single or divided doses (Le., from 1 to 4 doses per day), although variations will necessarily occur depending upon the species, weight and condition of the subject being treated and the particular route of administration chosen.
  • a dosage level that is in the range of about 0.07 mg to about 21 mg per kg of body weight per day is most desirably employed.
  • Variations may nevertheless occur depending upon the species of animal being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out.
  • dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.
  • the compounds of formulas l-VI may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by either of the three routes previously indicated, and such administration may be carried out in single or multiple doses. More particularly, such therapeutic agents can be administered in a wide variety of different dosage forms, Le., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like.
  • Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc.
  • oral pharmaceutical compositions can be suitably sweetened and/or flavored.
  • the therapeutically-effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.
  • tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably com, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • disintegrants such as starch (and preferably com, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting pu ⁇ oses.
  • compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
  • solutions of a compound of the formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt thereof, in either sesame or peanut oil or in aqueous propylene glycol may be employed.
  • the aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic.
  • These aqueous solutions are suitable for intravenous injection pu ⁇ oses.
  • the oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
  • the compounds of formulas l-VI topically when treating inflammatory conditions of the skin, and this may be done by way of creams, jellies, gels, pastes, patches, ointments and the like, in accordance with standard pharmaceutical practice.
  • This invention relates both to methods of treating disorders or conditions that can be treated by altering circadian rhythms in which the NOS inhibiting compound and the SSRI and/or NK-1 receptor antagonist are administered together, as part of the same pharmaceutical composition, and to methods in which these active agents are administered separately as part of an appropriate dose regimen designed to obtain the benefits of the combination therapy.
  • the appropriate dose regimen, the amount of each dose administered, and specific intervals between doses of each active agent will depend on the subject being treated, and the source and severity of the condition.
  • the NOS inhibiting compound will be administered to an average 70 kg adult human in an amount ranging from about 0.01 to about 10 mg per kg body weight of the subject being treated per day, in single or divided doses, preferably from about 1 to about 3 mg/kg
  • the SSRI will be administered in an amount ranging from about 0.2 to about 30 mg per kg body weight of the subject being treated per day, in single or divided doses
  • the NK-1 receptor antagonist will be administered in an amount ranging from about 0.16 to about 500 mg per day, in single or divided doses. Variations may nevertheless occur depending upon the species of animal being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out.
  • dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Cette invention concerne de nouvelles combinaisons pharmaceutiques pour des composés présentant une activité comme inhibiteur de l'oxyde nitrique-synthase (NOS). Cette invention concerne plus particulièrement l'utilisation d'inhibiteurs de NOS, notamment des inhibiteurs de NOS neuronaux (N-NOS) sélectifs: seuls ou en combinaison avec un autre agent actif, en particulier, un antagoniste de récepteur SSRI ou NK-1, pour le traitement de troubles ou d'états pathologiques. Le traitement pouvant être déclenché ou facilité par modification des rythmes circadiens. Entre autres exemples de tels troubles ou états pathologiques figurent : la cécité, l'obésité, les troubles affectifs saisonniers, les troubles bipolaires, le décalage horaire, les troubles du rythme circadien du sommeil, le manque de sommeil, la parasomnie, les troubles du sommeil paradoxal, l'hypersomnie, les troubles du cycle sommeil-éveil, la narcolepsie et les troubles du sommeil liés au travail en équipe ou aux horaires de travail irréguliers ; l'enurésie nocturne et le syndrome d'Ekbom.The present invention relates to novel pharmaceutical combinations for compounds having activity as a nitric oxide synthase (NOS) inhibitor. This invention relates more particularly to the use of NOS inhibitors, in particular selective neural NOS inhibitors (N-NOS): alone or in combination with another active agent, in particular an SSRI or NK-1 receptor antagonist, for the treatment of disorders or medical conditions. Treatment can be triggered or facilitated by modifying circadian rhythms. Other examples of such disorders or medical conditions include: blindness, obesity, seasonal affective disorder, bipolar disorder, jet lag, circadian sleep rhythm disorder, lack of sleep, parasomnia, sleep disorders REM sleep, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders related to teamwork or irregular work schedules; nocturnal enuresis and Ekbom syndrome.

Description

. - .
NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS
Background Of The Invention The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, REM sleep disorders, hypersomnia, parasomnias, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.
This invention also relates to the use of a NOS inhibitor in combination with an NK-1 receptor antagonist (e.g.. a substance P receptor antagonist), alone or in combination with one or more additional active agents, for the treatment of any of the foregoing disorders. This invention also relates to the use of a NOS inhibitor in combination with a selective serotonin reuptake inhibitor (SSRI), optionally in combination with one or more additional active agents, for the treatment of any of the foregoing disorders. This invention also relates to the use of a NOS inhibitor in combination with both an NK-1 receptor antagonist and an SSRI, alone or in combination with one or more additional active agents, for the treatment of any of the foregoing disorders.
There are three known isoforms of NOS - an inducible form (iNOS) and two constitutive forms referred to as, respectively, neuronal NOS (nNOS) and endothelial NOS (eNOS). Each of these enzymes carries out the conversion of arginine to citrulline while producing a molecule of nitric oxide (NO) in response to various stimuli. It is believed that excess nitric oxide (NO) production by NOS plays a role in the pathology of a number of disorders and conditions in mammals. For example, NO produced by iNOS is thought to play a role in diseases that involve systemic hypotension such as toxic shock and therapy with certain cytokines. It has been shown that cancer patients treated with cytokines such as interleukin 1 (IL-1), interleukin 2 (IL-2) or tumor necrosis factor (TNF) suffer cytokine-induced shock and hypotension due to NO produced from macrophages. (See Chemical & Engineering News, Dec. 20, p. 33, (1993)). iNOS inhibitors can reverse this. It is also believed that iNOS plays a role in the pathology of diseases of the central nervous system such as ischemia. For example, inhibition of iNOS has been shown to ameliorate cerebral ischemic damage in rats, see Am. J. Phvsiol.. 268, p. R286 (1995)). Suppression of adjuvant induced arthritis by selective inhibition of iNOS is reported in Eur. J. Pharmacol.. 273, p. 15-24 (1995).
NO produced by nNOS is thought to play a role in diseases such as cerebral ischemia, pain, and opiate tolerance. For example, inhibition of nNOS decreases infarct volume after proximal middle cerebral artery occlusion in the rat, see J. Cerebr. Blood Flow Metab., 14, p. 924- 929 (1994). nNOS inhibition has also been shown to be effective in antinociception, as evidenced by activity in the late phase of the formalin-induced hindpaw licking and acetic acid-induced abdominal constriction assays, see Br. J. Pharmacol., 110, p. 219-224 (1993). In addition, subcutaneous injection of Freund's adjuvant in the rat induces an increase in NOS-positive neurons in the spinal cord that is manifested in increased sensitivity to pain, which can be treated with NOS inhibitors, see Japanese Journal of Pharmacology, 75, p. 327-335 (1997). Finally, opioid withdrawal in rodents has been reported to be reduced by nNOS inhibition. (See Neuropsychopharmacol.. 13, p. 269-293 (1995)). Summary of the Invention
This invention relates to a method of treating a disorder or condition that can be treated by altering circadian rhythms in a mammal, including a human, comprising administering to said mammal:
(a) a NOS inhibiting compound, or pharmaceutically acceptable salt thereof; and (b) an NK-1 receptor antagonist or a pharmaceutically acceptable salt thereof; wherein the active agents "a" and "b" above are administered in amounts that render the combination of the two agents effective in treating such disorder or condition.
This invention also relates to a pharmaceutical composition for treating a disorder or condition that can be treated by altering circadian rhythms in a mammal, including a human, comprising:
(a) a NOS inhibiting compound, or pharmaceutically acceptable salt thereof;
(b) an NK-1 receptor antagonist or a pharmaceutically acceptable salt thereof; and
(c) a pharmaceutically acceptable carrier; wherein the active agents "a" and "b" are present in such composition in amounts that render the combination of the two agents effective in treating such disorder.
This invention also relates to a method of treating a condition or disorder that can be treated by altering circadian rhythms in a mammal, including a human, comprising administering to said mammal:
(a) a NOS inhibiting compound or pharmaceutically acceptable salt thereof; (b) an NK-1 receptor antagonist or a pharmaceutically acceptable salt thereof; and
(c) a selective serotonin reuptake inhibitor (SSRI) or pharmaceutically acceptable salt thereof; wherein the active agents "a", "b" and "c" above are administered in amounts that render the combination of the three agents effective in treating such disorder or condition. This invention also relates to a pharmaceutical composition for treating a disorder or condition that can be treated by altering circadian rhythms in a mammal, including a human, comprising: (a) a NOS inhibiting compound or pharmaceutically acceptable salt thereof;
(b) an NK-1 receptor antagonist or pharmaceutically acceptable salt thereof;
(c) an SSRI or pharmaceutically acceptable salt thereof; and
(d) a pharmaceutically acceptable carrier; wherein the active agents "a", "b" and "c" are present in such composition in amounts that render the combination of the three agents effective in treating such disorder or condition.
This invention also relates to a method for treating a disorder or condition that can be treated by altering circadian rhythms in a mammal, including a human, comprising administering to said mammal: (a) a NOS inhibiting compound or pharmaceutically acceptable salt thereof; and
(b) an SSRI or a pharmaceutically acceptable salt thereof; wherein the active agents "a" and "b" are administered in amounts that render the combination of the two agents effective in treating such disorder or condition.
This invention also relates to a pharmaceutical composition for treating a disorder or condition that can be treated by altering circadian rhythms in a mammal, including a human, comprising:
(a) a NOS inhibiting compound or pharmaceutically acceptable salt thereof;
(b) an SSRI or a pharmaceutically acceptable salt thereof; and
(c) a pharmaceutically acceptable carrier; wherein the active agents "a" and "b" are present in such composition in amounts that render the combination of the two agents effective in treating such disorder or condition.
This invention also relates to a method for treating a disorder or condition that can be treated by altering circadian rhythms in a mammal, including a human, comprising administering to said mammal an amount of a NOS inhibiting compound or pharmaceutically acceptable salt thereof that is effective in treating such disorder or condition.
This invention also relates to a pharmaceutical composition for treating a disorder or condition that can be treated by altering circadian rhythms in a mammal, including a human, comprising an amount of a NOS inhibiting compound or pharmaceutically acceptable salt thereof that is effective in treating such disorder condition, and a pharmaceutically acceptable carrier; The term "treating" as used herein, refers to reversing, alleviating, inhibiting or slowing the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, refers to the act of treating, as "treating" is defined immediately above.
This invention also relates to a pharmaceutical composition for treating a disorder or condition selected from blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, REM sleep disorders, hypersomnia, parasomnias, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome in a mammal, including a human, comprising an amount of a NOS inhibiting compound or pharmaceutically acceptable salt thereof that is effective in treating such condition or disorder and a pharmaceutically acceptable carrier.
This invention also relates to a method of treating a disorder or condition selected from blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, REM sleep disorders, hypersomnia, parasomnias, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome in a mammal, including a human, comprising administering to said mammal an amount of a NOS inhibiting compound or pharmaceutically acceptable salt thereof that is effective in treating or preventing such condition or disorder.
A more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is blindness.
Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is restless-legs syndrome. Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is jet lag.
Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is a parasomnia.
Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is nocturnal enuresis.
Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is a sleep-wake cycle disorder.
Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is hypersomnia. Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is seasonal affective disorder.
Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is a sleep disorder associated with shift work or irregular work schedules. Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is circadian sleep rhythms disorder.
Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is a REM sleep disorder.
Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is bipolar disorder.
Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is sleep deprivation. Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is narcolepsy.
Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is obesity. This invention also relates to a method of treating a disorder or condition selected from dysthymia, major depressive disorder, bipolar disorder, seasonal affective disorder and other mood disorders; anxiety disorders (e.g.. generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social phobias, agoraphobia and other phobias), blindness, obesity, stroke, jet lag, sleep disorders such as circadian sleep rhythm disorders, narcolepsy, sleep apnea, REM sleep disorder, parasomnias, sleep-wake cycle disorders, sleep deprivation, insomnia, hypersomnia, and sleep disorders associated with advancing age, shift work or irregular work schedules; nocturnal enuresis, restless-legs syndrome and cognitive disorders such as dementias (e.g., age related dementia and senile dementia of the Alzheimer's type) and memory disorders in a mammal, including a human, comprising administering to said mammal:
(a) a NOS inhibiting compound or pharmaceutically acceptable salt thereof; and
(b) an NK-1 receptor antagonist or a pharmaceutically acceptable salt thereof; wherein the active agents "a" and "b" above are administered in amounts that render the combination of the two agents effective in treating such disorder or condition. This invention also relates to a pharmaceutical composition for treating a disorder or condition selected from dysthymia, major depressive disorder, bipolar disorder, seasonal affective disorder and other mood disorders; anxiety disorders (e.g., generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social phobias, agoraphobia and other phobias), blindness, obesity, stroke, jet lag, sleep disorders such as circadian sleep rhythm disorders, narcolepsy, sleep apnea, REM sleep disorder, parasomnias, sleep-wake cycle disorders, sleep deprivation, insomnia, hypersomnia, and sleep disorders associated with advancing age, shift work or irregular work schedules; nocturnal enuresis, restless-legs syndrome and cognitive disorders such as dementias (e.g., age related dementia and senile dementia of the Alzheimer's type) and memory disorders in a mammal, including a human, comprising:
(a) a NOS inhibiting compound, or pharmaceutically acceptable salt thereof;
(b) an NK-1 receptor antagonist or a pharmaceutically acceptable salt thereof; and
(c) a pharmaceutically acceptable carrier; wherein the active agents "a" and "b" are present in such composition in amounts that render the combination of the two agents effective in treating such disorder.
This invention also relates to a method of treating a disorders or condition selected from dysthymia, major depressive disorder, bipolar disorder, seasonal affective disorder and other mood disorders; anxiety disorders (e.g., generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social phobias, agoraphobia and other phobias), blindness, obesity, stroke, jet lag, sleep disorders such as circadian sleep rhythm disorders, narcolepsy, sleep apnea, REM sleep disorder, parasomnias, sleep-wake cycle disorders, sleep deprivation, insomnia, hypersomnia, and sleep disorders associated with advancing age, shift work or irregular work schedules; nocturnal enuresis, restless-legs syndrome and cognitive disorders such as dementias (e.g., age related dementia and senile dementia of the Alzheimer's type) and memory disorders in a mammal, including a human, comprising administering to said mammal:
(a) a NOS inhibiting compound or pharmaceutically acceptable salt thereof; (b) an NK-1 receptor antagonist or a pharmaceutically acceptable salt thereof; and
(c) a selective serotonin reuptake inhibitor (SSRI) or pharmaceutically acceptable salt thereof; wherein the active agents "a", "b" and "c" above are administered in amounts that render the combination of the three agents effective in treating such disorder or condition. This invention also relates to a pharmaceutical composition for treating a disorder or condition selected from dysthymia, major depressive disorder, bipolar disorder, seasonal affective disorder and other mood disorders; anxiety disorders (e.g., generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social phobias, agoraphobia and other phobias), blindness, obesity, stroke, jet lag, sleep disorders such as circadian sleep rhythm disorders, narcolepsy, sleep apnea, REM sleep disorder, parasomnias, sleep-wake cycle disorders, sleep deprivation, insomnia, hypersomnia, and sleep disorders associated with advancing age, shift work or irregular work schedules; nocturnal enuresis, restless-legs syndrome and cognitive disorders such as dementias (e.g., age related dementia and senile dementia of the Alzheimer's type) and memory disorders in a mammal, including a human,
(a) a NOS inhibiting compound or pharmaceutically acceptable salt thereof;
(b) an NK-1 receptor antagonist or pharmaceutically acceptable salt thereof;
(c) an SSRI or pharmaceutically acceptable salt thereof; and
(d) a pharmaceutically acceptable carrier; wherein the active agents "a", "b" and "c" are present in such composition in amounts that render the combination of the three agents effective in treating such disorder or condition.
This invention also relates to a method for treating a disorder or condition selected from dysthymia, major depressive disorder, bipolar disorder, seasonal affective disorder and other mood disorders; anxiety disorders (e.g., generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social phobias, agoraphobia and other phobias), blindness, obesity, stroke, jet lag, sleep disorders such as circadian sleep rhythm disorders, sleep apnea, narcolepsy, sleep apnea, REM sleep disorder, parasomnias, sleep-wake cycle disorders, sleep deprivation, insomnia, hypersomnia, and sleep disorders associated with advancing age, shift work or irregular work schedules; nocturnal enuresis, restless-legs syndrome and cognitive disorders such as dementias (e.g., age related dementia and senile dementia of the Alzheimer's type) and memory disorders in a mammal, including a human, comprising administering to said mammal: (a) a NOS inhibiting compound or pharmaceutically acceptable salt thereof; and
(b) an SSRI or a pharmaceutically acceptable salt thereof; wherein the active agents "a" and "b" are administered in amounts that render the combination of the two agents effective in treating such disorder or condition.
This invention also relates to a pharmaceutical composition for treating a disorder or condition selected from dysthymia, major depressive disorder, bipolar disorder, seasonal affective disorder and other mood disorders; anxiety disorders (e.g., generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social phobias, agoraphobia and other phobias), blindness, obesity, stroke, jet lag, sleep disorders such as circadian sleep rhythm disorders, sleep apnea, narcolepsy, sleep apnea, REM sleep disorder, parasomnias, sleep-wake cycle disorders, sleep deprivation, insomnia, hypersomnia, and sleep disorders associated with advancing age, shift work or irregular work schedules; nocturnal enuresis, restless-legs syndrome and cognitive disorders such as dementias (e.g., age related dementia and senile dementia of the Alzheimer's type) and memory disorders in a mammal, including a human, comprising: (a) a NOS inhibiting compound or pharmaceutically acceptable salt thereof;
(b) an SSRI or a pharmaceutically acceptable salt thereof; and
(c) a pharmaceutically acceptable carrier; wherein the active agents "a" and "b" are present in such composition in amounts that render the combination of the two agents effective in treating such disorder or condition. This invention also relates to any of the above methods and pharmaceutical compositions wherein the disorder or condition is selected from hypersomnias, parasomnias, restless-legs syndrome, sleep-wake cycle disorders and sleep disorders associated with shift work or irregular work schedules.
This invention also relates to any of the above methods and pharmaceutical compositions wherein the NOS inhibiting compound is a compound of the formula I, II, III, IV, V or VI, as defined below.
Examples of NOS inhibiting compounds that can be used in the methods and pharmaceutical compositions of the present invention are compounds of the formula
Figure imgf000009_0001
wherein ring A is a fused 5-7 membered saturated or unsaturated ring wherein from zero to two of the ring members are heteroatoms selected, independently, from nitrogen, oxygen and sulfur, with the proviso that no two adjacent ring members can both be heteroatoms;
X is oxygen or a bond; n is an integer from two to six; and
R1 and R2 are selected, independently, from (Ci-Ce) alkyl, aryl, tetrahydronaphthalene and aralkyl, wherein said aryl and the aryl moiety of said aralkyl is phenyl or naphthyl and the alkyl moiety is straight or branched and contains from 1 to 6 carbon atoms, and wherein said
Figure imgf000009_0002
alkyl, said aryl, said tetrahydronaphthalene and the aryl moiety of said aralkyl may optionally be substituted with from one to three substituents, preferably from zero to two substituents, that are selected, independently, from halo (e.g., chloro, fluoro, bromo, iodo), nitro, hydroxy, cyano, amino, (C C4) alkoxy, and (Cι-C4) alkylamino; or R1 and R2 form, together with the nitrogen to which they are attached, a piperazine, azetidine, piperidine or pyrrolidine ring or an azabicyclic ring containing from 6 to 14 ring members, from 1 to 3 of which are nitrogen and the rest of which are carbon, wherein examples of said azabicyclic rings are the following
Figure imgf000009_0003
also R1 or R2 may be connected onto the (CH2)n group to form a ring of from 4 to 7 members; wherein R3 and R4 are selected from hydrogen, (CrC6)alkyl, phenyl, naphthyl, (d- C6)alkyl-C(=0)-, HC(=0)-, (C1-C6)alkoxy-(C=0)-, phenyl-C(=0)-, naphthyl-C(=0)-, and R6R7NC(=0)- wherein R6 and R7 are selected, independently, from hydrogen and (Cι-C6)alkyl;
R5 is selected from hydrogen, (C CβJalkyl, phenyl, naphthyl, phenyl-(C1-C6)alkyl- and naphthyl(C1-C6)alkyl-; and wherein said piperazine, azetidine, piperidine and pyrrolidine rings may optionally be substituted with one or more substituents, preferably with from zero to two substituents that are selected, independently, from (C1-C6)alkyl, amino, (C-ι-C6) alkylamino, [di^C^CeJalkyljamino, phenyl substituted 5 to 6 membered heterocyclic rings containing from 1 to 4 rings nitrogen atoms, benzoyl, benzoylmethyl, benzylcarbonyl, phenylaminocarbonyl, phenylethyl and phenoxycarbonyl, and wherein the phenyl moieties of any of the foregoing substituents may optionally be substituted with one or more substituents, preferably with from zero to two substituents, that are selected, independently, from halo, (Cι-C3)alkyl, (C C3)a\Woxy, nitro, amino, cyano, CF3 and OCF3; and the pharmaceutically acceptable salts of such compounds. The following compounds are preferred NOS inhibitors of the formula I: 6-[4-(3-Amino-cyclohexyloxy)-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(3-Amino-cyclopentyloxy)-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(3-Amino-cyclobutyloxy)-naphthalen-1-yl]-pyridin-2-yiamine;
6-[4-(4-Amino-cyclohexyloxy)-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(2-Amino-cyclopentyloxy)-indan-4-yl]-pyridin-2-ylamine; 6-[4-(2-Amino-cyclobutyloxy)-indan-4-yl]-pyridin-2-ylamine; 6-[4-(2-Amino-cyclopropyloxy)-indan-4-yl]-pyridin-2-ylamine; 6-[4-(3-Amino-cyclohexyloxy)-indan-4-yl]-pyridin-2-ylamine;
6-[4-(3-Amino-cyclopentyloxy)-indan-4-yl]-pyridin-2-ylamine; 6-[4-(3-Amino-cyclobutyloxy)-indan-4-yl]-pyridin-2-ylamine; 6-[4-(4-Amino-cyclohexyloxy)-indan-4-yl]-pyridin-2-ylamine; 6-[4-Piperidin-3-ylmethoxy)-6,7,8,9-tetrahydro-5H-benzocyclohepten-1-yl]-pyridin-2- ylamine;
6-[4-(2-Pyrrolidinyl-ethoxy)-6,7,8,9-tetrahydro-5H-benzocyclohepten-1-yl]-pyridin-2- ylamine;
6-[4-(2-Amino-cyclohexyloxy)-6,7,8,9-tetrahydro-5H-benzocyclohepten-1-yl]-pyridin-2- ylamine; 6-[4-(2-Dimethylamino-ethoxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(2-Pyrrolidin-1-yl-ethoxy)-naphthalen-1-yl]-pyridin-2-ylamine; 6-(4-{2-[(Benzo[1,3]dioxol-5-ylmethyl)-amino]-ethoxy}-naphthalen-1-yl)-pyridin-2- ylamine; 6-{4-[2-(6,7-Dimethoxy-3,4-dihydro-1 H-isoguinolin-2-yl)-ethoxy]-naphthalen-1-yl}- pyridin-2-ylamine;
3-{2-[4-(6-Amino-pyridin-2-yl)-naphthalen-1 -yloxy]-ethyl}-3-aza-bicyclo[3.1.0]hex-6- ylamine; 6-{4-[2-(4-Phenethyl-piperazin-1 -yl)-ethoxy]-naphthalen-1 -yl}-pyridin-2-ylamine;
6-{4-[2-(3-Amino-pyrrolidin-1-yl)-ethoxy]-naphthalen-1-yl}-pyridin-2-ylamine;
6-[4-(1-Benzyl-piperidin-4-yloxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(1-Benzyl-pyrrolidin-3-yloxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(Piperidin-4-yloxy)-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(Pyrrolidin-3-yloxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(1-lsobutyl-piperidin-4-yloxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(1-Furan-2-ylmethyl-piperidin-4-yloxy)-naphthalen-1-yi]-pyridin-2-ylamine;
6-[4-(1-lsobutyl-pyrrolidin-3-yloxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(1-Furan-2-ylmethyl-pyrrolidin-3-yloxy)-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1 -yl]-pyridin-2-ylamine;
6-[4-(2-Diisopropylamino-ethoxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(1-Methyl-piperidin-4-yloxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(1-Methyl-pyrrolidin-3-yloxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(3-Dimethylamino-propoxy)-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(1-Aza-bicyclo[2.2.2]oct-3-yloxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(2-Piperidin-1-yl-ethoxy)-naphthalen-1-yl]-pyridin-2-ylamine
6-{4-[2-(3,4-Dihydro-1 H-isoguinolin-2-yl)-ethoxy]-naphthalen-1-yl}-pyridin-2-ylamine;
6-{4-[2-(4-Dimethylamino-piperidin-1-yl)-ethoxy]-naphthalen-1-yl}-pyridin-2-ylamine;
6-{4-[2-(tert-Butyl-methyl-amino)-ethoxy]-naphthalen-1-yl}-pyridin-2-ylamine; 6-{4-[2-(4-Methyl-piperazin-1-yl)-ethoxy]-naphthalen-1-yl}-pyridin-2-ylamine;
6-{4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-naphthalen-1-yl}-pyridin-2-ylamine;
6-{4-[2-(7,8-Dihydro-5H-[1 ,3]dioxolo[4,5-g]isoquinolin-6-yl)-ethoxy]-naphthalen-1-yl}- pyridin-2-ylamine;
6-[4-(Piperidin-2-ylmethoxy)-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(1-Methyl-piperidin-2-ylmethoxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(1-Methyl-piperidin-3-ylmethoxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(2-Amino-cyclohexyloxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(Piperidin-3-ylmethoxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(1-lsobutyl-azetidin-3-yloxy)-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(1-Furan-2-ylmethyl-azetidin-3-yloxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(Azetidin-3-yloxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(1-Methyl-pyrrolidin-2-ylmethoxy)-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(Azetidin-2-ylmethoxy)-naphthalen-1-yl]-pyridin-2-ylamine; 6-[7-(2-Dimethylamino-ethoxy)-indan-4-yl]-pyridin-2-ylamine; 6-[7-(2-Pyrrolidin-1-yl-ethoxy)-indan-4-yl]-pyridin-2-ylamine; 6-{7-[2-(Benzyl-methyl-amino)-ethoxy]-indan-4-yl}-pyridin-2-ylamine; 6-{7-[2-(4-Phenethyl-piperazin-1-yl)-ethoxy]-indan-4-yl}-pyridin-2-ylamine;
6-{7-[2-(4-lsobutyl-piperazin-1-yl)-ethoxy]-indan-4-yl}-pyridin-2-ylamine; 6-[7-(2-Morpholin-4-yl-ethoxy)-indan-4-yl]-pyridin-2-ylamine; 6-[7-(2-Diisopropylamino-ethoxy)-indan-4-yl]-pyridin-2-ylamine;
6-{7-[2-(7,8-Dihydro-5H-[1 ,3]dioxolo[4,5-g]isoguinolin-6-yl)-ethoxy]-indan-4-yl}-pyridin-2- ylamine;
6-{7-[2-(4-Methyl-piperazin-1-yl)-ethoxy]-indan-4-yl}-pyridin-2-ylamine; 6-{7-[2-(tert-Butyl-methyl-amino)-ethoxy]-indan-4-yl}-pyridin-2-ylamine; 6-{7-[2-(4-Dimethylamino-piperidin-1-yl)-ethoxy]-indan-4-yl}-pyridin-2-ylamine; 6-[8-(2-Dimethylamino-ethoxy)-1 ,2,3,4-tetrahydro-1 ,4-methano-naphthalen-5-yl]-pyridin- 2-ylamine;
6-[8-(2-Pyrrolidin-1-yl-ethoxy)-1 ,2,3,4-tetrahydro-1 ,4-methano-naphthalen-5-yl]-pyridin- 2-ylamine;
6-[4-(2-Dimethylamino-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(2-Pyrrolidin-1-yl-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2-ylamine; 6-{4-[2-(tert-Butyl-methyl-amino)-ethoxy]-5,6,7,8-tetrahydro-naphthalen-1-yl}-pyridin-2- ylamine;
6-[4-(2-Diisopropylamino-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(2-Diethylamino-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2-ylamine; 6-{4-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)-ethoxy]-5,6,7,8-tetrahydro-naphthalen-1-yl}- pyridin-2-ylamine;
6-[4-(2-Piperidin-1-yl-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(2-Morpholin-4-yl-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2-ylamine; 6-{4-[2-(7,8-Dihydro-5H-[1 ,3]dioxolo[4,5-g]isoquinolin-6-yl)-ethoxy]-5,6,7,8-tetrahydro- naphthalen-1-yl}-pyridin-2-ylamine; 6-{4-[2-(4-Methyl-piperazin-1-yl)-ethoxy]-5,6,7,8-tetrahydro-naphthalen-1-yl}-pyridin-2- ylamine;
6-{4-t2-(4-Dimethylamino-piperidin-1-yl)-ethoxy]-5,6,7,8-tetrahydro-naphthalen-1-yl}- pyridin-2-ylamine;
6-{4-[2-(7,8-Dihydro-5H-[1 ,3]dioxolo[4,5-g]isoquinolin-6-yl)-ethoxy]-5,6,7,8-tetrahydro- naphthalen-1 -yl}-pyridin-2-ylamine;
6-[4-(1-lsobutyl-piperidin-3-ylmethoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2- ylamine; 6-[4-(1-Methyl-piperidin-3-ylmethoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2- ylamine;
6-{4-[2-(2-Diethylamino-ethoxy)-ethoxy]-5,6,7,8-tetrahydro-naphthalen-1-yl}-pyridin-2- ylamine; 6-[4-(Piperidin-3-ylmethoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(2-Amino-cyclohexyloxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(Pyrrolidin-2-ylmethoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2-ylamine; and 6-[4-(2-Dimethylamino-ethoxy)-6,7,8,9-tetrahydro-5H-benzocyclohepten-1-yl]-pyridin-2- ylamine; and the pharmaceutically acceptable salts of the foregoing compounds.
The following are additional examples of NOS inhibiting compounds of the formula I. 6-[4-(2-Amino-cyclopentyloxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(2-Amino-cyclobutyloxy)-5,6,7,8-tetrahydro-naphthalen-1-ylj-pyridin-2-ylamine; 6-[4-(2-Amino-cyclopropyloxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(3-Amino-cyclohexyloxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(3-Amino-cyciopentyloxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(3-Amino-cyclobutyloxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(4-Amino-cyclohexyloxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(2-Amino-cyclopentyloxy)-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(2-Amino-cyclobutyloxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(2-Amino-cyclopropyloxy)-naphthalen-1-yl]-pyridin-2-ylamine; 6-[4-(2-(4-Dimethylamino-piperidin-1-yl)-ethoxy))-6,7,8,9-tetrahydro-5H- benzocyclohepten-1-yl]-pyridin-2-ylamine; and
6-[4-(2-(4-Methyl-piperazin-1-yl)-ethoxy))-6,7,8,9-tetrahydro-5H-benzocyclohepten-1-yl]- pyridin-2-ylamine.
Other examples of NOS inhibiting compounds that can be used in the methods and pharmaceutical compositions of this invention are compounds of the formula
Figure imgf000013_0001
and the pharmaceutically acceptable salts thereof, wherein each ( )n represents (CH2)n; R1 and R2 are selected, independently, from hydrogen, (CrC6) alkyl, tetrahydronaphthalene and aralkyl, wherein the aryl moiety of said aralkyl is phenyl or naphthyl and the alkyl moiety is straight or branched and contains from 1 to 6 carbon atoms, and wherein said (d-C6) alkyl and said tetrahydronaphthalene and the aryl moiety of said aralkyl may optionally be substituted with from one to three substituents, preferably from zero to two substituents, that are selected, independently, from halo (e.g., chloro, fluoro, bromo, iodo), nitro, hydroxy, cyano, amino, (C1-C4) alkoxy, and (Cι-C4) alkylamino; or R1 and R2 form, together with the nitrogen to which they are attached, a piperazine, piperidine or pyrrolidine ring or an azabicyclic ring containing from 6 to 14 ring members, from 1 to 3 of which are nitrogen and the rest of which are carbon, wherein examples of said azabicyclic rings are the following:
Figure imgf000014_0001
wherein R3 and R4 are selected from hydrogen, (CrC6)alkyl, phenyl, naphthyl, (C C6)alkyl-C(=0)-, HC(=0)-, (C C6)alkoxy-(C=0)-, phenyl-C(=0)-, naphthyl-C(=0)-, and R7R8NC(=0)- wherein R7 and R8 are selected, independently, from hydrogen and (Cι-C6)alkyl;
R5 is selected from hydrogen, (d-C^alkyl, phenyl, naphthyl, phenyl-(C C6)alkyl- and naphthyl(C C6)alkyl-; and wherein said piperazine, piperidine and pyrrolidine rings may optionally be substituted with one or more substituents, preferably with from zero to two substituents that are selected, independently, from (Cι-C6)alkyl, amino, (CfC6) alkylamino, [di-(C1-C6)alkyl]amino, cyclohexyl, methanesulfonyl, phenoxyacetyl, furanylcarbonyl, trifluoromethylphenyl, phenoxyacetyl, benzenesulfonyl, isoquinolinyl, quinolinyl, hydroxyphenylethyl, aminophenylethyl, phenyl substituted 5 to 6 membered heterocyclic rings containing from 1 to 4 rings nitrogen atoms, benzoyl, aminoethyl, aminophenylpropionyl, cyclohexylaminocarbonyl, benzylaminocarbonylamino, morpholinocarbonyl, pyrrolidinocarbonyl, phenylthiazolyl, ethoxycarbonylmethyl, benzoylmethyl, benzylcarbonyl, benzylcarbonylamino, phenylaminocarbonyl, phenylethyl, phenylpropyl, benzhydryl, methylcarbonyl, methoxymethylcarbonyl, phenylaminopropanonyl, phenoxymethylcarbonyl, cyclopentylcarbonyl and phenoxycarbonyl, and wherein the phenyl moieties of any of the foregoing substituents may optionally be substituted with one or more substituents, preferably with from zero to two substituents, that are selected, independently, from halo, (C C3)alkyl, (C C3)alkoxy, nitro, amino, cyano, CF3 and OCF3; n is 0,1 or 2; m is 0,1 , or 2; each R8 and each R9 is selected, independently, from (d-C- alkyl, aryl-(C C4)alkyl wherein said aryl is selected from phenyl and naphthyl; allyl and phenallyl;
X and Y are selected, independently, from methyl, methoxy, hydroxy and hydrogen; and
R10 is hydrogen or (d-C6) alkyl; with the proviso that R8 is absent when N is zero and R9 is absent when m is zero. Examples of preferred compounds of the formula II are those wherein NR1R2 is:
4-phenoxycarbonylpiperazin-1 -yl;
4-(4-fluorophenylacetyl)piperazin-1-yl;
4-phenylethylpiperazin-1 -yl;
4-phenoxymethylcarbonylpiperazin-1-yl; 4-phenylaminocarbonylpiperazin-1-yl;
4-benzoylmethylpiperazin-1-yl; or
4-benzylcarbonylpiperazin-1 -yl.
Other preferred compounds of the formula II are those wherein NR R2 is a group of the formula
Figure imgf000015_0001
wherein NR3R4 is NH2.
Other preferred compounds of the formula II are those wherein NR1R2 is a group of the formula
Figure imgf000016_0001
Figure imgf000016_0002
wherein R5 is aralkyl, exj., benzyl, and R6 is (4-fluoro)phenylacetyl.
Specific preferred compounds of the formula II include:
1-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-ethanone; 1 -(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1 -yl)-2-methoxy-ethanone;
1-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-2-phenoxy-ethanone;
(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-cyclopentyl-methanone;
1-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-2-phenyl-ethanone;
3-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-3-aza-bicyclo[3.1.0]hex-6-ylamine; 2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1 -yl)-1 -phenyl-ethanone;
1-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-2-(4-fluoro-phenyl)- ethanone;
6-{4-[2-(4-Phenethyl-piperazin-1-yl)-ethyl]-phenyl}-pyridin-2-ylamine;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-1-phenyl-ethanol; {2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-(3-oxa-9-aza-bicyclo[3.3.1]non-7-yl)-amine;
6-(4-{2-[4-(2-Amino-2-phenyl-ethyl)-piperazin-1-yl]-ethyl}-phenyl)-pyridin-2-ylamine;
6-{4-[2-(4-Amino-2,6-dimethyl-piperidin-1-yl)-ethyl]-phenyl}-pyridin-2-ylamine;
6-{4-[2-(4-Methyl-piperazin-1-yl)-ethyl]-phenyl}-pyridin-2-ylamine;
(3-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-dimethyl-amine; 6-[4-(2-Amino-ethyl)-phenyl]-pyridin-2-ylamine;
6-{4-[2-(8-Aza-spiro[4.5]dec-8-yl)-ethyl]-phenyl}-pyridin-2-ylamine;
6-[4-[2-(4-lsobutyl-piperazin-1-yl)-ethyl]-phenyl}-pyridin-2-ylamine;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-N-isopropyl-acetamide;
4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazine-1 -carboxylic acid p-tolyl-amide; 6-(4-{2-[4-(3-Phenyl-propyl)-piperazin-1-yl]-ethyl}-phenyl)-pyridin-2-ylamine; 1-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-2-(4-chloro-phenyl)- ethanone;
8-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-3-benzyl-1 ,3,8-triaza-spiro[4.5]decane-2,4- dione; N-(1-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-pyrrolidin-3-yl)-2-(4-fluoro-phenyl)- acetamide;
8-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-ylamine; 3-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-3-aza-bicyclo[3.2.1]oct-8-ylamine; 2-Amino-1-(4-{2-[4-(6-amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-3-phenyl-propan-1- one;
6-{4-[2-(4-Amino-piperidin-1-yl)-ethyl]-phenyl}-pyridin-2-ylamine; 6-{4-[2-(4-Benzhydryl-piperazin-1-yl)-ethyl]-phenyl}-pyridin-2-ylamine; 6-{4-[2-(4-Benzhydryl-piperidin-1-yl)-ethyl]-phenyl}-pyridin-2-ylamine; 6-{4-[(Cyclohexyl-methyl-amino)-methyi]-phenyl}-pyridin-2-ylamine; 6-{4-[(Cyclohexyl-methyl-amino)-methyl]-2-methoxy-phenyl}-pyridin-2-ylamine;
6-[4-(Phenethylamino-methyl)-phenyl]-pyridin-2-ylamine; 6-[2-Methoxy-4-(phenethylamino-methyl)-phenyl]-pyridin-2-ylamine; 6-[4-(4-Amino-piperidin-1-ylmethyl)-phenyl}-pyridin-2-ylamine; 6-{4-[(Cyclohexyl-methyl-amino)-methyl]-2-fluoro-phenyl}-pyridin-2-ylamine; Other compounds of the formula II include:
1-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methoxy-phenyl]-ethyl}-piperazin-1-yl)-2-phenyl- ethanone;
6-{4-[2-(4-lsobutyl-piperazin-1-yl)-ethyl]-2-methoxy-phenyl}-pyridin-2-ylamine; 3-{2-[4-(6-Amino-pyridin-2-yl)-2-methoxy-phenyl]-ethyl}-3-aza-bicyclo[3.1.0]hex-6-ylamine; {2-[4-(6-Amino-pyridin-2-yl)-2-methoxy-phenyl]-ethyl}-(3-oxa-9-aza-bicyclo[3.3.1 ]non-7-yl)- amine;
6-(4-{2-[4-(2-Amino-2-phenyl-ethyl)-piperazin-1-yl]-ethyl}-2-methoxy-phenyl)-pyridin-2- ylamine;
6-{4-[2-(4-Amino-2-methoxy-piperidin-1-yl)-ethyl]-2-methoxy-phenyl}-pyridin-2-ylamine; 2-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methoxy-phenyl]-ethyl}-piperazin-1-yl)-N-isopropyl- acetamide;
6-[4-(4-Amino-piperidin-1-ylmethyl)-2-methoxy-phenyl}-pyridin-2-ylamine; 1-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methyl-phenyl]-ethyl}-piperazin-1-yl)-2-phenyl- ethanone; 6-{4-[2-(4-lsobutyl-piperazin-1-yl)-ethyl]-2-methyl-phenyl}-pyridin-2-ylamine;
3-{2-[4-(6-Amino-pyridin-2-yl)-2-methyl-phenyl]-ethyl}-3-aza-bicyclo[3.1.0]hex-6-ylamine; 2-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methyl-phenyl]-ethyl}-piperazin-1-yl)-1-phenyl- ethanone; 1-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methyl-phenyl]-ethyl}-piperazin-1-yl)-2-(4-fluoro- phenyl)-ethanone;
6-{4-[2-(4-Phenethyl-piperazin-1-yl)-ethyl]-2-methyl-phenyl}-pyridin-2-ylamine;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methyl-phenyl]-ethyl}-piperazin-1-yl)-1-phenyl-ethanol; {2-[4-(6-Amino-pyridin-2-yl)-2-methyl-phenyl]-ethyl}-(3-oxa-9-aza-bicyclo[3.3.1]non-7-yl)- amine;
6-(4-{2-[4-(2-Amino-2-phenyl-ethyl)-piperazin-1-yl]-ethyl}-2-methyl-phenyl)-pyridin-2- ylamine;
6-{4-[2-(4-Amino-2,6-dimethyl-piperidin-1-yl)-ethyl]-2-methyl-phenyl}-pyridin-2-ylamine; 2-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methyl-phenyl]-ethyl}-piperazin-1-yl)-N-isopropyl- acetamide;
6-[4-(4-Amino-piperidin-1-ylmethyl)-2-methyl-phenyl}-pyridin-2-ylamine;
N-(1-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-pyrrolidin-3-yl)-2-phenyl-acetamide;
N-(1-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-pyrrolidin-3-yl)-2-(3-trifluoromethylphenyl)- acetamide;
N-(1-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-pyrrolidin-3-yl)-2-(4-tolyl)-acetamide;
N-(1-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-pyrrolidin-3-yl)-2-(4-methoxyphenyl)- acetamide;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methoxy-phenyl]-ethyl}-piperazin-1-yl)-1-phenyl- ethanone;
1-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methoxy-phenyl]-ethyl}-piperazin-1-yl)-2-(4-fluoro- phenyl)-ethanone;
N-(1-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-pyrrolidin-3-yl)-2-cyclohexyl-acetamide;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-1-(4-tolyl)-ethanone; 2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-1-(4-methoxyphenyl)- ethanone;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-1-(4-chlorophenyl)- ethanone;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-1-(4-fluorophenyl)-ethanone; 2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1 -yl)-1 -cyclohexyl-ethanone;
1-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-fluoro-phenyl]-ethyl}-piperazin-1-yl)-2-phenyl-ethanone;
6-{4-[2-(4-lsobutyl-piperazin-1-yl)-ethyl]-2-fluoro-phenyl}-pyridin-2-ylamine;
3-{2-[4-(6-Amino-pyridin-2-yl)-2-fluoro-phenyl]-ethyl}-3-aza-bicyclo[3.1.0]hex-6-ylamine;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-fluoro-phenyl]-ethyl}-piperazin-1-yl)-1-phenyi-ethanone; 1 -(4-{2-[4-(6-Amino-pyridin-2-yl)-2-fluoro-phenyl]-ethyl}-piperazin-1 -yl)-2-(4-fluoro-phenyl)- ethanone;
6-{4-[2-(4-Phenethyl-piperazin-1-yl)-ethyl]-2-fluoro-phenyl}-pyridin-2-ylamine;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-fluoro-phenyl]-ethyl}-piperazin-1-yl)-1-phenyl-ethanol; {2-[4-(6-Amino-pyridin-2-yl)-2-fluoro-phenyl]-ethyl}-(3-oxa-9-aza-bicyclo[3.3.1]non-7-yl)- amine;
6-(4-{2-[4-(2-Amino-2-phenyl-ethyl)-piperazin-1-yl]-ethyl}-2-fluoro-phenyl)-pyridin-2- ylamine; 6-{4-[2-(4-Amino-2-fluoro-piperidin-1-yl)-ethyl]-2-fluoro-phenyl}-pyridin-2-ylamine;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-fluoro-phenyl]-ethyl}-piperazin-1-yl)-N-isopropyl- acetamide;
6-[4-(4-Amino-piperidin-1-ylmethyl)-2-fluoro-phenyl}-pyridin-2-ylamine;
6-{4-[2-(4-Amino-2,6-diethyl-piperidin-1-yl)-ethyl]-phenyl}-pyridin-2-ylamine; 6-{4-[2-(4-Amino-2,6-dibenzyl-piperidin-1-yl)-ethyl]-phenyl}-pyridin-2-ylamine;
{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-(9-(4-fluoro)-ben--yl-3-oxa-9-aza- bicyclo[3.3.1]non-7-yl)-amine;
{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-(9-(4-chloro)-benzyl-3-oxa-9-aza- bicyclo[3.3.1]non-7-yl)-amine; {2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-(9-(4-methyl)-benzyl-3-oxa-9-aza- bicyclo[3.3.1 ]non-7-yl)-amine; and
{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-(9-(4-methoxy)-benzyl-3-oxa-9-aza- bicyclo[3.3.1 ]non-7-yl)-amine.
Other examples of NOS inhibiting compounds that can be used in the methods and pharmaceutical compositions of this invention are compounds of the formula
Figure imgf000019_0001
wherein X is CHOH, CH2, or CHR10 wherein R10, together with X, the CH2 group adjacent to X and the nitrogen of NR1R2, forms a five or six membered saturated ring;
R1, R2, R3 and R4 are selected, independently, from hydrogen (d-C6) alkyl, tetrahydronaphthalene, aryl and aralkyl, wherein said aryl and the aryl moiety of said aralkyl is phenyl or naphthyl and the alkyl moiety is straight or branched and contains from 1 to 6 carbon atoms, and wherein said (d-d.) alkyl and said tetrahydronaphthalene and the aryl moiety of said aralkyl may optionally be substituted with from one to three substituents, preferably from zero to two substituents, that are selected, independently, from halo (e.g., chloro, fluoro, bromo, iodo), nitro, hydroxy, cyano, amino, (d-C4) alkoxy, and (d-d) alkylamino; or R1 and R2, together with the nitrogen to which they are attached, form a piperazine, piperidine or pyrrolidine ring or an azabicyclic ring containing from 6 to 14 ring members, from 1 to 3 of which are nitrogen and the rest of which are carbon, wherein examples of said azabicyclic rings are the following
Figure imgf000020_0001
wherein R5 and R6 are selected from hydrogen, (d-C6)alkyl, phenyl, naphthyl, (d- C6)alkyl-C(=0)-, HC(=0)-, (d-C6)alkoxy-(C=0)-, phenyl-C(=0)-, naphthyl-C(=0)-, and R8R9NC(=0)- wherein R8 and R9 are selected, independently, from hydrogen and (d-C6)alkyl;
R7 is selected from hydrogen, (C1-C6)alkyl, phenyl, naphthyl, phenyl-(d-C6)alkyl- and naphthyl(d-C6)alkyl-; and wherein said piperazine, piperidine and pyrrolidine rings may optionally be substituted with one or more substituents, preferably with from zero to two substituents that are selected, independently, from (C1-C6)alkyl, amino, (C C6) alkylamino, [di-(d-C6)alkyl]amino, phenyl substituted 5 to 6 membered heterocyclic rings containing from 1 to 4 rings nitrogen atoms, benzoyl, benzoylmethyl, benzylcarbonyl, phenylaminocarbonyl, phenylethyl and phenoxycarbonyl, and wherein the phenyl moieties of any of the foregoing substituents may optionally be substituted with one or more substituents, preferably with from zero to two substituents, that are selected, independently, from halo, (d-C3)alkyl, (d-C3)alkoxy, nitro, amino, cyano, CF3 and OCF3; and wherein R3 and R4, together with the carbon to which they are attached, form an optionally substituted carbocyclic ring of from 3 to 8 members; and the pharmaceutically acceptable salts of such compounds. More specific embodiments of compounds of the formula III include: (a) compounds of the formula III wherein R1, R2, R3 and R4 are selected, independently, from (d-C6)alkyl; (b) compounds of the formula III wherein R3 and R4 are selected, independently, from (Cι-C6)alkyl, and R1 and R2, together with the nitrogen to which they are attached, form a ring;
(c) compounds of the formula III wherein one of R1 and R2 is selected from (d- C6)alkyl, and the other is selected from phenyl or phenyl-(Cι-C6)alkyl;
(d) compounds of the formula III wherein R1 and R2, together with the nitrogen to which they are attached, form a piperazine, piperidine or pyrrolidine ring; and
(e) compounds of the formula III wherein R and R2 are selected, independently from (Cι-C6)alkyl, and R3 and R4, together with the carbon to which they are attached, form a ring.
Examples of preferred compounds of the formula III are:
6-[2-lsopropoxy-4-((4-phenethylpiperazin-1-yl)-ethyl)-phenyl]-pyridin-2-ylamine;
6-[2-lsobutoxy-4-((4-phenethylpiperazin-1-yl)-ethyl)-phenyl]-pyridin-2-ylamine;
6-[2-lsobutoxy-4-((4-dimethylaminoethyl)-phenyl]-pyridin-2-ylamine; 6-[2-lsopropoxy-(N-(2-methyl)propyl)-4-(pyrrolidin-3-yl)-phenyl]-pyridin-2-ylamine;
1-[4-(6-Amino-pyridin-2-yl)-3-isopropoxy-phenyl]-2-(4-phenethyl-piperazin-1-yl)-ethanol;
6-[2-Cyclopentyloxy-4-((4-dimethylaminoethyl)-phenyl]-pyridin-2-ylamine;
6-[2-Cyclopentyloxy-4-((4-phenethylpiperazin-1-yl)-ethyl)-phenyl]-pyridin-2-ylamine; and the pharmaceutically acceptable salts of the foregoing compounds. Other examples of specific compounds of the formula III are:
6-[2-Cyclohexyloxy-4-((4-phenethylpiperazin-1-yl)-ethyl)-phenyl]-pyridin-2-ylamine;
6-[2-Cyclobutyloxy-4-((4-phenethylpiperazin-1-yl)-ethyl)-phenyl]-pyridin-2-ylamine;
6-[2-Cyclopropyloxy-4-((4-phenethylpiperazin-1-yl)-ethyl)-phenyl]-pyridin-2-ylamine;
6-[2-lsopentyloxy-4-((4-phenethylpiperazin-1-yl)-ethyl)-phenyl]-pyridin-2-ylamine; 6-[2-lsohexyloxy-4-((4-phenethylpiperazin-1-yl)-ethyl)-phenyl]-pyridin-2-ylamine;
6-[2-Cyclopentyloxy-(N-(2-methyl)propyl)-4-(pyrrolidin-3-yl)-phenyl]-pyridin-2-ylamine;
6-[2-Cyclohexyloxy-(N-(2-methyl)propyl)-4-(pyrrolidin-3-yl)-phenyl]-pyridin-2-ylamine;
6-[2-Cyclobutyloxy-(N-(2-methyl)propyl)-4-(pyrrolidin-3-yl)-phenyl]-pyridin-2-ylamine;
6-[2-Cyclopropyloxy-(N-(2-methyl)propyl)-4-(pyrrolidin-3-yl)-phenyl]-pyridin-2-ylamine; 6-[2- Isopentyloxy -(N-(2-methyl)propyl)-4-(pyrrolidin-3-yl)-phenyl]-pyridin-2-ylamine;
6-[2-lsohexyloxy -(N-(2-methyl)propyl)-4-(pyrrolidin-3-yl)-phenyl]-pyridin-2-ylamine;
1-[4-(6-Amino-pyridin-2-yl)-3-isobutoxy-phenyl]-2-(4-phenethyl-piperazin-1-yl)-ethanol;
1-[4-(6-Amino-pyridin-2-yl)-3-isopropoxy-phenyl]-2-(6,7-dimethoxy-tetrahydroisoquinol- 2-yl)-ethanol; 1-[4-(6-Amino-pyridin-2-yl)-3-isopropoxy-phenyl]-2-(4-dimethylamino-pi peridin-1-yl)- ethanol;
1-[4-(6-Amino-pyridin-2-yl)-3-isopropoxy-phenyl]-2-(dimethylamino)-ethanol; and 1-[4-(6-Amino-pyridin-2-yl)-3-cyclopenyloxy-phenyl]-2-(4-phenethyl-piperazin-1-yl)- ethanol; and the pharmaceutically acceptable salts of the foregoing compounds. Other examples of NOS inhibiting compounds that can be used in the methods and pharmaceutical compositions of this invention are compounds of the formula
Figure imgf000022_0001
wherein R1 and R2 are selected, independently, from hydrogen, halo, hydroxy, ( d-C6)alkoxy, (d-C7)alkyl, (C2-C6)alkenyl, and (C2 - C10)alkoxyalkyl; and G is selected from hydrogen, (d-C6)alkyl, (d-C6)alkoxy-(C--C3)alkyl, aminocarbonyl-(Cι-
C3)alkyl-, (d-C3) alkylaminocarbonyl -(C C3) alkyl-, di-Kd-C^alkyljaminocarbony d-C^alkyl-, and N(R3)(R4)(C0-C4)alkyl-, wherein R3 and R4 are selected, independently, from hydrogen, (d-C ) alkyl, tetrahydronaphthalene and aralkyl, wherein the aryl moiety of said aralkyl is phenyl or naphthyl and the alkyl moiety is straight or branched and contains from 1 to 6 carbon atoms, and wherein said (d-C7) alkyl and said tetrahydronaphthalene and the aryl moiety of said aralkyl may optionally be substituted with from one to three substituents, preferably from zero to two substituents, that are selected, independently, from halo, nitro, hydroxy, cyano, amino, (d-C4) alkoxy, and (d-C ) alkylamino; or R3 and R4 form, together with the nitrogen to which they are attached, a piperazine, piperidine, azetidine or pyrrolidine ring or a saturated or unsaturated azabicyclic ring system containing from 6 to 14 ring members, from 1 to 3 of which are nitrogen, from zero to two of which are oxygen, and the rest of which are carbon; and wherein said piperazine, piperidine, azetidine and pyrrolidine rings and said azabicyclic ring systems may optionally be substituted with one or more substituents, preferably with from zero to two substituents, that are selected, independently, from (d-C6)alkyl, amino, (C C6) alkylamino, [di-(Cι-C6)alkyl]amino, phenyl substituted 5 to 6 membered heterocyclic rings containing from 1 to 4 ring nitrogen atoms, benzoyl, benzoylmethyl, benzylcarbonyl, phenylaminocarbonyl, phenylethyl and phenoxycarbonyl, and wherein the phenyl moieties of any of the foregoing substituents may optionally be substituted with one or more substituents, preferably with from zero to two substituents, that are selected, independently, from halo, (d-C3)alkyl, (Ci- C3)alkoxy, nitro, amino, cyano, CF3 and OCF3; and wherein said piperazine, piperidine, azetidine and pyrrolidine rings and said azabicyclic ring systems may be attached to -(C0-C )alkyl-O- (wherein the oxygen of said -(C0- 3D4
C )alkyl-0- is the oxygen atom depicted in structural formula I) at a nitrogen atom of the NR R' ring or at any other atom of such ring having an available bonding site; or G is a group of the formula A
Figure imgf000023_0001
wherein Z is nitrogen or CH, n is zero or one, q is zero, one, two or three and p is zero, one or two; and wherein the 2-amino piperidine ring depicted in structure I above may optionally be replaced with
Figure imgf000023_0002
and the pharmaceutically acceptable salts of such compounds.
Examples of compounds of the formula IV are those wherein G is N(R3)(R )(C0-C4) alkyl and N(R3)(R4) is amino, dimethylamino, methylbenzylamino, (d-C4)alkylamino, di-[(d- C4)alkyl]amino or one of the following groups:
Figure imgf000024_0001
Figure imgf000025_0001
Preferred compounds of the formula IV include those wherein R2 is hydrogen and R is (d - C3)alkoxy and is in the ortho position relative to the pyridine ring of formula IV.
Other compounds of the formula IV are those wherein G is a group of the formula A, as defined above, wherein Z is nitrogen.
Other compounds of the formula IV are those wherein R1 and R2 are selected, independently, from (d-C2)alkoxy.
Other compounds of the formula IV are those wherein G is a group of the formula A, as defined above, wherein Z is nitrogen, each of p and n is one and q is two. Other compounds of the formula IV are those wherein the 2-aminopyridine ring depicted in formula IV above is present.
Examples of preferred compounds of the formula IV are:
6-[4-(2-dimethylamino-ethoxy)-2-methoxy-phenyl]-pyridin-2-ylamine;
6-[4-(2-dimethylamino-ethoxy)-2,3-dimethyl-phenyl]-pyridin-2-ylamine; 6-[4-(2-dimethylamino-ethoxy)-3-methoxy-phenyl]-pyridin-2-ylamine;
6-[4-(2-dimethylamino-ethoxy)-3-ethoxy-phenyl]-pyridin-2-ylamine;
6-[4-(2-dimethylamino-ethoxy)-2-isopropyl-phenyl]-pyridin-2-ylamine;
6-[2-cyclopropyl-4-(2-dimethylamino-ethoxy)-phenyl]-pyridin-2-ylamine;
6-[2-cyclobutyl-4-(2-dimethylamino-ethoxy)-phenyl]-pyridin-2-ylamine; 6-[2-cyclopentyl-4-(2-dimethylamino-ethoxy)-phenyl]-pyridin-2-ylamine;
6-[4-(2-dimethylamino-ethoxy)-2-methoxy-5-propyl-phenyl]-pyridinylamine;
6- [4-(1-methylazetin-3-yloxy)-2-methoxy-5-ethyl-phenyl]-pyridin-2-ylamine
2-(6-amino-pyridin-2-yl)-5-(2-dimethylamino-ethoxy)-phenol;
6-[4-(2-dimethylamino-ethoxy)-2-propoxy-phenyl]-pyridin-2-ylamine; 6-[4-(2-dimethylamino-ethoxy)-2-isopropoxy-phenyl]-pyridin-2-ylamine; 6-[4-(2-dimethylamino-ethoxy)-2-ethoxy-phenyl]-pyridin-2-ylamine; 6-[4-(2-dimethylamino-ethoxy)-2-methoxy-5-propyl-phenyl]-pyridin-2-ylamine; 6-[5-allyl-4-(2-dimethylamino-ethoxy)-2-methoxy-phenyl]-pyridin-2-ylamine; 6-[3-allyl-4-(2-dimethylamino-ethoxy)-2-methoxy-phenyl]-pyridin-2-ylamine;
6-[4-(2-dimethylamino-ethoxy)-2,6-dimethyl-phenyl]-pyridin-2-ylamine; 6-[4-(2-dimethylamino-ethoxy)-2-isopropyl-phenyl]-pyridin-2-ylamine; and 6-[2-tert-butyl-4-(2-dimethylamino-ethoxy)-phenyl]-pyridin-2-ylamine.
Other examples of specific compounds of the formula IV are: 4-(6-amino-pyridin-2-yl)-3-methoxyphenol;
6-[4-(2-pyrrolidinyl-ethoxy)-2,3-dimethyl-phenyl]-pyridin-2-ylamine;
6-[4-(4-(N-methyl)piperidinyloxy)-2,3-dimethyl-phenyl]-pyridin-2-ylamine;
6-[4-(2-pyrrolidinyl-ethoxy)-3-methoxy-phenyl]-pyridin-2-ylamine;
6-{4-[2-(6,7-dimethoxy-3,4-dihydro-1 h-isoquinolin-2-yl)-ethoxy]-3-methoxy-phenyl}- pyridin-2-yiamine;
6-{3-methoxy-4-[2-(4-phenethyl-piperazin-1-yl)-ethoxy]-phenyl}-pyridin-2-ylamine;
6-{3-methoxy-4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenyl}-pyridin-2-yiamine;
6-{4-[2-(4-dimethylamino-piperidin-1-yl)-ethoxy]-3-methoxy-phenyl}-pyridin-2-ylamine;
6-[4-(2-pyrrolidinyl-ethoxy)-3-ethoxy-phenyl]-pyridin-2-ylamine; 4-(6-amino-pyridin-yl)-3-cyclopropyl-phenol;
6-[2-cyclopropyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-ylamine;
3-[3-(6-amino-pyridin-2yl)-4-cyclopropyl-phenoxy] -pyrrolidine-1 -carboxylic acid tert-butyl ester;
6-[2-cyclopropyl-4-(1-methyl-pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine; 4-(6-amino-pyridin-2-yl)-3-cyclobutyl-phenol;
6-[2-cyclobutyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-ylamine;
6-[2-cyclobutyl-4-(1-methyl-pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
4-(6-amino-pyridin-2-yl)-3-cyclopentyl-phenoI;
6-[2-cyclopentyl-4-(2-pyrrolidin-1yl-ethoxy)-phenyl]-pyridin-2-ylamine; 3-[4-(6-amino-pyridin-2yl)-3-methoxy-phenoxy]-pyrrolidine-1 -carboxylic acid tert butyl ester;
6-[4-(1-methyl-pyrrolidin-3-yloxy)-2-methoxy-phenyl]-pyridin-2-ylamine;
4-[4-(6-amino-pyridin-2yl)-3-methoxy-phenoxy]-piperidine-1 -carboxylic acid tert butyl ester; 6-[2-methoxy-4-(1-methyl-piperidin-4-yloxy)-phenyl]-pyridin-2-ylamine;
6-[4-(allyloxy)-2-methoxy-phenyl]-pyridin-2-ylamine;
4-(6-amino-pyridin-2-yl)-3-methoxy-6-allyl-phenol; 4-(6-amino-pyridin-2-yl)-3-methoxy-2-allyl-phenol;
4-(6-amino-pyridin-2-yl)-3-methoxy-6-propyl-phenor,
6-[2-isopropyl-4-(pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropyl- -(piperidin-3-yloxy)-phenyl]-pyridin-2-ylamine; 6-[2-isopropyl-4-(1-methyl-azetidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropyl-4-(1-methyl-piperidin-4-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropyl-4-(1-methyl-pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropyl-4-(1-methyl-pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropyl-4-(2-methyl-2-aza-bicyclo[2.2.1]hept-5-yloxy)-phenyl]-pyridin-2-ylamine; 6-[4-(2-dimethylamino-ethoxy)-2-methoxy-phenyl]-pyridin-2-ylamine;
6-{4-[2-(benzyl-methyl-amino)-ethoxy]-2-methoxy-phenyl}-pyridin-2-ylamine;
6-[2-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-ylamine;
2-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-acetamide;
6-[4-(2-amino-ethoxy)-2-methoxy-phenyl]-pyridin-2-ylamine; 6-{4-[2-(3,4-dihydro-1 h-isoquinolin-2-yl)-ethoxy]-2-methoxy-phenyl}-pyridin-2-ylamine;
2-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-ethanol;
6-{2-methoxy-4-[2-(2,2,6,6-tetramethyl-piperidin-1-yl)-ethoxy]-phenyl}-pyridin-2-ylamine;
6-{4-[2-(2,5-dimethyl-pyrrolidin-1-yl)-ethoxy]-2-methoxy-phenyl}-pyridin-2-ylamine;
6-{4-[2-(2,5-dimethyl-pyrrolidin-1-yl)-ethoxy]-2-methoxy-phenyl}-pyridin-2-ylamine; 2-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-1 -(2,2,6, 6-tetramethyl-piperidin-1 -yl)- ethanone;
6-[2-methoxy-4-(1-methyl-pyrrolidin-2-ylmethoxy)-phenyl]-pyridin-2-ylamine;
6-{4-[2-(benzyl-methyl-amino)-ethoxy]-2-propoxy-phenyl}-pyridin-2-ylamine;
6-[4-(2-ethoxy-ethoxy)-2-methoxy-phenyl]-pyridin-2-ylamine; 6-[4-(2-ethoxy-ethoxy)-2-isopropoxy-phenyl]-pyridin-2-ylamine;
6-[2-methoxy-4-(3-methyl-butoxy)-phenyl]-pyridin-2-ylamine;
6-{4-[2-(benzyl-methyl-amino)-ethoxy]-2-ethoxy-phenyl}-pyridin-2-ylamine;
6-[2-ethoxy-4-(3-methyl-butoxy)-phenyl]-pyridin-2-ylamine;
1-(6-amino-3-aza-bicyclo[3.1.0]hex-3-yl)-2-[4-(6-amino-pyridin-2-yl)-3-ethoxy-phenoxy]- ethanone;
6-[2-ethoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-ylamine;
3-{2-[4-(6-amino-pyridin-2-yl)-3-ethoxy-phenoxy]-ethyl}-3-aza-bicyclo[3.1.0]hex-6- ylamine;
1-(6-amino-3-aza-bicyclo[3.1.0]hex-3-yl)-2-[4-(6-amino-pyridin-2-yl)-3-methoxy- phenoxyj-ethanone;
3-{2-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-ethyl}-3-aza-bicyclo[3.1.0]hex-6- ylamine;
6-[2-isopropoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-ylamine; -
6-{4-[2-(benzyl-methyl-amino)-ethoxy]-2-isopropoxy-phenyl}-pyridin-2-ylamine;
6-[5-allyl-2-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-ylamine;
6-[2-methoxy-4-(pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-methoxy-4-(1-methyl-pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine; 6-[2-ethoxy-4-(pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropoxy-4-(pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-methoxy-4-(piperidin-4-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-methoxy-4-(2,2,6,6-tetramethyl-piperidin-4-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropoxy-4-(pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine; 3-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxyj-azetidine-1 -carboxylic acid tert-butyl ester;
6-[4-(azetidin-3-yloxy)-2-methoxy-phenyl]-pyridin-2-ylamine;
6-[2-methoxy-4-(1-methyl-azetidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropoxy-4-(pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine; 6-[2-isopropoxy-4-(pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-methoxy-4-(pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-methoxy-4-(1-methyl-pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-methoxy-4-(1-methyl-pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-methoxy-4-(2-methyl-2-aza-bicyclo[2.2.1]hept-5-yloxy)-phenyl]-pyridin-2-ylamine; 6-[2-methoxy-4-(1-methyl-piperidin-4-yloxy)-phenyl]-pyridin-2-ylamine;
6-[4-(1-ethyl-piperidin-4-yloxy)-2-methoxy-phenyl]-pyridin-2-ylamine;
6-[5-allyl-2-methoxy-4-(1-methyl-pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2,6-dimethyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-pyridin-2-ylamine;
6-[2,6-dimethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-ylamine; 6-{2,6-dimethyl-4-[3-(4-methyl-piperazin-1-yl)-propoxy]-phenyl}-pyridin-2-ylamine;
6-[2,6-dimethyl-4-(2-morpholin-4-yl-ethoxy)-phenyl]-pyridin-2-ylamine;
6-{4-[2-(benzyl-methyl-amino)-ethoxy]-2,6-dimethyl-phenyl}-pyridin-2-ylamine;
2-[4-(6-amino-pyridin-2-yl)-3,5-dimethyl-phenoxy]-acetamide;
6-[4-(2-amino-ethoxy)-2,6-dimethyl-phenyl]-pyridin-2-ylamine; 6-[2-isopropyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyI]-pyridin-2-ylamine;
2-(2,5-dimethyl-pyrrolidin-1-yl)-6-[2-isopropyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]- py rid ine;
6-{4-[2-(3,5-dimethyl-piperidin-1-yl)-ethoxy]-2-isopropyl-phenyl}-pyridin-2-ylamine; and
6-[2-tert-butyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-ylamine. Other examples of NOS inhibitors that can be used in the methods and pharmaceutical compositions of this invention are compounds of the formula
Figure imgf000029_0001
wherein R1 and R2 are selected, independently, from hydrogen, hydroxy, methyl and methoxy; and G is a group of the formula
Figure imgf000029_0002
(A) (B) wherein n is zero or one;
Y is NR3R4, (d-C6)alkyl or aralkyl, wherein the aryl moiety of said aralkyl is phenyl or naphthyl and the alkyl moiety is straight or branched and contains from 1 to 6 carbon atoms, and wherein said (C C6)alkyl and the aryl moiety of said aralkyl may be substituted with from one to three substituents, preferably from zero to two substituents, that are selected, independently, from halo (e.g., chloro, fluoro, bromo or iodo), nitro, hydroxy, cyano, amino, (d-C4)alkoxy and (d-C4) alkylamino;
X is N when Y is (d-C6) alkyl, aralkyl, or substituted (d-C6)alkyl, and X is CH when Y is NR3R4; q is zero, one or two; m is zero, one or two; and
R3 and R4 are selected, independently, from (C C6) alkyl, tetrahydronaphthalene and aralkyl, wherein the aryl moiety of said aralkyl is phenyl or naphthyl and the alkyl moiety is straight or branched and contains from 1 to 6 carbon atoms, and wherein said (d-C6) alkyl and said tetrahydronaphthalene and the aryl moiety of said aralkyl may optionally be substituted with from one to three substituents, preferably from zero to two substituents, that are selected, independently, from halo (e.g., chloro, fluoro, bromo or iodo), nitro, hydroxy, cyano, amino, (d-C ) alkoxy, and (d-C ) alkylamino; or R3 and R4 form, together with the nitrogen to which they are attached, a piperazine, piperidine or pyrrolidine ring or an azabicyclic ring containing from 6 to 14 ring members, from 1 to 3 of which are nitrogen and the rest of which are carbon, wherein an example of said azabicyclic rings is the 3-aza-bicyclo[3.1.0]hex-6-ylamine ring; . -
and wherein said piperazine, piperidine and pyrrolidine rings may optionally be substituted with one or more substituents, preferably with from zero to two substituents, that are selected, independently, from amino, (C C6) alkylamino, [di-(d-C6)alkyl]amino, phenyl substituted 5 to 6 membered heterocyclic rings containing from 1 to 4 rings nitrogen atoms, benzoyl, benzoylmethyl, benzylcarbonyl, phenylaminocarbonyl, phenylethyl and phenoxycarbonyl, and wherein the phenyl moieties of any of the foregoing substituents may optionally be substituted with one or more substituents, preferably with from zero to two substituents, that are selected, independently, from halo, (d-C3)alkyl, (d-C3)alkoxy, nitro, amino, cyano, CF3 and OCF3; and the pharmaceutically acceptable salts of such compounds. Examples of preferred compounds of the formula V are those wherein NR3R4 is:
4-phenylethylpiperazin-1 -yl;
4-methylpiperazin-1 -yl; phenethylamino; or
3-aza-bicyclo[3.1.0]hex-6-ylamine. Other preferred compounds of the formula V are those wherein NR3R4 is a group of the formula
Figure imgf000030_0001
wherein NR5R6 is NH,
Specific preferred compounds of formula V include: 3-{2-[4'-(6-Amino-pyridin-2-yl)-biphenyl-4-yl]-ethyl}-3-aza-bicyclo[3.1.0]hex-6-ylamine;
6-[4'-(4-Phenethyl-piperazin-1-ylmethyl)-biphenyl-4-yl]-pyridin-2-ylamine;
3-[4'-(6-Amino-pyridin-2-yl)-biphenyl-4-ylmethyl]-3-aza-bicyclo[3.1.0]hex-6-ylamine;
3-[4'-(6-Amino-pyridin-2-yl)-biphenyl-3-ylmethyl]-3-aza-bicyclo[3.1.0]hex-6-ylamine;
2-Amino-N-[4'-(6-amino-pyridin-2-yl)-biphenyl-3-yl]-propionamide; 2-Amino-N-[4'-(6-amino-pyridin-2-yl)-biphenyl-3-yl]-3-phenyl-propionamide;
6-[4-(1-Benzyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-pyridin-2-ylamine;
6-[4-(1-Benzyl-piperidin-3-yl)-phenyl]-pyridin-2-ylamine;
6-[4-(1-Benzyl-piperidin-2-ylmethyl)-phenyl]-pyridin-2-ylamine;
6-{4-[1-(2,2-Diphenyl-ethyl)-piperidin-2-ylmethyl]-phenyl}-pyridin-2-ylamine; 6-[3-(2-Dimethylamino-cyclopentylmethyl)-phenyl]-pyridin-2-ylamine;
6-[3-(2-(4-Methylpiperazin-1-yl)-cyclopentylmethyl)-phenyl]-pyridin-2-ylamine;
6-[4-(Piperidin-4-yl)-phenyl]-pyridin-2-ylamine;
Figure imgf000031_0001
LO o LO o LΩ
CN CN CO CO
8-[4-(6-Amino-pyridin-2-yl)-phenyl]-3-isobutyl-3-aza-bicyclo[3.2.1]octan-8-ol; 8-[4-(6-Amino-pyridin-2-yl)-phenyl]-3-furan-2-ylmethyl-3-aza-bicyclo[3.2.1]octan-8-ol; and
8-[4-(6-Amino-pyridin-2-yl)-phenyl]-3-benzyl-3-aza-bicyclo[3.2.1]octan-8-ol.
Other examples of NOS inhibitors that can be employed in the methods and pharmaceutical composition of this invention are compounds of the formula
Figure imgf000032_0001
wherein n and m in the bridging rings are independently 1 , 2 or 3, and a carbon in one of said bridging rings may be substituted by a heteroatom selected from O, S and N, with the proviso that a bridgehead carbon can only be substituted by nitrogen, and R1 and R2 are independently selected from Ci to C6 alkyl, which may be linear, branched or cyclic or contain both linear and cyclic or branched and cyclic moieties, wherein each of R1 and R2 may be independently optionally substituted with from one to three substituents, preferably from zero to two substituents, that are selected, independently, from halo (e.g., chloro, fluoro, bromo, iodo), nitro, hydroxy, cyano, amino, (d-d) alkoxy, and (d-C ) alkylamino; or R1 and R2 form, together with the nitrogen to which they are attached, a piperazine, azetidine, piperidine or pyrrolidine ring or an azabicyclic ring containing from 6 to 14 ring members, from 1 to 3 of which are nitrogen and the rest of which are carbon, wherein the distal nitrogen on said piperazine or azabicyclic ring is optionally substituted with groups R3 and R4 wherein R3 and R4 are selected from hydrogen, Ci to C6 alkyl, phenyl, naphthyl, d to C6 alkyl-C(=0)-, HC(=0)-, d to C6 alkoxy-(C=0)-, phenyl-C(=0)-, naphthyl-C(=0)-, and R6R7NC(=0)- wherein R6 and R7 are selected, independently, from hydrogen and Ci to C6 alkyl, with the proviso that when said azabicyclic ring is a spirocyclic ring, the distal nitrogen on said spirocyclic ring is optionally substituted with R5 wherein R5 is selected from hydrogen, C1 to C6 alkyl, phenyl, naphthyl, phenyl-d to C6 alkyl- and naphthyl d to C6 alkyl-; and wherein said piperazine, azetidine, piperidine and pyrrolidine rings may optionally be substituted with one or more substituents, preferably with from zero to two substituents that are selected, independently, from d to C6 alkyl, amino, d to C6 alkylamino, [di-C C6 alkyljamino, phenyl substituted 5 to 6 membered heterocyclic rings containing from 1 to 4 rings nitrogen atoms, benzoyl, benzoylmethyl, benzylcarbonyl, phenylaminocarbonyl, phenylethyl and phenoxycarbonyl, and wherein the phenyl moieties of any of the foregoing substituents may optionally be substituted with one or more substituents, preferably with from zero to two substituents, that are selected, independently, from halo, d to C3 alkyl, Ci to C3 alkoxy, nitro, amino, cyano, CF3 and OCF3; with the proviso that no carbon atom is substituted with more than one substituent selected from hydroxy, amino, alkoxy, alkylamino and dialkylamino; and the pharmaceutically acceptable salts of said compounds.
Examples of the azabicyclic rings that may be formed by NR1R2 in the above compounds of formula VI are
Figure imgf000033_0001
Figure imgf000033_0002
and
Figure imgf000033_0003
wherein R3 and R4 are selected from hydrogen, d to C6 alkyl, phenyl, naphthyl, d to C6 alkyl-C(=0)-, HC(=0)-, C^ to C6 alkoxy-(C=0)-, phenyl-C(=0)-, naphthyl-C(=0)-, and R6R7NC(=0)- wherein R6 and R7 are selected, independently, from hydrogen and Ci to C6 alkyl; and
R5 is selected from hydrogen, d to C6 alkyl, phenyl, naphthyl, phenyl-d to C6 alkyl- and naphthyl d to C6 alkyl-.
Preferred compounds of the formula IV include those wherein NR1R2 is an optionally substituted piperidine, azetidine, piperazine or pyrrolidine ring or a 3-aza-bicyclo[3.1.0]hex-6- ylamine ring; and wherein said piperazine, azetidine, piperidine, pyrrolidine and 3-aza-bicyclo[3.1.0]hex- 6-ylamine rings may optionally be substituted with one or more substituents, preferably with from zero to two substituents that are selected, independently, from d to C6 alkyl, amino, d to C6 alkylamino, [di-d to C6 alkyljamino, phenyl, substituted 5 to 6 membered heterocyclic rings containing from 1 to 4 rings nitrogen atoms, benzoyl, benzoylmethyl, benzylcarbonyl, phenylaminocarbonyl, phenylethyl and phenoxycarbonyl, and wherein the phenyl moieties of any of the foregoing substituents may optionally be substituted with one or more substituents, preferably with from zero to two substituents, that are selected, independently, from halo, Ci to C3 alkyl, C-i to C3 alkoxy, nitro, amino, cyano, CF3 and OCF3; and the pharmaceutically acceptable salts of said compounds. The following compounds are preferred compounds of the formula VI: 6-[8-(2-Dimethylamino-ethoxy)-1 ,2,3,4-tetrahydro-1 ,4-methano-naphthalen-5-yl]-pyridin-
2-ylamine; and
6-[8-(2-Pyrrolidin-1-yl-ethoxy)-1 ,2,3,4-tetrahydro-1 ,4-methano-naphthalen-5-yl]-pyridin- 2-ylamine.
Other compounds of the formula VI are the following: 6-[8-(2-Dimethylamino-ethoxy)-1 ,2,3,4-tetrahydro-1 ,4-ethano-naphthalen-5-yl]-pyridin-2- ylamine;
6-[8-(2-Pyrrolidin-1 -yl-ethoxy)-1 ,2,3,4-tetrahydro-1 ,4-ethano-naphthalen-5-yl]-pyridin-2- ylamine;
6-[8-(2-(4-Dimethylamino-piperidin-1-yl)-ethoxy)-1,2,3,4-tetrahydro-1 ,4-methano- naphthalen-5-yl]-pyridin-2-ylamine;
6-[8-(2-(6,7-Dimethoxy-teyrahydroisoquinol-2-yl)-ethoxy)-1 ,2,3,4-tetrahydro-1,4- methano-naphthalen-5-yl]-pyridin-2-ylamine; and
6-[8-(2-(4-Methylpiperazin-1-yl)-ethoxy)-1,2,3,4-tetrahydro-1 ,4-methano-naphthalen-5- yl]-pyridin-2-ylamine. Compounds of formulas l-VI may contain chiral centers and therefore may exist in different enantiomeric and diastereomeric forms. This invention relates to the above methods of treatment using and the above pharmaceutical compositions comprising all optical isomers and all stereoisomers of compounds of the formulas l-VI and mixtures thereof. The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.
The term "one or more substituents", as used herein, refers to a number of substituents that equals from one to the maximum number of substituents possible based on the number of available bonding sites.
The terms "halo" and "halogen", as used herein, unless otherwise indicated, include chloro, fluoro, bromo and iodo.
Formulas I - VI above include compounds identical to those depicted but for the fact that one or more hydrogen, carbon or other atoms are replaced by isotopes thereof. Such compounds may be useful as research and diagnostic tools in metabolism pharmacokinetic studies and in binding assays.
Examples of SSRI's that can be used in the methods and pharmaceutical compositions of this invention are sertraline, fluoxetine, paroxetine, citalopram and fluvoxamine. Examples of NK-1 receptor antagonists that can be used in the methods and pharmaceutical compositions of this invention are the following compounds and their pharmaceutically acceptable salts:
2-(Diphenylmethyl)-N-((2-difluoromethoxy)phenyl)methyl-1-azabicyclo[2.2.2]octan-3- amine; (2S,3S)-N-(2-Methoxy-5-trifluoromethoxyphenyl)methyl-2-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-amine;
(2S,3S)-2-Phenyl-3-[2-(2,2,2-trifluoroethoxy)benzyl]-aminopiperidine;
(2S,3S)-3-(2-Methoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
(2S,3S)-1-(5,6-Dimethoxyhexyl)-3-(2-methoxy-5-trifluoromethoxybenzyl)amino-2- phenylpiperidine;
(2S,3S)-2-Phenyl-3-(2-trifluoromethoxybenzyl)aminopiperidine;
(2S,3S)-3-(2-Hydroxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
(2S,3S)-3-[5-Chloro-2-(2,2,2-trifluoroethoxy)-benzyl]amino-2-phenylpiperidine;
(2S,3S)-2-Phenyl-3-(3-trifluoromethoxybenzyl)-aminopiperidine; (2S,3S)-3-(5-t-Butyl-2-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
(2S,3S)-3-[5-lsopropyl-2-(2,2,2-trifluoroethoxy)-benzyl]amino-2-phenylpiperidine;
(2S,3S)-3-[5-Dimethylamino-2-(2,2,2-trifluoroethoxy)-benzyl]amino-2-phenylpiperidine;
(2S,3S)-3-(2-Difluoromethoxy-5-N,N-dimethylamino-benzyl)amino-2-phenylpiperidine;
(2S,3S)-3-[2,5-bis(difluoromethoxy)benzyl]amino-2-phenylypiperidine; (2S,3S)-3-(5-t-ButyI-2-difluoromethoxybenzyl)amino-2-phenylpiperidine;
(2S,3S)-3-(2-lsopropoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
(2S,3S)-3-(2-Difluoromethoxy-5-trifluoromethoxybenzyl)-amino-2-phenylpiperidine;
(2S,3S)-3-(2-Ethoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine; (2S,3S)-3-(2-Difluoromethoxy-5-nitrobenzyl)amino-2-phenylpiperidine; (2S,3S)-3-(2-Difluoromethoxy-5-isopropylbenzyl)amino-2-phenylpiperidine; (2S,3S)-3-[5-Acetamido-2-(2,2,2-trifluoroethoxy)-benzyl]amino-2-phenylypiperidine; (2S,3S)-3-(2-Difluoromethoxy-5-ethylbenzyl)amino-2-phenylpiperidine; cis-3-(5-t-Butyl-2-methoxybenzyl)amino-2-(3-trifluoromethoxyphenyl)piperidine; cis-2-(3,5-Dibromophenyl)-3-(2-methoxy-5-trifluoromethoxybenzyl)aminopiperidine; and (2S-3S)-3-(2-Difluoromethoxy-5-methylbenzyl)amino-2-phenylpiperidine. Further examples of NK-1 receptor antagonists are:
(2S,3S)-3-(5-tert-butyl-2-methoxybenzyl)amino-2-(3-trifluoromethoxyphenyl)piperidine; (2S,3S)-3(-5-tert-butyl-2-trifluoromethoxybenzyl)amino-2-phenylpiperidine; 2-(diphenylmethyl)-N-(2-methoxy-5-trifluoromethoxy-phenyl)methyl-1- azabicyclo[2.2.2]octan-3-amine;
(2S,3S)-2-phenyl-3-[2-(2,2,2-trifluoroethoxybenzyl)-aminopiperidine; cis-3-ι 2-chlorobenzylamino)-2-phenylpiperidine; cis-3 2-trifluoromethylbenzylamino)-2-phenyl-piperidine; cis-3 2-methoxybenzylamino )-2-(2-fluorophenyl)-piperidine; cis-3-ι 2-methoxybenzylamino )-2-(2-chlorophenyl)-piperidine; cis-3 2-methoxybenzylamino ); -2-(2-methylphenyl)-piperidine; cis-3 2-methoxybenzylamino^ )-2-(3-methoxyphenyl)-piperidine; cis-3 2-methoxybenzylamino )-2-(3-fluorophenyl)-piperidine; cis-3-ι 2-methoxybenzylamino )-2-(3-chlorophenyl)-piperidine; cis-3- 2-methoxybenzylamino )-2-phenylpiperidine; cis-3 2-methoxybenzylamino^ )-2-(3-methylphenyl)-piperidine; cis-3 2-methoxybenzylamino )^ -2-(4-fiuorophenyl)-piperidine; cis-3 2-methoxybenzylamino; )-2-(3-thienyl)-piperidine; cis-3-ι (2-methoxybenzylamino ))-2-phenylazacyclo-heptane; 3-(2-methoxybenzylamino)-4-methyl-2-phenylpiperidine; 3-(2-methoxybenzylamino)-5-methyl-2-phenylpiperidine; 3-(2-methoxybenzylamino)-6-methyl-2-phenylpiperidine; (2S,3S)-3-(2-methoxybenzylamino)-2-phenyipiperidine;
(2S,3S)-1-(5-carboethoxypent-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine; (2S,3S)-1-(6-hydroxy-hex-l-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine; (2S,3S)-1-(4-hydroxy-4-phenylbut-1-yl)-3-(2-methoxy-benzylamino)-2-phenylpiperidine; (2S,3S)-1-(4-oxo-4-phenylbut-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine; (2S,3S)-1-(5,6-dihydroxyhex-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine; cis-3-(5-fluoro-2-methoxybenzylamino)-2-phenyl-piperidine; (2S,3S)-1-[4-(4-fluorophenyl)-4-oxobut-1-yl]-3-(2-methoxybenzylamino)-2- phenylpiperidine; (2S,3S)-1-[4-[4-fluorophenyl)-4-hydroxybut-1-yl]-3-(2-methoxybenzylamino)-2- phenylpiperidine; cis-3-(2-methoxy-5-methylbenzylamino)-2-phenyl-piperidine;
(2S,3S)-1-(4-benzamidobut-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine; cis-3-(2-methoxynaphth-1 -ylmethylamino)-2-phenyl-piperidine;
(2S,3S)-3-(2-methoxybenzylamino)-1-(5-N-methyl-carboxamidopent-1-yl)-2- phenylpiperidine;
(2S,3S)-1-(4-cyanobut-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
(2S,3S)-1-[4-(2-naphthamido)but-1-yl]-3-(2-methoxy-benzylamino)-2-phenylpiperidine; (2S,3S)-1-(5-benzamidopent-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
(2S,3S)-1-(5-aminopent-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
(2S,3S)-3-(5-chloro-2-methoxybenzylamino)-2-phenyl-piperidine;
(2S,3S)-3-(2,5-dimethoxybenzylamino)-2-phenyl-piperidine; cis-3-(3,5-difluoro-2-methoxybenzylamino)-2-phenyl-piperidine; cis-3-(4,5-difluoro-2-methoxybenzylamino)-2-phenyl-piperidine; cis-3-(2,5-dimethoxybenzylamino)-1-[4-(4-fluorophenyl)-4-oxobut-1-yl]-2-phenylpiperidine; cis-3-(5-chloro-2-methoxybenzylamino)-1-(5,6-dihydroxyhex-1-yl)-2-phenylpiperidine; cis-1-(5,6-dihydroxyhex-1-yl)-3-(2,5-dimethoxy-benzylamino)-2-phenylpiperidine; cis-2-phenyl-3-[-2(prop-2-yloxy)benzylamino]piperidine; cis-3-(2,5-dimethoxybenzyl)amino-2-(3-methoxy-phenyl)piperidine hydrochloride; cis-3-(5-chloro-2-methoxybenzyl)amino-2-(3-methoxy-phenyl)piperidine dihydrochloride; cis-3-(5-chloro-2-methoxybenzyl)amino-2-(3-chloro-phenyl)piperidine dihydrochloride;
3-(2-methoxybenzylamino)-2,4-diphenylpiperidine; cis-3-(2-methoxybenzylamino)-2-phenylpyrrolidine; (2S,3S)-3-(5-ethyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(5-n-butyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(2-methoxy-5-n-propylbenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(5-isopropyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(5-s-butyl-2-methoxybenzyl)amino-2-phenyl-piperidine; (2S,3S)-3-(5-t-butyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(2-methoxy-5-phenylbenzyl)amino-2-phenyl-piperidine;
2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3- ylaminomethyl)phenyl]-methylamide;
N-(4,5-dimethylthiazol-2-yl)-N-[4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-yl- aminomethyl)phenyl]-methanesulfonamide;
{5-[(4,5-dimethylthiazol-2-yl)methylamino]-2-methoxybenzyl}-((2S,3S)-2-phenylpiperidin-3- yl)amine;
{5-(4,5-dimethylthiazol-2-ylamino)-2-methoxybenzyl}-((2SI3S)-2-phenylpiperidin-3-ylamine; . .
4,5-dimethylthiazole-2-sulfonic acid methyl-[3-((2S,3S)-2-phenylpiperidin-3- ylaminomethyl)-4-trifluoromethoxyphenyl]-amide;
2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3- ylaminomethyl)phenyl]-methylamide; 2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-
3-ylaminomethyl)phenyl]-isopropylamide;
2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3- ylaminomethyl)phenyl]-isopropylamide;
2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3- ylaminomethyl)phenyl]-isobutylamide;
2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3- ylaminomethyl)phenyl]-isobutylamide;
(2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]- octan-3-amine; (2S,3S)-N-(5-tert-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1- azabicyclo[2.2.2]octan-3-amine;
(2S,3S)-N-(5-methyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan- 3-amine;
(2S,3S)-N-(5-ethyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3- amine;
(2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1- azabicyclo[2.2.2]octan-3-amine;
(2S,3S)-N-(5-sec-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1- azabicyclo[2.2.2]octan-3-amine; (2S,3S)-N-(5-n-propyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1- azabicyclo[2.2.2]octan-3-amine,
(3R,4S,5S,6S)-N,N-diethyl-5-(5-isopropyl-2-methoxy-benzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxamide;
(3R,4S,5S,6S)-N,N-diethyl-5-(2,5-dimethoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxamide;
(3R,4S,5S,6S)-5-(5-isopropyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-2-methylthiobenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid; (3R,4S,5S,6S)-5-(2,5-dimethoxybenzylamino)-6-diphenyl-methyl-1-azabicyclo-
[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid; (3R,4S,5S,6S)-5-(5-ethyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxyl-5-n-propylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid; (3R,4S,5S,6S)-5-(5-sec-butyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(5-N-methyl-methanesulfonylamino-2-methoxy-benzylamino)-6- diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfinylbenzyl-amino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-trifluoromethoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfonylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid; (3R,4S,5S,6S)-5-(5-dimethyiamino-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(5-isopropyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methylthiobenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(2,5-dimethoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid; (3R,4S,5S,6S)-5-(5-€thyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-n-propylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(5-sec-butyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(5-N-methyl-methanesulfonylamino-2-methoxybenzyl-amino)-6- diphenylmethyl-1 -azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfinylbenzylamino)-6-diphenylmethyI-1- azabicyclo[2.2.2]octane-2-carboxylic acid; (3R,4S,5S,6S)-5-(2-methoxy-5-trifluoromethoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfonylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid; and (3R,4S,5S,6S)-5-(5-dimethylamino-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
Figure imgf000040_0001
These compounds can be prepared as described in PCT Patent Application WO 95/08549, which published in March 30, 1995.
Other examples of NK-1 receptor antagonists that can be used in the methods and pharmaceutical composition of this invention are those referred to in the following references, all of which are incorporated herein by reference in their entireties: United States Patent 5,162,339, which issued on November 11, 1992; United States Patent 5,232,929, which issued on August 3, 1993; World Patent Application WO 92/20676, published November 26, 1992; World Patent Application WO 93/00331, published January 7, 1993; U.S. Patent No. 5,773,450, World Patent Application WO 92/21677, published December 10, 1992; World Patent Application WO 93/00330, published January 7, 1993; World Patent Application WO 93/06099, published April 1, 1993; World Patent Application WO 93/10073, published May 27, 1993; World Patent Application WO 92/06079, published April 16, 1992; World Patent Application WO 92/12151, published July 23, 1992; World Patent Application WO 92/15585, published September 17, 1992; World Patent Application WO 93/10073, published May 27, 1993; World Patent Application WO 93/19064, published September 30, 1993; World Patent Application WO 94/08997, published April 28, 1994; World Patent Application WO 94/04496, published March 3, 1994; United States Patent Application 988,653, filed December 10, 1992; United States Patent Application 026,382, filed March 4, 1993; United States Patent Application 123,306, filed September 17, 1993, and United States Patent Application 072,629, filed June 4, 1993. All of the foregoing World Patent Applications designate the United States and were filed in the U.S. Receiving Office of the PCT. : European Patent Application EP 499,313, published August 19, 1992; European Patent Application EP 520,555, published December 30, 1992; European Patent Application EP 522,808, published January 13, 1993; European Patent Application EP 528,495, published February 24, 1993; PCT Patent Application WO 93/14084, published July 22, 1993; PCT Patent Application WO 93/01169, published January 21 , 1993; PCT Patent Application WO 93/01165, published January 21, 1993; PCT Patent Application WO 93/01159, published January 21 , 1993; PCT Patent Application WO 92/20661, published November 26, 1992; European Patent Application EP 517,589; published December 12, 1992; European Patent Application EP 428,434, published May 22, 1991; European Patent Application EP 360,390, published March 28, 1990; PCT Patent Application WO 95/19344, published July 20, 1995; PCT Patent Application WO 95/23810, published September 8, 1995; PCT Patent Application WO 95/20575, published August 3, 1995; and PCT Patent Application WO 95/28418, published October 26, 1995.
Preferred embodiments of this invention relate to the above methods and pharmaceutical compositions that employ an SSRI wherein said SSRI is sertraline. Other preferred embodiments of this invention are the method and pharmaceutically compositions referred to above that employ sertraline in combination with a NOS inhibiting composition of the formula I, II, III, IV, V or VI.
Other preferred embodiments of this invention are the pharmaceutical compositions and methods referred to above that employ sertraline in combination with an NK-1 receptor antagonist, wherein said NK-1 receptor antagonist is selected from one of the following compounds in the pharmaceutically acceptable salts:
2-(Diphenylmethyl)-N-((2-difluoromethoxy)phenyl)methyl-1-azabicyclo[2.2.2]octan-3- amine;
(2S,3S)-N-(2-Methoxy-5-trifluoromethoxyphenyl)methyl-2-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-amine; (2S,3S)-2-Phenyl-3-[2-(2,2,2-trifluoroethoxy)benzyl]-aminopiperidine;
(2S,3S)-3-(2-Methoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
(2S,3S)-1-(5,6-Dimethoxyhexyl)-3-(2-methoxy-5-trifluoromethoxybenzyl)amino-2- phenylpiperidine;
(2S,3S)-2-Phenyl-3-(2-trifluoromethoxybenzyl)aminopiperidine; (2S,3S)-3-(2-Hydroxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
(2S,3S)-3-[5-Chloro-2-(2,2,2-trifluoroethoxy)-benzyl]amino-2-phenylpiperidine;
(2S,3S)-2-Phenyl-3-(3-trifluoromethoxybenzyl)-aminopiperidine;
(2S,3S)-3-(5-t-Butyl-2-trifluoromethoxybenzyl)amino-2-phenylpiperidine; (2S,3S)-3-[5-lsopropyl-2-(2,2,2-trifluoroethoxy)-benzyl]amino-2-phenylpiperidine;
(2S,3S)-3-[5-Dimethylamino-2-(2,2,2-trifluoroethoxy)-benzyl]amino-2-phenylpiperidine;
(2S,3S)-3-(2-Difluoromethoxy-5-N,N-dimethylamino-benzyl)amino-2-phenylpiperidine;
(2S,3S)-3-[2,5-bis(difluoromethoxy)benzyl]amino-2-phenylypiperidine; (2S,3S)-3-(5-t-Butyl-2-difluoromethoxybenzyl)amino-2-phenylpiperidine;
(2S,3S)-3-(2-lsopropoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
(2S,3S)-3-(2-Difluoromethoxy-5-trifluoromethoxybenzyl)-amino-2-phenylpiperidine;
(2S,3S)-3-(2-Ethoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
(2S,3S)-3-(2-Difluoromethoxy-5-nitrobenzyl)amino-2-phenylpiperidine; (2S,3S)-3-(2-Difluoromethoxy-5-isopropylbenzyl)amino-2-phenylpiperidine;
(2S,3S)-3-[5-Acetamido-2-(2,2,2-trifluoroethoxy)-benzyl]amino-2-phenylypiperidine;
(2S,3S)-3-(2-Difluoromethoxy-5-ethylbenzyl)amino-2-phenylpiperidine; cis-3-(5-t-Butyl-2-methoxybenzyl)amino-2-(3-trifluoromethoxyphenyl)piperidine; cis-2-(3,5-Dibromophenyl)-3-(2-methoxy-5-trifluoromethoxybenzyl)aminopiperidine; (2S-3S)-3-(2-Difluoromethoxy-5-methylbenzyl)amino-2-phenylpiperidine;
(2S,3S)-3-(5-tert-butyl-2-methoxybenzyl)amino-2-(3-trifluoromethoxyphenyl)piperidine;
(2S,3S)-3(-5-tert-butyl-2-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
2-(diphenylmethyl)-N-(2-methoxy-5-trifluoromethoxy-phenyl)methyl-1- azabicyclo[2.2.2]octan-3-amine; cis-3-(2-chlorobenzylamino)-2-phenylpiperidine; cis-3-(2-trifluoromethylbenzylamino)-2-phenyl-piperidine; cis-3-(2-methoxybenzylamino)-2-(2-fluorophenyl)-piperidine; cis-3-(2-methoxybenzylamino)-2-(2-chlorophenyl)-piperidine; cis-3-(2-methoxybenzylamino)-2-(2-methylphenyl)-piperidine; cis-3-(2-methoxybenzylamino)-2-(3-methoxyphenyl)-piperidine; cis-3-(2-methoxybenzylamino)-2-(3-fluorophenyl)-piperidine; cis-3-(2-methoxybenzylamino)-2-(3-chlorophenyl)-piperidine; cis-3-(2-methoxybenzylamino)-2-phenylpiperidine; cis-3-(2-methoxybenzylamino)-2-(3-methylphenyl)-piperidine; cis-3-(2-methoxybenzyiamino)-2-(4-fluorophenyl)-piperidine; cis-3-(2-methoxybenzylamino)-2-(3-thienyl)-piperidine; cis-3-(2-methoxybenzylamino)-2-phenylazacyclo-heptane;
3-(2-methoxybenzylamino)-4-methyl-2-phenylpiperidine;
3-(2-methoxybenzylamino)-5-methyl-2-phenylpiperidine; 3-(2-methoxybenzylamino)-6-methyl-2-phenylpiperidine;
(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
(2S,3S)-1-(5-carboethoxypent-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
(2S,3S)-1-(6-hydroxy-hex-l-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine; (2S,3S)-1-(4-hydroxy-4-phenylbut-1-yl)-3-(2-methoxy-benzylamino)-2-phenylpiperidine;
(2S,3S)-1-(4-oxo-4-phenylbut-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
(2S,3S)-1-(5,6-dihydroxyhex-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine; cis-3-(5-fluoro-2-methoxybenzylamino)-2-phenyl-piperidine; (2S,3S)-1-[4-(4-fluorophenyl)-4-oxobut-1-yl]-3-(2-methoxybenzylamino)-2- phenylpiperidine;
(2S,3S)-1-[4-[4-fluorophenyl)-4-hydroxybut-1-yl]-3-(2-methoxybenzylamino)-2- phenylpiperidine; cis-3-(2-methoxy-5-methylbenzylamino)-2-phenyl-piperidine; (2S,3S)-1-(4-benzamidobut-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine; cis-3-(2-methoxynaphth-1-ylmethylamino)-2-phenyl-piperidine;
(2S,3S)-3-(2-methoxybenzylamino)-1-(5-N-methyl-carboxamidopent-1-yl)-2- phenylpiperidine;
(2S,3S)-1-(4-cyanobut-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine; (2S,3S)-1-[4-(2-naphthamido)but-1-yl]-3-(2-methoxy-benzylamino)-2-phenylpiperidine;
(2S,3S)-1-(5-benzamidopent-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
(2S,3S)-1-(5-aminopent-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
(2S,3S)-3-(5-chloro-2-methoxybenzylamino)-2-phenyl-piperidine;
(2S,3S)-3-(2,5-dimethoxybenzylamino)-2-phenyl-piperidine; cis-3-(3,5-difluoro-2-methoxybenzylamino)-2-phenyl-piperidine; cis-3-(4,5-difluoro-2-methoxybenzylamino)-2-phenyl-piperidine; cis-3-(2,5-dimethoxybenzylamino)-1-[4-(4-fluorophenyl)-4-oxobut-1-yl]-2-phenylpiperidine; cis-3-(5-chloro-2-methoxybenzylamino)-1-(5,6-dihydroxyhex-1-yl)-2-phenylpiperidine; cis-1-(5,6-dihydroxyhex-1-yl)-3-(2,5-dimethoxy-benzylamino)-2-phenylpiperidine; cis-2-phenyl-3-[-2(prop-2-yloxy)benzylamino]piperidine; cis-3-(2,5-dimethoxybenzyl)amino-2-(3-methoxy-phenyl)piperidine hydrochloride; cis-3-(5-chloro-2-methoxybenzyl)amino-2-(3-methoxy-phenyl)piperidine dihydrochloride; cis-3-(5-chloro-2-methoxybenzyl)amino-2-(3-chloro-phenyl)piperidine dihydrochloride;
3-(2-methoxybenzylamino)-2,4-diphenylpiperidine; cis-3-(2-methoxybenzylamino)-2-phenylpyrrolidine;
(2S,3S)-3-(5-ethyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(5-n-butyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(2-methoxy-5-n-propylbenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(5-isopropyl-2-methoxybenzyl)amino-2-phenyl-piperidine; (2S,3S)-3-(5-s-butyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(5-t-butyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(2-methoxy-5-phenylbenzyl)amino-2-phenyl-piperidine; 2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3- ylaminomethyl)phenyl]-methylamide;
N-(4,5-dimethylthiazol-2-yl)-N-[4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-yl- aminomethyl)phenyl]-methanesulfonamide; {5-[(4,5-dimethylthiazol-2-yl)methylamino]-2-methoxybenzyl}-((2S,3S)-2-phenylpiperidin-3- yl)amine;
{5-(4,5-dimethylthiazol-2-ylamino)-2-methoxybenzyl}-((2S,3S)-2-phenylpiperidin-3-ylamine;
4,5-dimethylthiazole-2-sulfonic acid methyl-[3-((2S,3S)-2-phenylpiperidin-3- ylaminomethyl)-4-trifluoromethoxyphenyl]-amide; 2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3- ylaminomethyl)phenyl]-methylamide;
2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-
3-ylaminomethyl)phenyl]-isopropylamide;
2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3- ylaminomethyl)phenyl]-isopropylamide;
2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3- ylaminomethyl)phenyl]-isobutylamide;
2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3- ylaminomethyl)phenyl]-isobutylamide; (2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]- octan-3-amine;
(2S,3S)-N-(5-tert-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1- azabicyclo[2.2.2]octan-3-amine;
(2S,3S)-N-(5-methyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan- 3-amine;
(2S,3S)-N-(5-ethyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3- amine;
(2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1- azabicyclo[2.2.2]octan-3-amine; (2S,3S)-N-(5-sec-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1- azabicyclo[2.2.2]octan-3-amine;
(2S,3S)-N-(5-n-propyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1- azabicyclo[2.2.2]octan-3-amine,
(3R,4S,5S,6S)-N,N-diethyl-5-(5-isopropyl-2-methoxy-benzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxamide;
(3R,4S,5S,6S)-N,N-diethyl-5-(2,5-dimethoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxamide; (3R,4S,5S,6S)-5-(5-isopropyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-2-methylthiobenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid; (3R,4S,5S,6S)-5-(2,5-dimethoxybenzylamino)-6-diphenyl-methyl-1-azabicyclo-
[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(5-ethyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxyl-5-n-propylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(5-sec-butyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid; (3R,4S,5S,6S)-5-(5-N-methyl-methanesulfonylamino-2-methoxy-benzylamino)-6- diphenylmethyl-1 -azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methyisulfιnylbenzyl-amino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-trifluoromethoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfonylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(5-dimethylamino-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid; (3R,4S,5S,6S)-5-(5-isopropyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methylthiobenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(2,5-dimethoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(5-ethyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid; (3R,4S,5S,6S)-5-(2-methoxy-5-n-propylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(5-sec-butyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid; (3R,4S,5S,6S)-5-(5-N-methyl-methanesulfonylamino-2-methoxybenzyl-amino)-6- diphenylmethyl-1 -azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfιnylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-trifluoromethoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfonylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid; and
(3R,4S,5S,6S)-5-(5-dimethylamino-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
Figure imgf000046_0001
Detailed Description of the Invention In the discussion that follows, formulas I, II, III, IV, V and VI are defined as set forth above in the Summary of the Invention.
Compounds of the formula I and their pharmaceutically acceptable salts can be prepared as described below and in U.S. provisional application 60/057094, filed August 27, 1997, entitled "2-Aminopyrindines Containing Fused Ring Substituents", and World Patent Application 99/10339, published March 4, 1999, having the same title and claiming priority from provisional application 60/057094. The foregoing application is incorporated herein by reference in its entirety.
In Schemes 1-3 and the discussion of Schemes 1-3 that follow, all substituents are defined as they are defined above for compounds of the formula I. SCHEME 1
Figure imgf000047_0001
(2) (3)
Figure imgf000047_0002
(5)
Figure imgf000047_0003
(6)
Figure imgf000047_0004
IA
(X = bond, ring A = benzo)
(7) Scheme 2
Figure imgf000048_0001
(11)
Figure imgf000048_0002
(12)
Scheme 2 continued
1.LiAIH4, AICI3
NH2OHHCI
Figure imgf000049_0001
(13)
Figure imgf000049_0002
IB
(X = O, ring A = benzo)
Scheme 3
Figure imgf000050_0001
Figure imgf000050_0002
(16) (17)
Figure imgf000050_0003
IB
(ring A = benzo, X = 0) Scheme 1 illustrates a method of preparing compounds of the formula I wherein X is a bond and ring A is benzo. Schemes 2 and 3 illustrate methods of preparing compounds of the formula I wherein X is oxygen and ring A is benzo. The starting materials used in the procedures of Schemes 1 and 2 are either commercially available, known in the art or readily obtainable from known compounds by methods that will be apparent to those skilled in the art.
Referring to Scheme 1 , the compound of formula (2) is cooled to about -70°C in dry tetrahydrofuran (THF), and then a solution of n-butyl lithium is added to it. The resulting solution is then treated with triethyl borate and allowed to warm to room temperature to form the compound of formula (3). The compound of formula (3) is reacted with the compound of formula (4) to form the compound of formula (5). This reaction is generally carried out in an aqueous ethanol solvent, in the presence of sodium carbonate and tetrakistriphenylphoshine palladium, at about the reflux temperature.
The compound of the formula (6) can be formed in the following manner. First, the compound of formula (5) is reacted with N-bromosuccinimide (NBS) and bis-(1-cyano-1-aza)- cyclohexane in carbon tetrachloride and refluxed for about 8 hours, with additional portions of the initiator being added at about 1 , 2 and 4 hours. After evaporation of the solvent, the product of this reaction is reacted with triethylammonium cyanide in methylene chloride at about room temperature to form the compound of formula (6). Saturation of a solution of the compound of formula (6) in ethanol with hydrogen chloride, followed by refluxing the mixture and then heating in aqueous hydrochloric acid, yields the compound of formula (7).
The compound of the formula (7) that is formed in the preceding step can be converted into the compound of formula IA in the following manner. First, the compound of formula (7) is reacted with the appropriate compound of the formula R2R1NH and N-ethyl-N-dimethylaminopropyl carbodiimide (EDAC) in the presence of a base. Examples of suitable bases are those selected from trialkylamines, alkali metal carbonates and alkaline earth metal carbonates. This reaction is typically conducted in a solvent such as acetonitrile, methylene chloride or N,N-dimethylformamide (DMF), at a temperature from about room temperature to about 100°C, preferably at about room temperature. Preferably, the reaction is conducted in the presence of a catalytic additive such as N-hydroxysuccinamide or hydroxybenzotriazole.
The product of the foregoing reaction is then reduced using methods well known to those of skill in the art. For example, the reduction can be carried out using lithium aluminum hydride in tetrahydrofuran, with or without aluminum chloride, or using borane methyl sulfide in tetrahydrofuran, at a temperature of about -78°C to about 0°C, preferably at about -70°C, to yield the desired compound of formula IA. Referring to scheme 2, the compound of formula (8) is reacted with tetrabutylammonium tribromide in 1 ,2-dichloroethane at about room temperature. The product of this reaction is then treated with benzyl bromide and potassium carbonate in a solvent such as acetonitrile, at about the reflux temperature of the reaction mixture, to form the compound of formula (9). The compound of formula (9) is then converted into 1-benzyloxy-naphthalene-4-boronic acid by the procedure described above for preparing the boronic acid derivative of formula (3) in Scheme 1.
Reaction of 1-benzyoxy-napthalene-4-boronic acid with the compound of formula (10) in an ethanol solvent, in the presence of sodium carbonate and tetrakistriphenyl palladium, at about the reflux temperature of the reaction mixture, yields the compound of formula (11 ).
The compound of formula (11) can be converted into the compound of formula (13) using the following two step process. The compound of formula (11) is reacted with ammonium formate and ten percent palladium on carbon, in an ethanol solvent, at about the reflux temperature of the reaction mixture, to yield the analogous compound to that having formula (11), wherein the benzyloxy group of formula (11) is replaced with a hydroxy group. The compound of formula (12) is then formed by reacting the above hydroxy derivative with 2-bromoethylacetate and potassium carbonate in acetonitrile at about the reflux temperature of the reaction mixture.
Basic hydrolysis of the compound of formula (12), followed by reaction with N-ethyl-N-3- dimethylaminopropylcarbodiimide (EDAC) and the appropriate compound having the formula R1R2NH yields the desired compound of the formula (13). The base hydrolysis is typically carried out using an alkali metal or alkaline earth metal hydroxide in a mixture of THF, methanol and water at about room temperature. The reaction with R1R2NH and EDAC is generally carried out using the procedure described above for the preparation of compounds of the formula IA from those of formula (7) in Scheme 1. The compound of formula (13) can be converted into the desired compound of formula IB as follows. The compound of formula (13) is reduced to form the corresponding compound wherein the carbonyl group is replaced by a methylene group, after which the 2,5-dimethylpyrrolyl protecting group is removed. The reduction can be earned out using methods well known to those of skill in the art, for example, using lithium aluminum hydride in tetrahydrofuran, with or without aluminum chloride, or using borane methyl sulfide in tetrahydrofuran, at a temperature of about -78°C to about 0°C, preferably at about -70°C.
Removal of the 2,5-dimethylpyrτolyl protecting group can be accomplished by reaction with hydroxylamine hydrochloride. This reaction is generally carried out in an alcoholic or aqueous alcoholic solvent, at a temperature from about room temperature to about the reflux temperature of the reaction mixture, preferably at about the reflux temperature, for about 8 to about 72 hours.
Compounds of the formula I that are identical to those of formula IB but for the fact that ring A is other than benzo can be prepared in an analogous fashion, starting with the appropriate compound that is analogous to that of formula (8), wherein the unsubstituted benzo ring of formula (8) is replaced by a ring other than benzo that is within the definition of ring A.
Referring to Scheme 3, the known 1-fluoronaphthalene (14) is brominated with bromine in acetic acid at a temperature from about room temperature to about the reflux temperature of the reaction mixture for about 1 to about 48 hours, and the bromide cooled to about -70°C in dry tetrahydrofuran (THF), and then a solution of n-butyl lithium is added to it. The resulting solution is then treated with triethyl borate and allowed to warm to room temperature to form the compound of formula (15). The compound of formula (15) is reacted with the compound of formula (4) to form the compound of formula (16). This reaction is generally carried out in an aqueous ethanol solvent, in the presence of sodium carbonate and tetrakistriphenylphoshine palladium, at about the reflux temperature. The compound of formula (16) is then treated with an alkali metal alkoxide prepared from a compound of the formula HO(CH2)nNR1R2 and sodium hydride in a polar solvent such as dimethylformamide, at a temperature from room temperature to 140°C for about 1 to about 48 hours. This reaction produces the corresponding compound of formula (17), which is then deblocked to remove the 2,5-dimethylpyrrolyl protecting group by reaction with hydroxylamine hydrochloride. This reaction is generally carried out in an alcoholic or aqueous alcoholic solvent, at a temperature from about room temperature to about the reflux temperature of the reaction mixture, preferably at about the reflux temperature, for about 8 to about 72 hours.
Compounds of the formula I that are identical to those of formula IA and IB but for the fact that ring A is other than benzo can be prepared in an analogous fashion, starting with the appropriate starting materials that are analogous to those of formulas (2), (8) and (14), in Schemes 1, 2 and 3, respectively, wherein the unsubstituted benzo ring of such starting materials is replaced by a ring other than benzo that is within the definition of ring A.
The preparation of other compounds of the formula I not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.
In each of the reactions discussed or illustrated above, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, Le., about 1 atmosphere, is preferred as a matter of convenience.
Compounds of the formula II and their pharmaceutically acceptable salts can be prepared as described in published PCT patent application WO 97/36871, which designates the United States and was published on October 9, 1997. The foregoing application is incoφorated herein by reference in its entirety. Compounds of the formula III and their pharmaceutically acceptable salts can be prepared as described below and in U.S. provisional patent application 60/057739 of John A. Lowe, III, entitled "6-Phenyipyridin-2-yl-amine Derivatives", filed on August 28, 1997; and in counterpart World Patent Application WO 99/11620, published March 11, 1999. The foregoing applications are incorporated herein by reference in their entirety.
Schemes 4 and 5 below illustrate methods of preparing compounds of the formula III.
SCHEME 4
Figure imgf000054_0001
(18) (19)
Figure imgf000054_0002
SCHEME 4 (continued.
HCI, H2O,EtOH
(23)
Figure imgf000055_0001
III
(25) (X=CH2)
SCHEME 5
Figure imgf000056_0001
Figure imgf000056_0002
F
Figure imgf000056_0003
III (X=CH2)
Referring to Scheme 4, the compound of formula (18) is reacted with a compound of the formula CHR3R4Br or CHR2R4i and potassium carbonate, in a solvent such as acetonitrile, at about the reflux temperature of the reaction mixture, to convert the hydroxy group of formula (18) into a group having the formula -OCHR3R4 . The resulting compound is then reduced, at about room temperature, using hydrogen gas in the presence of 10% palladium on carbon, in an ethanol solvent, to form 3-OCHR3R4-4-aminotoluene, which is then reacted with sodium nitrite and cuprous bromide in concentrated sulfuric acid to form 3-OCHR3R4-4-bromotoluene.
The 3-OCHR3R -4-bromotoluene produced in the foregoing reaction is then cooled to about -70°C in dry tetrahydrofuran (THF), and a solution of n-butyl lithium is added to it. The resulting solution is then treated with triethyl borate and allowed to warm to room temperature to form the compound of formula (19). The compound of formula (19) is reacted with the compound of formula (20) to form the compound of formula (21). This reaction is generally carried out in an aqueous ethanol solvent, in the presence of sodium carbonate and tetrakistriphenylphosphine palladium, at about the reflux temperature of the reaction mixture.
The compound of the formula (23) can be formed in the following manner. First, the compound of formula (21) is reacted with N-bromosuccinimide (NBS) and bis-(1-cyano-1-aza)- cyclohexane (formula (22)) in carbon tetrachloride and refluxed for about 8 hours, with additional portions of the initiator being added at about 1 , 2 and 4 hours. After evaporation of the solvent, the product of this reaction is reacted with triethylammonium cyanide in methylene chloride at about room temperature to form the compound of formula (23). Saturation of a solution of the compound of formula (23) in ethanol with hydrogen chloride, followed by refluxing the mixture and then heating in aqueous hydrochloric acid, yields the compound of formula (24). Hydrolysis of the compound of formula VIII yields the corresponding compound of formula (25). The base hydrolysis is typically carried out using an alkali metal or alkaline earth metal hydroxide in a mixture of ethanol and water at a temperature from about room temperature to about the reflux temperature of the solvent.
The compound of the formula (25) that is formed in the preceding step can be converted into the compound of formula III (wherein X is CH2) in the following manner. First, the compound of formula (25) is reacted with the appropriate compound of the formula R2R1NH and N-ethyl-N- dimethylaminopropyl carbodiimide (EDAC) in the presence of a base. Examples of suitable bases are those selected from trialkylamines, alkali metal carbonates and alkaline earth metal carbonates. This reaction is typically conducted in a solvent such as acetonitrile, methylene chloride or N,N-dimethylformamide (DMF), at a temperature from about room temperature to about 100°C, preferably at about room temperature. Preferably, the reaction is conducted in the presence of a catalytic additive such as N-hydroxysuccinamide or hydroxybenzotriazole. The product of the foregoing reaction is then reduced using methods well known to those of skill in the art. For example, the reduction can be carried out using lithium aluminum hydride in tetrahydrofuran, with or without aluminum chloride, or using borane methyl sulfide in tetrahydrofuran, at a temperature of about -78°C to about 0°C, preferably at about -70°C, to yield the desired compound of formula III (wherein X is CH2).
Referring to Scheme 5, 4-bromo-3-fluorotoluene is first converted to the boronic acid derivative and then coupled to 6-bromo-2-(t-butylcarbonylamino)pyridine to form compound of the formula (26) in the following manner. A halogen-metal exchange reaction is carried out on 3-fluoro-4-bromotoluene in tetrahydrofuran, ether, dimethoxyethane, hexane or another suitable ethereal or hydrocarbon solvent, at a temperature from -100°C to about room temperature, using butyl lithium or another suitable alkyl lithium reagent, followed by reaction with a borate triester such as triethyl or triisopropyl borate, for about 1 to about 48 hours at a temperature from about -100°C to about the reflux temperature. The intermediate boronic acid derivative is then converted into the compound of formula (26) in an aqueous ethanol solvent, in the presence of sodium carbonate and tetrakistriphenylphosphine palladium, at about the reflux temperature of the reaction mixture, using 6-bromo-2-(t-butylcarbonylamino)pyridine as the coupling partner. The compound of formula (26) is then converted into a compound of the formula (27) by displacement of the fluoro group from the alcohol with a suitable alkoxide, which is formed in a solvent such as dimethylformamide, tetrahydrofuran or dioxane, and a metal hydride such as sodium hydride, at a temperature from about room temperature to about the reflux temperature, for a period of about 5 minutes to about 5 hours. The reaction with the compound of formula (26) is carried out in this reaction system at a temperature from room temperature to about the reflux temperature for a period from about 1 to about 48 hours.
The compound of formula (27) is then converted into the corresponding compound of the formula (25) in the following manner. First, the compound of formula (27) is reacted with N- bromosuccinimide (NBS) and bis-(1-cyano-1-aza)-cyclohexane (formula (22) in Scheme 4) in carbon tetrachloride and refluxed for about 8 hours, with additional portions of the initiator being added after about 1, 2 and 4 hours, to brominate the methyl group of such compound. After evaporation of the solvent, the product of this reaction is reacted with triethylammonium cyanide in methylene chloride at about room temperature to form the corresponding compound wherein the bromo substituent is replaced by cyano. The resulting cyano derivative is then hydrolyzed to form the corresponding compound of formula (25). The base hydrolysis is typically carried out using an alkali metal or alkaline earth metal hydroxide in a mixture of ethanol and water at a temperature from about room temperature to about the reflux temperature of the solvent.
The compound of the formula (25) that is formed in the preceding step can be converted into the compound of formula I in the following manner. First, the compound of formula (25) is reacted with the appropriate compound of the formula R2R1NH and N-ethyl-N-dimethylaminopropyl carbodiimide (EDAC) in the presence of a base. Examples of suitable bases are those selected from trialkylamines, alkali metal carbonates and alkaline earth metal carbonates. This reaction is typically conducted in a solvent such as acetonitrile, methylene chloride or N,N-dimethylformamide (DMF), at a temperature from about room temperature to about 100°C, preferably at about room temperature. Preferably, the reaction is conducted in the presence of a catalytic additive such as N-hydroxysuccinamide or hydroxybenzotriazole.
The product of the foregoing reaction is then reduced using methods well known to those of skill in the art to yield the desired compound of formula III (wherein X is CH2). For example, the reduction can be carried out using lithium aluminum hydride in tetrahydrofuran, with or without aluminum chloride, or using borane methyl sulfide in tetrahydrofuran, at a temperature of about -
78°C to about 0°C, preferably at about -70°C.
Compounds of the formula III wherein X is CHOH can be prepared using a procedure analogous to that described in Example 1 of this application. Compounds of the formula I wherein X is part of a five or six membered saturated ring may be prepared using a procedure analogous to that described in Example 2.
The starting materials used in the procedures of Schemes 4 and 5 are either commercially available, known in the art or readily obtainable form known compounds by methods that will be apparent to those skilled in the art.
The preparation of other compounds of the formula III not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.
In each of the reactions discussed or illustrated above, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, Le., about 1 atmosphere, is preferred as a matter of convenience.
Compounds of the formula IV and their pharmaceutically acceptable salts can be prepared as described in World Patent Application W098/34919, entitled "4-Amino-6-(2- substituted-4-phenoxy)-substituted-pyridines", published August 13, 1998; and U.S. provisional application 60/037533, filed February 10, 1997 from which that International application claims priority. The foregoing applications are incoφorated herein by reference in their entirety.
Schemes 6-14 below illustrate methods of preparing compounds of the formula IV.
SCHEME 6
Figure imgf000060_0001
Figure imgf000060_0002
(30)
Figure imgf000060_0003
(31)
SCHEME 6 CONTINUED
Figure imgf000061_0002
Figure imgf000061_0003
(35) IVA SCHEME 7
Figure imgf000062_0001
IVA
K2CO3 K2CO3/heat
GX GX
DMF or acetone DMF or acetone
Figure imgf000062_0002
(G=CH2C(=O)NR3R4) (G=CH2CH2NR3R4)
IVC
SCHEME 8
Figure imgf000063_0001
(36) (Bn = benzyl) (37)
(32A) (32B)
Figure imgf000063_0003
CONTINUED AS WITH COMPOUND (32) IN SCHEME 1
SCHEME 9
Figure imgf000064_0001
(38) IVF
SCHEME 10
Figure imgf000065_0001
IVD
Figure imgf000065_0002
IVG
SCHEME 11
Figure imgf000066_0001
(39)
(40)
Figure imgf000066_0002
(42)
Figure imgf000066_0003
(43)
(44) SCHEME 12
Figure imgf000067_0001
IVL SCHEME 12 CONTINUED
Figure imgf000068_0001
Figure imgf000068_0002
Figure imgf000068_0003
IVL SCHEME 13
Figure imgf000069_0001
(45) (46)
Figure imgf000069_0002
(47)
Figure imgf000069_0003
IVN SCHEME 14
Figure imgf000070_0001
IVP
Figure imgf000070_0002
IVA Scheme 6 illustrates a method for preparing compounds of the formula I wherein G is hydrogen, R1 is -OR wherein R is (d-C6)alkyl and R2 is hydrogen. These compounds are referred to in Scheme I as compounds of the formula "IA".
Referring to Scheme 6, the compound of formula (28) is reacted with excess potassium carbonate and one equivalent of tosyl chloride in acetone, at a temperature from about 0°C to about 80CC, preferably at the reflux temperature of the reaction mixture. A compound of the formula RX, wherein R is (d-C6)alkyl and X is iodo, chloro or bromo, is then added to the reaction mixture and the mixture is allowed to react at a temperature ranging from about 0°C to about 80°C, preferably at the reflux temperature of the mixture. This reaction yields a compound of the formula (29). The compound of formula (29) is then converted into the corresponding compound of formula (30) by reacting it with potassium hydroxide in ethanol, using water as the solvent. This reaction can be carried out at a temperature from about room temperature to about the reflux temperature of the reaction mixture. Preferably, the reaction mixture is heated to reflux and allowed to react at that temperature. The compound of formula (30) is then reacted with potassium carbonate and benzyl bromide in acetone, at a temperature from about room temperature to about 80°C, to form the corresponding compound of formula (31). Preferably, the reaction is conducted at about the reflux temperature. Reaction of the resulting compound of formula (31) with butyl lithium in tetrahydrofuran (THF) at about -78°C, followed by the addition of triethyl borate and allowing the reaction mixture to warm to ambient temperature, yields the corresponding phenylboronic acid derivative of formula (32).
Reacting the phenylboronic acid derivative of formula (32) with 2-bromo-6-(2,5-dimethyl- pyrrol-1-yl)-pyridine (33), sodium carbonate and tetrakis(triphenylphosphine)palladium(0) in ethanol/water or THF/water, at a temperature from about room temperature to about the reflux temperature of the reaction mixture, preferably at about the reflux temperature, yields the corresponding compound of formula (34). Alternatively, the reactant of formula (33) can be replaced with another compound of the formula
Figure imgf000071_0001
wherein P is a nitrogen protecting group such as trityl, acetyl, benzyl, trimethylacetyl, t- butoxycarbonyl, benzyloxycarbonyl, trichloroethyloxycarbonyl or another appropriate nitrogen protecting group and wherein the hydrogen that is bonded to the protected nitrogen is absent when P is a protecting group that forms a ring with the protected nitrogen, as in the case of P = 2,5-dimethylpyrrolyl. Such protecting groups are well known to those of skill in the art. The above compounds of the formula (33A) are either commercially available, known in the scientific literature or easily obtaining using well known methods and reagents.
The benzyl substituent can be removed from the compound of formula (34) by reacting such compound with ammonium formate in water or a lower alcohol solvent, or in a mixture of one or more of these solvents, at a temperature from about room temperature to about the reflux temperature of the reaction mixture. This reaction is preferably carried out at the reflux temperature in the presence of about 20% palladium hydroxide on carbon. The resulting compound of formula (35) is then converted into the desired compound of formula IVA by reacting it with hydroxylamine in a solvent selected from water, lower alcohols and mixtures of these solvents, at a temperature from about room temperature to about the reflux temperature of the solvent, preferably at about the reflux temperature.
The procedure of Scheme 6 can also be used to make compounds of the formula IV wherein R1 and R2 are other than as specified above and depicted in the scheme. This can be accomplished by using a compound of the formula
Figure imgf000072_0001
as the starting material and then carrying out the series of reactions, as described above, that are represented in Scheme 6 as reactions (30)→(31)→(32)→(33)→(34)→(35)→(IVA).
Scheme 7 illustrates a method for preparing compounds of the formula IV wherein G is hydrogen into the corresponding compounds of formula IV wherein G is other than hydrogen. Referring to Scheme 7, a compound of the formula IVA can be converted into the corresponding compound of formula IVC by reacting it with the compound of the formula GX, wherein X is iodo, chloro, or bromo, and G is CH2CH2NR R4, and potassium carbonate in either dimethylformamide (DMF) or acetone at a temperature from about room temperature to about the reflux temperature of the mixture, preferably at about the reflux temperature. Compounds of the formula IVC can also be formed, as illustrated in Scheme 7, as by first preparing the corresponding compounds of formula IVB and then converting them, if so desired, into the corresponding compounds of formula IVC. Compounds of formula IVB can be formed by reacting the corresponding compounds of formula IVA with a compound of the formula GX, wherein X is defined as above and G is CH2C(=0)NR3R4, and potassium carbonate, in either DMF or acetone, at a temperature from about room temperature to about the reflux temperature of the reaction mixture. This reaction also is preferably carried out at about the reflux temperature.
The resulting compounds of formula of IVB can be converted into the corresponding compounds of formula IVC by reacting them with lithium aluminum hydride and aluminum chloride in a THF solvent, or with borane in THF. Other aluminum hydride reducing agents can also be _ -
used, such as diisobutyl aluminum hydride. Diborane can also be used. This reaction is generally carried out at temperatures ranging from room temperature to about the reflux temperature of the reaction mixture, and is preferably carried out at the reflux temperature. Other appropriate solvents include other organic ethers such as ethyl ether, dioxane and glyme, THF is preferred solvent.
Scheme 8 illustrates how certain compounds of the formula IV having different substituents R1 and R2 than are depicted in the processes of Scheme 6 can be prepared. Such compounds are prepared by a process similar to that depicted in Scheme 6, with the exception that the processes of Scheme 6 involved in the synthesis of compound (32) are replaced with those depicted in Scheme 8. Specifically, referring to Scheme 8, when R2 is hydrogen and R1 is fluoro at the ortho position, the compound of formula (36) is converted to the corresponding phenylboronic acid in a manner analogous to the conversion of compounds of the formula (31 ) into those of the formula (32) in Scheme (6). The resulting phenylboronic acid derivative is referred to in Scheme 8 as compound (32A). Similarly, as shown in Scheme 8, compounds of the formula IV wherein R and R2 are both methyl and are both at an ortho position relative to the pyridine ring, may be prepared by converting the compound of formula (37), as shown in Scheme 8, into the corresponding phenylboronic acid derivative designated as compound (32B), in a matter analogous to the conversion of compounds of formula (31) into those of the formula (32) in Scheme 6. The compounds of formulas (32A) and (32B) can then be transformed into the desired corresponding compounds of the formula IV using procedures analogous to those shown in Scheme 6.
Scheme 9 exemplifies methods of preparing compounds of the formula IV wherein G is NR3R4 and NR3R4 forms an N-methylpyrrolin-2-yl ring. Compounds of the formula IV wherein G is NR3R4 and NR R4 forms other nitrogen containing rings can be prepared in an analogous fashion. Referring to Scheme 9, the compound of formula IVD is allowed to react with 3- methanesulfonyloxy-pyrrolidine-1 -carboxylic acid tert-butyl ester to form the compound of formula (38). Other nitrogen protecting groups such as -C(=0)OCH2C6H5 and COOR (wherein R is benzyl, phenyl, t-butyl or a similar group) can be used to protect the pyrrolidine nitrogen. Also, the mesylate leaving group can be replaced with another appropriate leaving group. Preferably, a catalytic amount of tetrabutylammonium iodide (TBAI) is added to the reaction mixture. This alkylation reaction is typically carried out in the presence of an alkali metal alkoxide, preferable potassium tert-butoxide, in a high boiling polar organic solvent such as dimethylsulfoxide (DMSO) or DMF, preferably DMSO. The reaction temperature can range from about 50°C to about 100°C, and is preferably about 100°C. Reduction of the compound of formula XII yields the compound of formula IVF. This reduction is preferably accomplished using lithium aluminum hydride as the reducing agent and tetrahydrofuran (THF) or another organic ether (e.g., ethyl ether or glyme) as the solvent. Other aluminum hydride reducing agents can also be used, such as diisobutyl aluminum hydride. Diborane can also be used. The foregoing reaction is generally conducted at a temperature from about room temperature to about the reflux temperature of the reaction mixture, preferably at about the reflux temperature. As illustrated in Scheme 10, alkylation of the compound of formula IVD with 1-(2- chloroethyl)-pyrrolidine yields the compound of formula IVE. This reaction is generally conducted in the present of a base such as cesium carbonate, potassium carbonate, or sodium carbonate, preferably cesium carbonate, in a solvent such as acetone, DMSO or acetonitrile, preferably acetone, at a temperature from about room temperature to about the reflux temperature, preferably at about the reflux temperature.
Compounds of the formula IV wherein NR3R4 do not form a ring can also be prepared by the method illustrated in Scheme 10 and described above for the formation of the compound of formula IVE. Structural formula IVG, depicted in Scheme 5, includes such compounds.
Scheme 11 illustrates a method of preparing the benzeneboronic acid intermediates use in the syntheses described in Schemes 6 and 8 above wherein the benzene ring of the benzeneboronic acid contains a cycloalkyl substituent. Such intermediates can be used in the processes of Schemes 6 and 8 to form compounds of the formula IV wherein one or both of R1 and R2 are cycloalkyl groups. Referring to Scheme 11 , the compound of formula (39) is allowed to reflux, in the presence of magnesium metal, in THF or ethyl ether for about 8 hours, after which cyclobutanone is added to the reaction mixture. This reaction yields the compound of formula (40). Reduction of the compound of formula (40) using, for example, hydrogen gas and 10% palladium on carbon, in a lower alcohol solvent such as ethanol, at a temperature of about room temperature, yields the corresponding compound of formula (41).
Reaction of the compound of formula (41) with benzylbromide in the presence of a base such as potassium, cesium or sodium carbonate, in a solvent such as acetone, dichloroethane, chloroform or methylene chloride, at a temperature from about room temperature to about the reflux temperature of the reaction mixture, preferably at about the reflux temperature, yields the corresponding compound of formula (42).
The compound of formula (42) that was formed in the above step is then brominated by reaction with N-bromosuccinimide (NBS) and silica gel in a chlorinated hydrocarbon solvent such as carbon tetrachloride, methylene chloride or chloroform. This reaction is typically carried out at room temperature. The compound of formula (43) that is produced in this reaction can then be converted into the benzeneboronic acid derivative of formula (44) in the following manner. First, the compound of formula (43), in a solvent such as THF, is cooled to a temperature of about -78°C to about -70°C, after which n-butyl lithium is added. After stirring the reaction mixture for about 1 hour, triethyl borate is added and the mixture is allowed to stir for an additional 1-3 hours. The benzeneboronic acid intermediate can then be isolated by methods well known to of those skilled _ 74 _
in the art (e.g., quenching with ammonium chloride, adding water followed by concentrated hydrochloric acid, and then extracting with ethyl acetate).
Scheme 12 exemplifies a process for making compounds of the formula IV wherein G is alkenyl, as well as compounds of the formula IV wherein G is hydrogen and R2 is an alkyl or alkenyl group. Referring to Scheme 12, the compound of formula IVA is converted into the corresponding compound having the formula IVH using an alkylation reaction analogous to that used to convert the compound of formula IVD into that of formula IVG in Scheme 11. Heating the resulting compound of formula IVH to about 230°C yields the corresponding compounds of formulas IVJ and IVK. Hydrogenation of the compounds of formulas IVJ and IVK, using methods well know to those of skilled in the art (e.g., using hydrogen gas in ethanol of about 50 pounds per square inch, in the presence of 10% palladium on carbon at about room temperature) yields the corresponding alkyl derivatives of, respectively, formulas IVL and IVM. Alkylation of the compounds of formulas IVL and IVM (wherein G is hydrogen), using any of the alkylation methods described in Schemes 7, 9, and 10, and the appropriate alkylating agent, yields the corresponding desired compounds wherein G is other than hydrogen.
Scheme 13 illustrates an alternate method of preparing compounds of the formula IV wherein G is NR3R4(C0-C ) alkyl. Referring to Scheme 13, a compound of the formula (45) is reacted with bromine in acetic acid at a temperature from about 0°C to about 60°C, preferably at about room temperature. This reaction produces the corresponding compound having a bromine substituent para to the fluoro substituent, which can then be converted into the corresponding boronic acid derivative of formula (46) as described above for the synthesis of compounds of the formula (32) (in Scheme 6) and (44) (in Scheme 11).
Addition of the 2,5-dimethylpyrroyl protecting group as described above for the synthesis of compounds of the formula (34) (in Scheme 6) yields the corresponding compound of formula (47). The compound of formula (47) is then reacted with a compound of the fomnula R R4NOH and an alkali metal hydride, preferably sodium hydride, in a polar, organic solvent such as DMF or DMSO, preferably DMF, at a temperature between about 50°C and about 110°C, preferably at about 100°C, to form a compound that is identical to the corresponding desired compound of formula IVN, but for the presence of the 2,5-dimethylpyrrolyl protecting group. Removal of the protecting group, as described above for the preparation of compounds of the formula IVA (in Scheme 6) yields the desired compound of formula IVN.
Scheme 14 illustrates a method of synthesizing compounds of the formula I wherein G is an optionally substituted pyrrolidin-2-yl or pyrrolidin-3-yl group. Referring to Scheme 14, a compound of the formula IVA is reacted with a compound of the formula
Figure imgf000076_0001
triphenylphosphine and diethylazodicarboxylate or another water soluble azodicarboxylate in THF under standard Mitsunobo reaction conditions. Typically, the reactants are combined at about 0°C and then allowed to warm to room temperature. (If an alkyl substituent on the pyrrolidine nitrogen other than methyl is desired in the final product of formula IVP, this can be accomplished by replacing the BOC group of formula (49) with a group of the formula -C(=0)R, wherein R is the desired alkyl group).
The compound of formula (48) that is formed in the above reaction (or the corresponding -C(=0)R protected compound) can be converted into the desired product having formula IVP (or a similar compound wherein the methyl substituent depicted in structure IVP is replaced with another alkyl group) by reducing it. This reduction can be accomplished by reacting the product from the preceding reaction with lithium aluminum hydride and aluminum chloride in THF or borane in THF as described above for the formation of compounds of the formula IVC.
The corresponding compound of formula IV wherein the alkyl substituent on the pyrrolidine nitrogen formula IVP is replaced with hydrogen can be obtained by reacting the compound of formula (48), or an alkyl analogue of (48), as referred to above, with trifluoroacetic acid or hydrochloric acid in a solvent such as dioxane, or ether, preferably dioxane, at a temperature from about 0°C to about reflux temperature of the reaction mixture, preferably at about the reflux temperature. The starting materials used in the procedures of Schemes 6-14 are, the syntheses of which are not described above, either commercially available, known in the art or readily obtainable from known compounds using method that will be apparent to those skilled in the art.
The preparation of other compounds of the formula IV not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.
In each of the reactions discussed or illustrated above, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, e., about 1 atmosphere, is preferred as a matter of convenience. Compounds of the formula V and their pharmaceutically acceptable salts can be prepared as described in World Patent Application W098/24766, entitled "6-Phenylpyridyl-2-amine Derivatives", published June 11, 1998, and the U.S. provisional application from which it claims priority, Ser. No. 60/032793, filed December 6, 1996. The foregoing applications are incoφorated herein by reference in their entirety. Schemes 15-19 below illustrate methods of preparing compounds of the formula V.
SCHEME 15
Figure imgf000077_0001
G=B SCHEME 16
Figure imgf000078_0001
1. alkylate
2. reduce NH2OH HCI
Figure imgf000078_0002
Figure imgf000078_0003
VA-a
SCHEME 17
Figure imgf000079_0001
VA-b
G=A, X=N n=1, q=1 , Y is benzyl
SCHEME 18
Figure imgf000080_0001
(60)
Figure imgf000080_0002
VA-c
G=A, q=1 χ=CH, Y=NR3R4 SCHEME 19
Figure imgf000081_0001
(Y = benzyl)
BuLi (64)
Figure imgf000081_0002
VA-d
G=A, q=0, X=N Y=H The starting materials used in the procedures of Schemes 15-19 are either commercially available, known in the art or readily obtainable from known compounds using methods that will be apparent to those skilled in the art.
Referring to Scheme 15, compound (50) is prepared by reaction of 1 ,4-dibromobenzene with an organolithium reagent, preferably butyl lithium, at a temperature from -100°C to about 0°C, followed by addition to 2-(2,5-dimethylpyrrolyl)-pyridine at a temperature from about 0°C to about 50°C in an ethereal solvent, preferably diethyl ether, for about 1 to 24 hours. Compound (51) is prepared by reacting (50) with a boronic acid derivative of the formula p-OHC(CH2)m- 2(C6H3R1R2)B(OH)2 in a solvent consisting of an alcohol, preferably ethanol, optionally mixed with water and a halogenated hydrocarbon, at a temperature from about 25°C to about 150°C, for about 1 to 24 hours, using a palladium-based catalyst, either palladium-zero or palladium-two oxidation state, typically with phosphine ligands, preferably tetrakis-triphenylphosphine palladium.
Compound (52) is prepared by reacting (51) with tosylmethylisocyanide in the presence of potassium t-butoxide and ethanol, in an ethereal solvent such as 1,2-dimethoxyethane, at a temperature from about -100°C to about 100°C, for about 1 to 24 hours. Compound (53) is prepared from (52) by basic hydrolysis of the nitrite using an alkali metal hydroxide in an aqueous alcohol-based solvent, such as aqueous ethanol, at a temperature from about 25°C to about 125°C, for about 30 minutes to 48 hours. Compound (54) is prepared from (53) by dehydrative coupling with ammonia, a primary or secondary amine of the fomnula R3R NH effected by a dehydrating agent such as a carbodiimide, for example, N-ethyl-N-(dimethylaminopropyl)- carbodiimide, in a solvent that is a halogenated hydrocarbon or a N.N-dialkylamide, such as dimethylformamide, at a temperature from about 0°C to about 100°C, for about 1 to 48 hours. Compound (55) is prepared from (54) by deblocking using hydroxylamine hydrochloride in an aqueous or alcoholic solvent, preferably aqueous ethanol, at a temperature from about 25°C to about 100°C, for about 1 to 48 hours, and may include deblocking a protecting group such a the t- butoxycarbonyl group by reaction with trifluoroacetic acid or a related polyhalogenated acetic acid or a gaseous hydrogen halide such as HCI, in a halogenated hydrocarbon, ethereal solvent or ethyl acetate, at a temperature from about -70°C to about 100°C, for about 10 minutes to 24 hours. The final compound in Scheme 15, VB, wherein G=B, is prepared by reduction of (55) with borane, a trialkyl borane, alane, or lithium aluminum hydride in an ethereal solvent, such as ethyl ether or tetrahydrofuran, at a temperature from about -100°C to about 100°C, for about 30 minutes to 24 hours, and optionally using cesium fluoride and an alkali metal or alkaline earth carbonate in an aqueous alcoholic solvent, at a temperature from about 25CC to about 125°C for 1 to 72 hours.
Referring to Scheme 16, compound (56) is prepared from (50) by reaction with 3-pyridyl boronic acid and a palladium catalyst, in either the palladium-zero or palladium-two oxidation state, with ligands typically comprised of trialkyl or triaryl phosphines, such as tetrakis-triphenylphosphine palladium, in an aqueous alcoholic solvent at a temperature from about 25°C to about 125°C for about 1 to 48 hours. Compound (57) is prepared from (56) by alkylation with an alkyl or aralkyl halide or sulfonate, in an ethereal, alcoholic , aqueous alcoholic, or dialkylamine-based solvent, such as dimethylformamide, at a temperature from about 0°C to about 125°C for about 30 minutes to 72 hours, followed by reduction with a borohydride- or aluminum hydride-based reagent, such as sodium borohydride, in an ethereal, alcoholic, or aqueous-alcoholic solvent, typically methanol, at a temperature from about 0°C to about 125°C for about 1 to 72 hours. The final compound in Scheme 16, compound VA-a, where G=A, n=1, and q=0, is prepared from (57) by deblocking with hydroxylamine hydrochloride in an alcoholic or aqueous-alcoholic solvent, typically aqueous ethanol, at a temperature from about 25°C to about 125°C for about 1 to 72 hours.
In the process of Scheme 16, the preferred value of Y in formulas (57) and VA-a is benzyl. Compounds of the formula VA-a wherein Y is benzyl can be converted into the corresponding compounds wherein Y is other than benzyl by debenzylation using hydrogen or ammonium formate in the presence of a noble metal catalyst, such as palladium, in an ethereal, halogenated hydrocarbon, alcoholic, or aqueous alcoholic solvent, at a temperature from 0CC to 100°C for a time from 30 minutes to 24 hours, followed by reductive amination with an alkyl or aralkyl aldehyde in the presence of a borohydride-based reagent such as sodium cyanoborohydride or sodium triacetoxyborohydride, in an ethereal, halogenated hydrocarbon, alcoholic, or aqueous-alcoholic solvent, at a temperature from 0°C to 100°C for a time from 1 to 72 hours.
Referring to Scheme 17, compound (58) is prepared by reductive amination of 2-(4- bromophenylmethyl)-piperidine with benzaldehyde and a borohydride-based reagent such as sodium cyanoborohydride or sodium triacetoxyborohydride, in an ethereal, halogenated hydrocarbon, alcoholic, or aqueous-alcoholic solvent, at a temperature from about 0°C to about 100°C for about 1 to 72 hours. Compound (59) is prepared from compound (58) by reaction of compound (58) with an organolithium reagent, typically butyl lithium, followed by addition of the resulting organolithium reagent to 2-(2,5-dimethylpyrrolyl)-pyridine, in an ethereal solvent such as ethyl ether, at a temperature from about -70°C to about 100°C for about 30 minutes to 48 hours. The final compound in Scheme 17, lA-b, wherein G=A, n=1, q=1 and Y is benzyl, is prepared from compound (59) by deblocking with hydroxylamine hydrochloride in an alcoholic or aqueous- alcoholic solvent, typically aqueous ethanol, at a temperature from about 25°C to about 125°C for about 1 to 72 hours.
Compounds of the formula lA-b can be converted into the corresponding compounds wherein Y is other than benzyl using the procedure described above for converting compounds of the formula lA-a into the analogous compounds wherein Y is other than benzyl.
Referring to Scheme 18, compound (60) is prepared from 6-bromo-2-(2,5- dimethylpyrrolyl)-pyridine and 4-formylphenylboronic acid in the presence of a palladium catalyst, . -
in either the palladium-zero or palladium-two oxidation state, with ligands typically comprised of trialkyl or triaryl phosphines, such as tetrakis-triphenylphosphine palladium, in an aqueous alcoholic solvent, at a temperature from about 25°C to about 125°C for about 1 to 48 hours. Compound (61) is then prepared from (60) by reaction of (60) with the enamine of a ketone or aldehyde, typically the moφholine or pyrrolidine enamine, in a aromatic hydrocarbon, hydrocarbon, or halogenated hydrocarbon solvent, preferably toluene, at a temperature from about 25°C to about 150°C for about 1 to 72 hours, followed by an aqueous hydrolysis step, typically with aqueous hydrochloric acid, and then reduction with hydrogen or ammonium formate in the presence of a noble metal catalyst, such as palladium, in an ethereal, halogenated hydrocarbon, alcoholic, or aqueous alcoholic solvent, at a temperature from about 0°C to about 100°C for about 30 minutes to 24 hours. The final compound in Scheme 18, VA, where G=A, q=1, X=CH, and Y=NR3R4, is prepared by reductive amination of compound (61) with ammonia, a primary amine, or a secondary amine in the presence of a borohydride-based reagent such as sodium cyanoborohydride or sodium triacetoxyborohydride, in an ethereal, halogenated hydrocarbon, alcoholic, or aqueous-alcoholic solvent, at a temperature from about 0°C to about 100°C for about 1 to 72 hours, followed by deblocking with hydroxylamine hydrochloride in an alcoholic or aqueous- alcoholic solvent, typically aqueous ethanol, at a temperature from about 25CC to about 125°C for about 1 to 72 hours.
Referring to Scheme 19, compound (62) is prepared from 3-(4-bromophenyl)-glutaric acid by dehydration with acetic anhydride or a similar dehydrating reagent, followed by reaction with benzylamine in a hydrocarbon, aromatic hydrocarbon, or halogenated hydrocarbon solvent, at a temperature from about 25°C to about 180°C for about 1 to 48 hours, followed by dehydration with acetic anhydride, or a similar dehydrating reagent, at a temperature from about 25CC to about reflux for about 1 to 48 hours. Compound (63) is prepared by reduction of (64) with borane, borane methyl sulfide, alane, or lithium aluminum hydride in an ethereal or hydrocarbon solvent, at a temperature from about 0°C to about 100°C for about 30 minutes to 48 hours. Compound (64) is prepared from compound (63) by reaction of compound (63) with an organolithium reagent, typically butyl lithium, followed by addition of the resulting organolithium reagent to 2-(2,5- dimethylpyrrolyl)-pyridine, in an ethereal solvent, such as ethyl ether, at a temperature from about - 70°C to about 100°C for about 30 minutes to 48 hours. The final compound in Scheme 19, VA-d, where G=A, Y=H, q=0, and X=N, is prepared by debenzylation of compound (64) using hydrogen or ammonium formate in the presence of a noble metal catalyst, such as palladium, in an ethereal, halogenated hydrocarbon, alcoholic, or aqueous alcoholic solvent, at a temperature from 0°C to 100°C for a time from 30 minutes to 24 hours, followed by deblocking with hydroxylamine hydrochloride in an alcoholic or aqueous-alcoholic solvent, typically aqueous ethanol, at a temperature from about 25°C to about 125°C for about 1 to 72 hours. - -
Compounds of the formula VA-d, which are prepared using the procedures of Scheme 19, can be converted into the analogous compounds wherein Y is alkyl or aralkyl, by reductive amination with an alkyl or aralkyl aldehyde in the presence of a borohydride-based reagent such as sodium cyanoborohydride or sodium triacetoxyborohydride, in an ethereal, halogenated hydrocarbon, alcoholic, or aqueous-alcoholic solvent, at a temperature from 0°C to 100°C for a time from 1 to 72 hours.
The preparation of other compounds of the formula V not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art. In each of the reactions discussed or illustrated above, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, he., about 1 atmosphere, is preferred as a matter of convenience.
Compounds of the formula VI can be prepared as described below and in the U.S. provisional application 60/087881, filed June 3, 1998, entitled "2-Aminopyridines Containing Fused
Ring Substituents"; and World Patent Application PCT/IB99/00825, filed May 7, 1999, designating the United States, which claims priority from provisional application 60/087881. The foregoing applications are incoφorated herein by reference in their entirety.
Scheme 20 below illustrates a method of preparing compounds of the formula VI.
Scheme 20
Figure imgf000086_0001
(68)
Figure imgf000086_0002
(69) (70)
Referring to Scheme 20, the compound of formula (65) is prepared by reaction of norbornylene and 2-hydroxypyrone followed by aromatization with palladium oxide, according to the procedure described in Syn. Commun., 5, 461, (1975). It is then reacted with tetrabutylammonium tribromide in 1 ,2-dichloroethane at about room temperature for about 10 minutes to about 10 hours. The product of this reaction is then treated with benzyl bromide and potassium carbonate in a solvent such as acetonitrile, at about the reflux temperature of the reaction mixture for about 1 to 48 hours, to form the compound of formula (66).
The compound of formula (66) is then converted into 5-benzyloxy-1 ,2,3,4-tetrahydro-1 ,4- methano-naphthalene-8-boronic acid by cooling the compound of formula III to about -70°C in dry tetrahydrofuran (THF), and adding a solution of n-butyl lithium to it. The resulting solution is then treated with triethyl borate and allowed to warm to room temperature for about 1 to 48 hours to form 5-benzyloxy-1,2,3,4-tetrahydro-1,4-methano-naphthalene-8-boronic acid. Reaction of 5- benzyloxy-1 ,2,3,4-tetrahydro-1 ,4-methano-naphthalene-8-boronic acid with 6-bromo-2-(2,5- dimethylpyrrolyl)pyridine in an ethanol solvent, in the presence of sodium carbonate and tetrakistriphenylphosphine palladium, at about the reflux temperature for about 1 to 48 hours of the reaction mixture, yields the compound of formula (67).
The compound of fomnula (67) can be converted into the compound of formula V using the following two step process. The compound of formula (67) is reacted with ammonium formate and ten percent palladium on carbon, in an ethanol solvent, at about the reflux temperature of the reaction mixture, for about 10 minutes to about 10 hours to yield the analogous compound to that having formula (67), wherein the benzyloxy group of formula (67) is replaced with a hydroxy group. The compound of formula (68) is then formed by reacting the above hydroxy derivative with 2- bromoethylacetate and potassium carbonate in acetonitrile at about the reflux temperature of the reaction mixture for about 1 to 48 hours. Basic hydrolysis of the compound of formula (68), followed by reaction with N-ethyl-N-3- dimethylaminopropylcarbodiim.de (EDAC) and the appropriate compound having the formula R1R2NH yields the desired compound of the formula (69). The base hydrolysis is typically carried out using an alkali metal or alkaline earth metal hydroxide in a mixture of THF, methanol and water at about room temperature for about 1 to 48 hours. The reaction with the appropriate compound of the formula R1R2NH and N-ethyl-N-dimethylaminopropyl carbodiimide (EDAC) is conducted in the presence of a base. Examples of suitable bases are those selected from trialkylamines, alkali metal carbonates and alkaline earth metal carbonates. This reaction is typically conducted in a solvent such as acetonitrile, methylene chloride or N,N-dimethylformamide (DMF), at a temperature from about room temperature to about 100°C, preferably at about room temperature for about 1 to 48 hours. Preferably, the reaction is conducted in the presence of a catalytic additive such as N-hydroxysuccinamide or hydroxybenzotriazole. The compound of formula (69) can be converted into the desired compound of formula I as follows. The compound of formula (69) is reduced to form the corresponding compound wherein the carbonyl group is replaced by a methylene group, after which the 2,5-dimethylpyrrolyl protecting group is removed. The reduction can be carried out using methods well known to those of skill in the art, for example, using lithium aluminum hydride in tetrahydrofuran, with or without aluminum chloride, or using borane methyl sulfide in tetrahydrofuran, at a temperature of about -78°C to about reflux, preferably at about -70°C to room temperature for about 1 to about 24 hours.
Removal of the 2,5-dimethylpyrrolyl protecting group can be accomplished by reaction with hydroxylamine hydrochloride. This reaction is generally carried out in an alcoholic or aqueous alcoholic solvent (preferably, using ethanol as the alcohol), at a temperature from about room temperature to about the reflux temperature of the reaction mixture, preferably at about the reflux temperature, for about 8 to about 72 hours.
Compounds of the formula VI wherein there is a heteroatom in one of the bridging rings can be prepared in an analogous fashion, starting with the appropriate compound that is analogous to that of formula (65), wherein the unsubstituted bridged ring of formula (65) is replaced by a bridged ring comprising a heteroatom.
The preparation of other compounds of the formula VI not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.
In each of the reactions discussed or illustrated above, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, e., about 1 atmosphere, is preferred as a matter of convenience. The compounds of formulas l-VI that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I, II, III, IV, V or VI from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the active base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.
The compounds of formulas I, II, III, IV, V and VI, and their pharmaceutically acceptable salts, are useful as NOS inhibitors Le., they possess the ability to inhibit the NOS enzyme in mammals, and therefore they are able to function as therapeutic agents in the treatment of the aforementioned disorders and diseases in an afflicted mammal.
The ability of compounds of formulas l-VI to inhibit NOS may be determined using procedures described in the literature. The ability of compounds of the formulae I to inhibit endothelial NOS may be determined by using the procedures described by Schmidt et aL in Proc. Natl. Acad. Sci. U.S.A., 88, pp. 365-369 (1991) and by Pollock et a]., in Proc. Natl. Acad. Sci. U.S.A., 88, pp. 10480-10484 (1991). The ability of compounds of the formulae I to inhibit inducible NOS may be determined using the procedures described by Schmidt et aL, in Proc. Natl. Acad, Sci. U.S.A., 88 pp. 365-369 (1991) and by Garvey et aL in J. Biol. Chem., 269, pp. 26669-26676 (1994). The ability of the compounds of the formulae I to inhibit neuronal NOS may be determined using the procedure described by Bredt and Snyder in Proc. Natl. Acad. Sci. U.S.A., 87, 682-685 (1990).
The compounds of formula l-VI and their pharmaceutically acceptable salts can be administered via either the oral, parenteral or topical routes. In general, these compounds are most desirably administered, when used as the single active agent for the treatment of disorders or conditions that can be treated by altering circadian rhythms, in dosages ranging from about 0.01 to about 250 mg per day, in single or divided doses (Le., from 1 to 4 doses per day), although variations will necessarily occur depending upon the species, weight and condition of the subject being treated and the particular route of administration chosen. However, a dosage level that is in the range of about 0.07 mg to about 21 mg per kg of body weight per day is most desirably employed. Variations may nevertheless occur depending upon the species of animal being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.
The compounds of formulas l-VI may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by either of the three routes previously indicated, and such administration may be carried out in single or multiple doses. More particularly, such therapeutic agents can be administered in a wide variety of different dosage forms, Le., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the therapeutically-effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight. For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably com, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting puφoses. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
For parenteral administration, solutions of a compound of the formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt thereof, in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection puφoses. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
Additionally, it is also possible to administer the compounds of formulas l-VI topically when treating inflammatory conditions of the skin, and this may be done by way of creams, jellies, gels, pastes, patches, ointments and the like, in accordance with standard pharmaceutical practice. This invention relates both to methods of treating disorders or conditions that can be treated by altering circadian rhythms in which the NOS inhibiting compound and the SSRI and/or NK-1 receptor antagonist are administered together, as part of the same pharmaceutical composition, and to methods in which these active agents are administered separately as part of an appropriate dose regimen designed to obtain the benefits of the combination therapy. The appropriate dose regimen, the amount of each dose administered, and specific intervals between doses of each active agent will depend on the subject being treated, and the source and severity of the condition. Generally, in carrying out the methods of this invention, the NOS inhibiting compound will be administered to an average 70 kg adult human in an amount ranging from about 0.01 to about 10 mg per kg body weight of the subject being treated per day, in single or divided doses, preferably from about 1 to about 3 mg/kg, the SSRI will be administered in an amount ranging from about 0.2 to about 30 mg per kg body weight of the subject being treated per day, in single or divided doses, and the NK-1 receptor antagonist will be administered in an amount ranging from about 0.16 to about 500 mg per day, in single or divided doses. Variations may nevertheless occur depending upon the species of animal being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.

Claims

1. A pharmaceutical composition for treating a disorder or condition that can be treated by altering circadian rhythms in a mammal, comprising a NOS inhibiting compound or pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition according to claim 1 , comprising:
(a) a NOS inhibiting compound, or pharmaceutically acceptable salt thereof; and
(b) an NK-1 receptor antagonist or a pharmaceutically acceptable salt thereof; wherein the agents "a" and "b" are present in such composition in amounts that render the combination of the two agents effective to treat a disorder or condition that can be treated by altering circadian rhythms.
3. A pharmaceutical composition according to claim 1, comprising:
(a) a NOS inhibiting compound or pharmaceutically acceptable salt thereof;
(b) an NK-1 receptor antagonist or pharmaceutically acceptable salt thereof; and
(c) an SSRI or pharmaceutically acceptable salt thereof; wherein the agents "a", "b" and "c" are present in such composition in amounts that render the combination of the three agents effective to treat a disorder or condition that can be treated by altering circadian rhythms.
4. A pharmaceutical composition according to claim 1 , comprising:
(a) a NOS inhibiting compound or pharmaceutically acceptable salt thereof; and (b) an SSRI or a pharmaceutically acceptable salt thereof; wherein the agents "a" and "b" are present in such composition in amounts that render the combination of the two agents effective to treat a disorder or condition that can be treated by altering circadian rhythms.
5. A pharmaceutical composition according to claim 1 wherein the disorder or condition is selected from blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, REM sleep disorders, hypersomnia, parasomnias, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.
6. A pharmaceutical composition according to any of claims 2, 3 or 4 wherein the disorder or condition is selected from dysthymia, major depressive disorder, bipolar disorder, seasonal affective disorder and other mood disorders; anxiety disorders including generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social phobias, agoraphobia and other phobias; blindness, obesity, stroke, jet lag, sleep disorders such as circadian sleep rhythm disorders, narcolepsy, sleep apnea, REM sleep _ .
disorder, parasomnias, sleep-wake cycle disorders, sleep deprivation, insomnia, hypersomnia, and sleep disorders associated with advancing age, shift work or irregular work schedules; nocturnal enuresis, restless-legs syndrome and cognitive disorders such as dementias and memory disorders.
7. A pharmaceutical composition according to claims 3 or 4, wherein the SSRI is sertraline, fluoxetine, fluvoxamine, citalopram or paroxetine.
8. A pharmaceutical composition according to claims 2 or 3, wherein the NK-1 receptor antagonist that is employed in said method is selected from the following compounds and their pharmaceutically acceptable salts: 2-(Diphenylmethyl)-N-((2-difluoromethoxy)phenyl)methyl-1 -azabicyclo[2.2.2]octan-3- amine;
(2S,3S)-N-(2-Methoxy-5-trifluoromethoxyphenyl)methyl-2-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-amine;
(2S,3S)-2-Phenyl-3-[2-(2,2,2-trifluoroethoxy)benzyl]-aminopiperidine; (2S,3S)-3-(2-Methoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
(2S,3S)-1-(5,6-Dimethoxyhexyl)-3-(2-methoxy-5-trifluoromethoxybenzyl)amino-2- phenylpiperidine;
(2S,3S)-2-Phenyl-3-(2-trifluoromethoxybenzyl)aminopiperidine;
(2S,3S)-3-(2-Hydroxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine; (2S,3S)-3-[5-Chloro-2-(2,2,2-trifluoroethoxy)-benzyl]amino-2-phenylpiperidine;
(2S,3S)-2-Phenyl-3-(3-trifluoromethoxybenzyl)-aminopiperidine;
(2S,3S)-3-(5-t-Butyl-2-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
(2S,3S)-3-[5-lsopropyl-2-(2,2,2-trifluoroethoxy)-benzyl]amino-2-phenylpiperidine;
(2S,3S)-3-[5-Dimethylamino-2-(2,2,2-trifluoroethoxy)-benzyl]amino-2- phenylpiperidine;
(2S,3S)-3-(2-Difluoromethoxy-5-N,N-dimethylamino-benzyl)amino-2-phenylpiperidine;
(2S,3S)-3-[2,5-bis(difluoromethoxy)benzyl]amino-2-phenylypiperidine;
(2S,3S)-3-(5-t-Butyl-2-difluoromethoxybenzyl)amino-2-phenylpiperidine;
(2S,3S)-3-(2-lsopropoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine; (2S,3S)-3-(2-Difluoromethoxy-5-trifluoromethoxybenzyl)-amino-2-phenylpiperidine;
(2S,3S)-3-(2-Ethoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine;
(2S,3S)-3-(2-Difluoromethoxy-5-nitrobenzyl)amino-2-phenylpiperidine;
(2S,3S)-3-(2-Difluoromethoxy-5-isopropylbenzyl)amino-2-phenylpiperidine;
(2S,3S)-3-[5-Acetamido-2-(2,2,2-trifluoroethoxy)-benzyl]amino-2-phenylypiperidine; (2S,3S)-3-(2-Difluoromethoxy-5-ethylbenzyl)amino-2-phenylpiperidine; cis-3-(5-t-Butyl-2-methoxybenzyl)amino-2-(3-trifluoromethoxyphenyl)piperidine; cis-2-(3,5-Dibromophenyl)-3-(2-methoxy-5-trifluoromethoxybenzyl)aminopiperidine; (2S-3S)-3-(2-Difluoromethoxy-5-methylbenzyl)amino-2-phenylpiperidine; (2S,3S)-3-(5-tert-butyl-2-methoxybenzyl)amino-2-(3-trifluoromethoxyphenyl)piperidine; (2S,3S)-3(-5-tert-butyl-2-trifluoromethoxybenzyl)amino-2-phenylpiperidine; 2-(diphenylmethyl)-N-(2-methoxy-5-trifluoromethoxy-phenyl)methyl-1- azabicyclo[2.2.2]octan-3-amine; cis-3 2-chlorobenzylamino)-2-phenylpiperidine; cis-3 2-trifluoromethylbenzylamino)-2-phenyl-piperidine; cis-3 2-methoxybenzylamino )-2-(2-fluorophenyl)-piperidine; cis-3 2-methoxybenzylamino )-2-(2-chlorophenyl)-piperidine; cis-3 2-methoxybenzylamino )-2-(2-methylphenyl)-piperidine; cis-3 2-methoxybenzylamino )-2-(3-methoxyphenyl)-piperidine; cis-3 2-methoxybenzylamino )-2-(3-fluorophenyl)-piperidine; cis-3 2-methoxybenzylamino; )-2-(3-chlorophenyl)-piperidine; cis-3-ι 2-methoxybenzylamino )-2-phenylpiperidine; cis-3 2-methoxybenzylamino )-2-(3-methylphenyl)-piperidine; cis-3 2-methoxybenzylamino; )-2-(4-fluorophenyl)-piperidine; cis-3-ι 2-methoxybenzylamino )-2-(3-thienyl)-piperidine; cis-3 (2-methoxybenzylamino ))-2-phenylazacyclo-heptane;
3-(2-methoxybenzylamino)-4-methyl-2-phenylpiperidine;
3-(2-methoxybenzylamino)-5-methyl-2-phenylpiperidine;
3-(2-methoxybenzylamino)-6-methyl-2-phenylpiperidine;
(2S,3S)-3-(2-methoxybenzyiamino)-2-phenylpiperidine;
(2S,3S)-1-(5-carboethoxypent-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
(2S,3S)-1-(6-hydroxy-hex-l-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
(2S,3S)-1-(4-hydroxy-4-phenylbut-1-yl)-3-(2-methoxy-benzylamino)-2-phenylpiperidine;
(2S,3S)-1-(4-oxo-4-phenylbut-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
(2S,3S)-1-(5,6-dihydroxyhex-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine; cis-3-(5-fluoro-2-methoxybenzylamino)-2-phenyl-piperidine;
(2S,3S)-1-[4-(4-fluorophenyl)-4-oxobut-1-yl]-3-(2-methoxybenzylamino)-2- phenylpiperidine;
(2S,3S)-1-[4-[4-fluorophenyl)-4-hydroxybut-1-yl]-3-(2-methoxybenzylamino)-2- phenylpiperidine; cis-3-(2-methoxy-5-methylbenzylamino)-2-phenyl-piperidine;
(2S,3S)-1-(4-benzamidobut-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine; cis-3-(2-methoxynaphth-1-ylmethylamino)-2-phenyl-piperidine; (2S,3S)-3-(2-methoxybenzylamino)-1-(5-N-methyl-carboxamidopent-1-yl)-2- phenylpiperidine;
(2S,3S)-1-(4-cyanobut-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
(2S,3S)-1-[4-(2-naphthamido)but-1-yl]-3-(2-methoxy-benzylamino)-2-phenylpiperidine; (2S,3S)-1-(5-benzamidopent-1-yl)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine;
(2S,3S)-1-(5-aminopent-1-yl)-3-(2-methoxybenzylamino)-2-phenylpiperidine;
(2S,3S)-3-(5-chloro-2-methoxybenzylamino)-2-phenyl-piperidine;
(2S,3S)-3-(2,5-dimethoxybenzylamino)-2-phenyl-piperidine; cis-3-(3,5-difluoro-2-methoxybenzylamino)-2-phenyl-piperidine; cis-3-(4,5-difluoro-2-methoxybenzylamino)-2-phenyl-piperidine; cis-3-(2,5-dimethoxybenzylamino)-1-[4-(4-fluorophenyl)-4-oxobut-1-yl]-2- phenylpiperidine; cis-3-(5-chloro-2-methoxybenzylamino)-1-(5,6-dihydroxyhex-1-yl)-2-phenylpiperidine; cis-1-(5,6-dihydroxyhex-1-yl)-3-(2,5-dimethoxy-benzylamino)-2-phenylpiperidine; cis-2-phenyl-3-[-2(prop-2-yloxy)benzylamino]piperidine; cis-3-(2,5-dimethoxybenzyl)amino-2-(3-methoxy-phenyl)piperidine hydrochloride; cis-3-(5-chloro-2-methoxybenzyl)amino-2-(3-methoxy-phenyl)piperidine dihydrochloride; cis-3-(5-chloro-2-methoxybenzyl)amino-2-(3-chloro-phenyl)piperidine dihydrochloride; 3-(2-methoxybenzylamino)-2,4-diphenylpiperidine; cis-3-(2-methoxybenzylamino)-2-phenylpyrrolidine;
(2S,3S)-3-(5-ethyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(5-n-butyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(2-methoxy-5-n-propylbenzyl)amino-2-phenyl-piperidine; (2S,3S)-3-(5-isopropyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(5-s-butyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(5-t-butyl-2-methoxybenzyl)amino-2-phenyl-piperidine;
(2S,3S)-3-(2-methoxy-5-phenylbenzyl)amino-2-phenyl-piperidine;
2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3- yiaminomethyl)phenyl]-methylamide;
N-(4,5-dimethylthiazol-2-yl)-N-[4-methoxy-3-((2S,3S)-2-phenyipiperidin-3-yl- aminomethyl)phenyl]-methanesulfonamide;
{5-[(4,5-dimethylthiazol-2-yl)methylamino]-2-methoxybenzyl}-((2S,3S)-2- phenylpiperidin-3-yI)amine; {5-(4,5-dimethylthiazol-2-ylamino)-2-methoxybenzyl}-((2S,3S)-2-phenylpiperidin-3- ylamine; 4,5-dimethylthiazole-2-sulfonic acid methyl-[3-((2S,3S)-2-phenylpiperidin-3- ylaminomethyl)-4-trifluoromethoxyphenyl]-amide;
2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3- ylaminomethyl)phenyl]-methylamide; 2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-
3-ylaminomethyl)phenyl]-isopropylamide;
2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3- ylaminomethyl)phenyl]-isopropylamide;
2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenyipiperidin-3- ylaminomethyl)phenyl]-isobutylamide;
2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3- ylaminomethyl)phenyl]-isobutylamide;
(2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]- octan-3-amine; (2S,3S)-N-(5-tert-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1- azabicyclo[2.2.2]octan-3-amine;
(2S,3S)-N-(5-methyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1- azabicyclo[2.2.2]octan-3-amine;
(2S,3S)-N-(5-ethyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan- 3-amine;
(2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1- azabicyclo[2.2.2]octan-3-amine;
(2S,3S)-N-(5-sec-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1- azabicyclo[2.2.2]octan-3-amine; (2S,3S)-N-(5-n-propyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1- azabicyclo[2.2.2]octan-3-amine,
(3R,4S,5S,6S)-N,N-diethyl-5-(5-isopropyl-2-methoxy-benzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxamide;
(3R,4S,5S,6S)-N,N-diethyl-5-(2,5-dimethoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxamide;
(3R,4S,5S,6S)-5-(5-isopropyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-2-methylthiobenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid; (3R,4S,5S,6S)-5-(2,5-dimethoxybenzylamino)-6-diphenyl-methyl-1-azabicyclo-
[2.2.2]octane-3-carboxylic acid; (3R,4S,5S,6S)-5-(2-methoxy-5-methylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(5-ethyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid; (3R,4S,5S,6S)-5-(2-methoxyl-5-n-propylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(5-sec-butyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(5-N-methyl-methanesulfonylamino-2-methoxy-benzylamino)-6- diphenylmethyl-1-azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfinylbenzyl-amino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-trifluoromethoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid; (3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfonylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(5-dimethylamino-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-3-carboxylic acid;
(3R,4S,5S,6S)-5-(5-isopropyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methylthiobenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(2,5-dimethoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid; (3R,4S,5S,6S)-5-(2-methoxy-5-methylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(5-ethyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-n-propylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(5-sec-butyl-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(5-N-methyl-methanesulfonylamino-2-methoxybenzyl-amino)-6- diphenylmethyl-1 -azabicyclo[2.2.2]octane-2-carboxylic acid; (3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfinylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid; (3R,4S,5S,6S)-5-(2-methoxy-5-trifluoromethoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
(3R,4S,5S,6S)-5-(2-methoxy-5-methylsulfonylbenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid; and
(3R,4S,5S,6S)-5-(5-dimethylamino-2-methoxybenzylamino)-6-diphenylmethyl-1- azabicyclo[2.2.2]octane-2-carboxylic acid;
Figure imgf000098_0001
9. A pharmaceutical composition according to any of claims 1 , 2, 3 or 4, wherein the NOS inhibiting compound is selected from the following compounds and their pharmaceutically acceptable salts:
6-[4-(3-Amino-cyclohexyloxy)-naphthalen-1 -yl]-pyridin-2-ylamine;
6-[4-(3-Amino-cyclopentyloxy)-naphthalen-1 -yl]-pyridin-2-ylamine;
6-[4-(3-Amino-cyclobutyloxy)-naphthalen-1 -yl]-pyridin-2-ylamine;
6-[4-(4-Amino-cyclohexyloxy)-naphthalen-1-yll-pyridin-2-ylamine; 6-[4-(2-Amino-cyclopentyloxy)-indan-4-yl]-pyridin-2-ylamine;
6-[4-(2-Amino-cyclobutyloxy)-indan-4-yl]-pyridin-2-ylamine;
6-[4-(2-Amino-cyclopropyloxy)-indan-4-yl]-pyridin-2-ylamine;
6-[4-(3-Amino-cyclohexyloxy)-indan-4-yl]-pyridin-2-ylamine;
6-[4-(3-Amino-cyclopentyloxy)-indan-4-yl]-pyridin-2-ylamine; 6-[4-(3-Amino-cyclobutyloxy)-indan-4-yl]-pyridin-2-ylamine;
6-[4-(4-Amino-cyclohexyloxy)-indan-4-yl]-pyridin-2-ylamine; 6-[4-Piperidin-3-ylmethoxy)-6,7,8,9-tetrahydro-5H-benzocyclohepten-1 -yl]- pyridin-2-ylamine;
6-[4-(2-Pyrrolidinyl-ethoxy)-6,7.8.9-tetrahydro-5H-benzocyclohepten-1 -yl]-pyridin- 2-ylamine; 6-[4-(2-Amino-cyclohexyloxy)-6,7,8,9-tetrahydro-5H-benzocyclohepten-1 -yl]- pyridin-2-ylamine;
6-[4-(2-Dimethylamino-ethoxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-[4-(2-Pyrrolidin-1 -yl-ethoxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-(4-{2-[(Benzo[1 ,3]dioxol-5-ylmethyl)-amino]-ethoxy}-naphthalen-1 -yl)-pyridin-2- ylamine;
6-{4-[2-(6,7-Dimethoxy-3,4-dihydro-1 H-isoquinolin-2-yl)-ethoxy]-naphthalen-1 - yl}-pyridin-2-ylamine;
3-{2-[4-(6-Amino-pyridin-2-yl)-naphthalen-1 -yloxy]-ethyl}-3-aza- bicycio[3.1 .01hex-6-ylamine; 6-{4-[2-(4-Phenethyl-piperazin-1 -yl)-ethoxy]-naphthalen-1 -yl}-pyridin-2-ylamine;
6-{4-[2-(3-Amino-pyrrolidin-1 -yl)-ethoxy]-naphthalen-1 -yl}-pyridin-2-ylamine; 6-[4-( 1 -Benzyl-piperidin-4-yloxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-[4-(1 -Benzyl-pyrrolidin-3-yloxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-[4-(Piperidin-4-yloxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-[4-(Pyrrolidin-3-yloxy)-naphthalen-1 -yl]-pyridin-2-ylamine;
6-[4-(1 -lsobutyl-piperidin-4-yloxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-[4-(1 -Furan-2-ylmethyl-piperidin-4-yloxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-[4-(1 -lsobutyl-pyrrolidin-3-yloxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-[4-(1 -Furan-2-ylmethyl-pyrrolidin-3-yloxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-[4-(2-Morpholin-4-yl-ethoxy)-naphthalen-1 -yl]-pyridin-2-ylamine;
6-[4-(2-Diisopropylamino-ethoxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-[4-(1 -Methyl-piperidin-4-yloxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-[4-(1 -Methyl-pyrrolidin-3-yloxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-[4-(3-Dimethylamino-propoxy)-naphthalen-1 -ylJ-pyridin-2-ylamine; 6-[4-(1-Aza-bicyclo[2.2.2]oct-3-yloxy)-naphthalen-1-yl]-pyridin-2-ylamine;
6-[4-(2-Piperidin-1 -yl-ethoxy)-naphthalen-1 -yl]-pyridin-2-ylamine 6-{4-[2-(3,4-Dihydro-1 H-isoquinolin-2-yl)-ethoxy]-naphthalen-1 -yl}-pyridin-2- ylamine; 6-{4-[2-(4-Dimethylamino-piperidin-1 -yl)-ethoxy]-naphthalen-1 -yl}-pyridin-2- ylamine;
6-{4-[2-(tert-Butyl-methyl-amino)-ethoxy]-naphthalen-1 -yl}-pyridin-2-ylamine;
6-{4-[2-(4-Methyl-piperazin-1 -yl)-ethoxy]-naphthalen-1 -yl}-pyridin-2-ylamine; 6-{4-[2-(4-Phenyl-piperidin-1 -yl)-ethoxy]-naphthalen-1 -yl}-pyridin-2-ylamine;
6-{4-[2-(7,8-Dihydro-5H-[1 ,3]dioxolo[4,5-g]isoquinolin-6-yl)-ethoxy]-naphthalen- 1 -yl}-pyridin-2-ylamine;
6-I4-(Piperidin-2-ylmethoxy)-naphthalen-1 -yl]-pyridin-2-ylamine;
6-[4-(1 -Methyl-piperidin-2-ylmethoxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-[4-(1 -Methyl-piperidin-3-ylmethoxy)-naphthalen-1 -yl]-pyridin-2-ylamine;
6-[4-(2-Amino-cyclohexyloxy)-naphthalen-1 -yl]-pyridin-2-ylamine;
6-[4-(Piperidin-3-ylmethoxy)-naphthalen-1 -yl]-pyridin-2-ylamine;
6-[4-(1 -lsobutyl-azetidin-3-yloxy)-naphthalen-1 -yl]-pyridin-2-ylamine;
6-[4-( 1 -Furan-2-ylmethyl-azetidin-3-yloxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-t4-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yloxy)-naphthalen-1 -yl]-pyridin-2- ylamine;
6-[4-( Azetidin-3-yloxy)-naphthalen- 1 -yl]-pyridin-2-ylamine;
6-[4-(1 -Methyl-pyrrolidin-2-ylmethoxy)-naphthalen-1 -yl]-pyridin-2-ylamine;
6-[4-(Azetidin-2-ylmethoxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-[7-(2-Dimethylamino-ethoxy)-indan-4-yl]-pyridin-2-ylamine;
6-[7-(2-Pyrrolidin-1 -yl-ethoxy)-indan-4-yl]-pyridin-2-ylamine;
6-{7-[2-(Benzyl-methyl-amino)-ethoxyl-indan-4-yl}-pyridin-2-ylamine;
6-{7-[2-(4-Phenethyl-piperazin-1 -yl)-ethoxy]-indan-4-yl}-pyridin-2-ylamine;
6-{7-[2-(4-lsobutyl-piperazin-1 -yl)-ethoxy]-indan-4-yl}-pyridin-2-ylamine; 6-[7-(2-Morpholin-4-yl-ethoxy)-indan-4-yl]-pyridin-2-ylamine;
6-[7-(2-Diisopropylamino-ethoxy)-indan-4-yl]-pyridin-2-ylamine;
6-{7-[2-(7,8-Dihydro-5H-[1 ,3]dioxolo[4,5-g]isoquinolin-6-yl)-ethoxyl-indan-4-yl}- pyridin-2-ylamine;
6-{7-[2-(4-Methyl-piperazin-1 -yl)-ethoxy]-indan-4-yl}-pyridin-2-ylamine; 6-{7-[2-(tert-Butyl-methyl-amino)-ethoxy]-indan-4-yl}-pyridin-2-ylamine;
6-{7-[2-(4-Dimethylamino-piperidin-1 -yl)-ethoxy]-indan-4-yl}-pyridin-2-ylamine;
6-[8-(2-Dimethylamino-ethoxy)-1 .2,3,4-tetrahydro-1 ,4-methano-naphthalen-5-yl]- pyridin-2-ylamine; 6-[8-(2-Pyrrolidin-1 -yl-ethoxy)-1 ,2,3,4-tetrahydro-1 ,4-methano-naphthalen-5-yl]- pyridin-2-ylamine;
6-[4-(2-Dimethylamino-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1 -yl]-pyridin-2- ylamine; 6-[4-(2-Pyrrolidin-1 -yl-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1 -yl]-pyridin-2- ylamine;
6-{4-[2-(tert-Butyl-methyl-amino)-ethoxy]-5,6,7,8-tetrahydro-naphthalen-1 -yl}- pyridin-2-ylamine;
6-[4-(2-Diisopropylamino-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1 -yl]-pyridin-2- ylamine;
6-[4-(2-Diethylamino-ethoxy)-5-6-7-8-tetrahydro-naphthalen-1 -yl]-pyridin-2- ylamine;
6-{4-[2-(3,4-Dihydro-1 H-isoquinolin-2-yl)-ethoxy]-5,6,7,8-tetrahydro-naphthalen- 1 -yl}-pyridin-2-ylamine; 6-[4-(2-Piperidin-1 -yl-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1 -yl]-pyridin-2- ylamine;
6-[4-(2-Morpholin-4-yl-ethoxy)-5,6,7,8-tetrahydro-naphthalen-1 -yl]-pyridin-2- ylamine;
6-{4-[2-(7,8-Dihydro-5H-[1 ,3]dioxolo[4,5-g]isoquinolin-6-yl)-ethoxy]-5.6,7,8- tetrahydro-naphthalen-1 -yl}-pyridin-2-ylamine;
6-{4-[2-(4-Methyl-piperazin-1 -yl)-ethoxy]-5,6,7,8-tetrahydro-naphthalen-1 -yl}- pyridin-2-ylamine;
6-{4-t2-(4-Dimethylamino-piperidin-1 -yl)-ethoxy]-5,6,7,8-tetrahydro-naphthalen-1 - yl}-pyridin-2-ylamine; 6-{4-[2-(7,8-Dihydro-5H-[1 ,3]dioxolo[4,5-g]isoquinolin-6-yl)-ethoxy]-5, 6,7,8- tetrahydro-naphthalen-1 -yl}-pyridin-2-ylamine;
6-[4-(1 -lsobutyl-piperidin-3-ylmethoxy)-5,6,7,8-tetrahydro-naphthalen-1 -yl]- pyridin-2-ylamine;
6-[4-(1 -Methyl-piperidin-3-ylmethoxy)-5,6,7,8-tetrahydro-naphthalen-1 -yl]-pyridin- 2-ylamine;
6-{4-[2-(2-Diethylamino-ethoxy)-ethoxy]-5,6,7,8-tetrahydro-naphthalen-1 -yl}- pyridin-2-ylamine;
6-[4-(Piperidin-3-ylmethoxy)-5,6,7,8-tetrahydro-naphthalen-1 -yl]-pyridin-2- ylamine; 6-[4-(2-Amino-cyclohexyloxy)-5,6,7,8-tetrahydro-naphthalen-1 -yl]-pyridin-2- ylamine;
6-[4-(Pyrrolidin-2-ylmethoxy)-5,6,7,8-tetrahydro-naphthalen-1 -yl]-pyridin-2- ylamine; and 6-[4-(2-Dimethylamino-ethoxy)-6,7,8,9-tetrahydro-5H-benzocyclohepten-1 -yl]- pyridin-2-ylamine;
6-[4-(2-Amino-cyclopentyloxy)-5,6,7,8-tetrahydro-naphthalen-1 -yl]-pyridin-2- ylamine;
6-[4-(2-Amino-cyclobutyloxy)-5,6,7,8-tetrahydro-naphthalen-1 -yl]-pyridin-2- ylamine;
6-[4-(2-Amino-cyclopropyloxy)-5,6,7,8-tetrahydro-naphthalen-1 -yl]-pyridin-2- ylamine;
6-[4-(3-Amino-cyclohexyloxy)-5,6,7,8-tetrahydro-naphthalen-1 -yl]-pyridin-2- ylamine; 6-[4-(3-Amino-cyclopentyloxy)-5,6,7,8-tetrahydro-naphthalen-1 -ylJ-pyridin-2- ylamine;
6-[4-(3-Amino-cyclobutyloxy)-5,6,7,8-tetrahydro-naphthalen-1 -yl]-pyridin-2- ylamine;
6-[4-(4-Amino-cyclohexyloxy)-5,6,7,8-tetrahydro-naphthalen-1 -yl]-pyridin-2- ylamine;
6-[4-(2-Amino-cyclopentyloxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-[4-(2-Amino-cyclobutyloxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-[4-(2-Amino-cyclopropyloxy)-naphthalen-1 -yl]-pyridin-2-ylamine; 6-[4-(2-(4-Dimethylamino-piperidin-1 -yl)-ethoxy))-6,7,8,9-tetrahydro-5H- benzocyclohepten-1 -yl]-pyridin-2-ylamine;
6-[4-(2-(4-Methyl-piperazin-1 -yl)-ethoxy))-6,7,8,9-tetrahydro-5H- benzocyclohepten-1 -yl]-pyridin-2-ylamine;
1 -(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-ethanone; 1-(4-{2-t4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-2-methoxy- ethanone;
1 -(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin- 1 -yl)-2-phenoxy- ethanone;
(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-cyclopentyl- methanone; 1 -(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1 -yl)-2-phenyl-ethanone; 3-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-3-aza-bicyclo[3.1.0]hex-6-ylamine; 2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1 -yl)-1 -phenyl-ethanone; 1 -(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1 -yl)-2-(4-fluoro-phenyl)- ethanone;
6-{4-[2-(4-Phenethyl-piperazin-1 -yl)-ethyl]-phenyl}-pyridin-2-ylamine; 2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1 -yl)-1 -phenyl-ethanol; {2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-(3-oxa-9-aza-bicyclo[3.3.1 ]non-7-yD- amine; 6-(4-{2-[4-(2-Amino-2-phenyl-ethyl)-piperazin-1 -yl]-ethyl}-phenyl)-pyridin-2-ylamine;
6-{4-[2-(4-Amino-2,6-dimethyl-piperidin-1-yl)-ethyl]-phenyl}-pyridin-2-ylamine; 6-{4-[2-(4-Methyl-piperazin-1 -yl)-ethyl]-phenyl}-pyridin-2-ylamine; (3-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-3-aza-bicyclo[3.1 .0]hex-6-yl)- dimethyl-amine; 6-[4-(2-Amino-ethyl)-phenyl]-pyridin-2-ylamine;
6-{4-[2-(8-Aza-spiro[4.5]dec-8-yl)-ethyl]-phenyl}-pyridin-2-ylamine; 6-{4-[2-(4-lsobutyl-piperazin-1-yl)-ethyl]-phenyl}-pyridin-2-ylamine; 2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1 -yl)-N-isopropyl- acetamide; 4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazine-1 -carboxylic acid p-tolyl- amide;
6-(4-{2-[4-(3-Phenyl-propyl)-piperazin-1-yl]-ethyl}-phenyl)-pyridin-2-ylamine; 1 -(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1 -yl)-2-(4-chloro-phenyl)- ethanone; 8-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-3-benzyl-1 ,3,8-triaza- spiro[4.5]decane-2,4-dione;
N-(1 -{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-pyrrolidin-3-yl)-2-(4-fluoro-phenyl)- acetamide;
8-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-8-aza-bicyclo[3.2.1 ]oct-3-ylamine; 3-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-3-aza-bicyclo[3.2.1 ]oct-8-ylamine;
2-Amino-1 -(4-{2-[4-(6-amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-3-phenyl- propan-1-one;
6-{4-[2-(4-Amino-piperidin-1 -yl)-ethyl]-phenyl}-pyridin-2-ylamine; 6-{4-[2-(4-Benzhydryl-piperazin-1 -yl)-ethyl]-phenyl}-pyridin-2-ylamine; 6-{4-[2-(4-Benzhydryl-piperidin-1-yl)-ethyl]-phenyl}-pyridin-2-ylamine; 6-{4-[(Cyclohexyl-methyl-amino)-methyl]-phenyl}-pyridin-2-ylamine; 6-{4-[(Cyclohexyl-methyl-amino)-methyl]-2-methoxy-phenyl}-pyridin-2-ylamine; 6-[4-(Phenethylamino-methyl)-phenyl]-pyridin-2-ylamine; 6-[2-Methoxy-4-(phenethylamino-methyl)-phenyl]-pyridin-2-ylamine;
6-[4-(4-Amino-piperidin-1 -ylmethyl)-phenyl}-pyridin-2-ylamine; 6-{4-[(Cyclohexyl-methyl-amino)-methyl]-2-fluoro-phenyl}-pyridin-2-ylamine; 1 -(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methoxy-phenyl]-ethyl}-piperazin-1 -yl)-2-phenyl- ethanone; 6-{4-[2-(4-lsobutyl-piperazin-1 -yl)-ethyl]-2-methoxy-phenyl}-pyridin-2-ylamine;
3-{2-[4-(6-Amino-pyridin-2-yl)-2-methoxy-phenyl]-ethyl}-3-aza-bicyclo[3.1 .0]hex-6- ylamine;
{2-[4-(6-Amino-pyridin-2-yl)-2-methoxy-phenyl]-ethyl}-(3-oxa-9-aza- bicyclo[3.3.1 ]non-7-yl)-amine; 6-(4-{2-[4-(2-Amino-2-phenyl-ethyl)-piperazin-1-yl]-ethyl}-2-methoxy-phenyl)- pyridin-2-ylamine;
6-{4-[2-(4-Amino-2-methoxy-piperidin-1 -yl)-ethyl]-2-methoxy-phenyl}-pyridin-2- ylamine;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methoxy-phenyl]-ethyl}-piperazin-1 -yl)-N- isopropyl-acetamide;
6-[4-(4-Amino-piperidin-1 -ylmethyl)-2-methoxy-phenyl}-pyridin-2-ylamine; 1 -(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methyl-phenyl]-ethyl}-piperazin-1 -yl)-2-phenyl- ethanone;
6-{4-[2-(4-lsobutyl-piperazin-1-yl)-ethyl]-2-methyl-phenyl}-pyridin-2-ylamine; 3-{2-[4-(6-Amino-pyridin-2-yl)-2-methyl-phenyl]-ethyl}-3-aza-bicyclo[3.1 .0]hex-6- ylamine;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methyl-phenyl]-ethyl}-piperazin-1 -yl)-1 -phenyl- ethanone;
1 -(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methyl-phenyl]-ethyl}-piperazin-1-yl)-2-(4-fluoro- phenyD-ethanone;
6-{4-[2-(4-Phenethyl-piperazin-1 -yl)-ethyl]-2-methyl-phenyl}-pyridin-2-ylamine; 2-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methyl-phenyl]-ethyl}-piperazin- 1 -yl)- 1 -phenyl- ethanol; {2-[4-(6-Amino-pyridin-2-yl)-2-methyl-phenyl]-ethyl}-(3-oxa-9-aza- bicyclo[3.3.1 ]non-7-yl)-amine;
6-(4-{2-[4-(2-Amino-2-phenyl-ethyl)-piperazin-1 -yl]-ethyl}-2-methyl-phenyl)-pyridin- 2-ylamine; 6-{4-[2-(4-Amino-2,6-dimethyl-piperidin-1 -yl)-ethyl]-2-methyl-phenyl}-pyridin-2- ylamine;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methyl-phenyl]-ethyl}-piperazin-1 -yl)-N- isopropyl-acetamide;
6-[4-(4-Amino-piperidin-1-ylmethyl)-2-methyl-phenyl}-pyridin-2-ylamine; N-(1 -{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-pyrrolidin-3-yl)-2-phenyl-acetamide;
N-(1 -{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-pyrrolidin-3-yl)-2-(3- trifluoromethylphenyD-acetamide;
N-(1 -{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-pyrrolidin-3-yl)-2-(4-tolyl)- acetamide; N-( 1 -{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-pyrrolidin-3-yl)-2-(4- methoxyphenyD-acetamide;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methoxy-phenyl]-ethyl}-piperazin-1-yl)-1 -phenyl- ethanone;
1 -(4-{2-[4-(6-Amino-pyridin-2-yl)-2-methoxy-phenyl]-ethyl}-piperazin-1 -yl)-2-(4- fluoro-phenyD-ethanone;
N-(1 -{2-l4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-pyrrolidin-3-yl)-2-cyclohexyl- acetamide;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyll-ethyl}-piperazin-1-yl)-1 -(4-tolyl)-ethanone;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-1-(4- methoxyphenyD-ethanone;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin- 1 -yl)- 1 -(4-chlorophenyl)- ethanone;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-piperazin-1-yl)-1-(4-fluorophenyl)- ethanone; 2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyll-ethyl}-piperazin-1-yl)-1-cyclohexyl- ethanone;
1-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-fluoro-phenyl]-ethyl}-piperazin-1-yl)-2-phenyl- ethanone;
6-{4-[2-(4-lsobutyl-piperazin-1-yl)-ethyl]-2-fluoro-phenyl}-pyridin-2-ylamine; - -
3-{2-[4-(6-Amino-pyridin-2-yl)-2-fluoro-phenyl]-ethyl}-3-aza-bicyclo[3.1 .0]hex-6- ylamine;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-fluoro-phenyl]-ethyl}-piperazin-1 -yl)-1 -phenyl- ethanone; 1 -(4-{2-[4-(6-Amino-pyridin-2-yl)-2-f luoro-phenyl]-ethyl}-piperazin-1 -yl)-2-(4-f luoro- phenyD-ethanone;
6-{4-[2-(4-Phenethyl-piperazin-1 -yl)-ethyl]-2-fluoro-phenyl}-pyridin-2-ylamine;
2-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-fluoro-phenyl]-ethyl}-piperazin-1 -yl)-1 -phenyl- ethanol; {2-[4-(6-Amino-pyridin-2-yl)-2-fluoro-phenyl]-ethyl}-(3-oxa-9-aza-bicyclo[3.3.1 ]non-
7-yl)-amine;
6-(4-{2-[4-(2-Amino-2-phenyl-ethyl)-piperazin-1 -yl]-ethyl}-2-fluoro-phenyl)-pyridin-2- ylamine;
6-{4-[2-(4-Amino-2-fluoro-piperidin-1 -yl)-ethyll-2-fluoro-phenyl}-pyridin-2-ylamine; 2-(4-{2-[4-(6-Amino-pyridin-2-yl)-2-fluoro-phenyl]-ethyl}-piperazin-1 -yl)-N-isopropyl- acetamide;
6-[4-(4-Amino-piperidin-1-yimethyl)-2-fluoro-phenyl}-pyridin-2-ylamine;
6-{4-[2-(4-Amino-2,6-diethyl-piperidin-1 -yl)-ethyl]-phenyl}-pyridin-2-ylamine;
6-{4-[2-(4-Amino-2,6-dibenzyl-piperidin-1 -yl)-ethyl]-phenyl}-pyridin-2-ylamine; {2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-(9-(4-fluoro)-benzyl-3-oxa-9-aza- bicyclo[3.3.1 ]non-7-yl)-amine;
{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-(9-(4-chloro)-benzyl-3-oxa-9-aza- bicyclo[3.3.1 ]non-7-yl)-amine;
{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-(9-(4-methyl)-benzyl-3-oxa-9-aza- bicyclo[3.3.1 ]non-7-yl)-amine;
{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-(9-(4-methoxy)-benzyl-3-oxa-9-aza- bicyclo[3.3.1 ]non-7-yl)-amine;
6-[2-lsopropoxy-4-((4-phenethylpiperazin-1 -yl)-ethyl)-phenyl]-pyridin-2-ylamine;
6-[2-lsobutoxy-4-((4-phenethylpiperazin-1 -yl)-ethyl)-phenyl]-pyridin-2-ylamine; 6-[2-lsobutoxy-4-((4-dimethylaminoethyl)-phenyl]-pyridin-2-ylamine;
6-[2-lsopropoxy-(N-(2-methyl)propyl)-4-(pyrrolidin-3-yl)-phenyl]-pyridin-2-ylamine;
1 -[4-(6-Amino-pyridin-2-yl)-3-isopropoxy-phenyl]-2-(4-phenethyl-piperazin-1 -yl)- ethanol;
6-[2-Cyclopentyloxy-4-((4-dimethylaminoethyl)-phenyl]-pyridin-2-ylamine; 6-[2-Cyclopentyloxy-4-((4-phenethylpiperazin-1 -yl)-ethyl)-phenyl]-pyridin-2- ylamine;
6-[2-Cyclohexyloxy-4-((4-phenethylpiperazin-1 -yl)-ethyl)-phenyl]-pyridin-2- ylamine; 6-[2-Cyclobutyloxy-4-((4-phenethylpiperazin-1 -yl)-ethyl)-phenyl]-pyridin-2- ylamine;
6-[2-Cyclopropyloxy-4-((4-phenethylpiperazin-1 -yl)-ethyl)-phenyl]-pyridin-2- ylamine;
6-[2-lsopentyloxy-4-((4-phenethylpiperazin-1 -yl)-ethyl)-phenyl]-pyridin-2-ylamine; 6-[2-lsohexyloxy-4-((4-phenethylpiperazin-1 -yl)-ethyl)-phenyl]-pyridin-2-ylamine;
6-[2-Cyclopentyloxy-(N-(2-methyl)propyl)-4-(pyrrolidin-3-yl)-phenyl]-pyridin-2- ylamine;
6-[2-Cyclohexyloxy-(N-(2-methyl)propyl)-4-(pyrrolidin-3-yl)-phenyl]-pyridin-2- ylamine;
6-[2-Cyclobutyloxy-(N-(2-methyl)propyl)-4-(pyrrolidin-3-yl)-phenyl]-pyridin-2- ylamine;
6-[2-Cyclopropyloxy-(N-(2-methyl)propyl)-4-(pyrrolidin-3-yl)-phenyl]-pyridin-2- ylamine; 6-[2- Isopentyloxy -(N-(2-methyl)propyl)-4-(pyrrolidin-3-yl)-phenyl]-pyridin-2- ylamine;
6-[2-lsohexyloxy -(N-(2-methyl)propyl)-4-(pyrrolidin-3-yl)-phenyl]-pyridin-2- ylamine;
1 -[4-(6-Amino-pyridin-2-yl)-3-isobutoxy-phenyl]-2-(4-phenethyl-piperazin-1 -yl)- ethanol;
1 -[4-(6-Amino-pyridin-2-yl)-3-isopropoxy-phenyl]-2-(6,7-dimethoxy- tetrahydroisoquinol-2-yl)-ethanol;
1 -[4-(6-Amino-pyridin-2-yl)-3-isopropoxy-phenyl]-2-(4-dimethylamino-pi peridin-1 - yl)-ethanol; 1 -[4-(6-Amino-pyridin-2-yl)-3-isopropoxy-phenyl]-2-(dimethylamino)-ethanol;
1 -[4-(6-Amino-pyridin-2-yl)-3-cyclopentyloxy-phenyl]-2-(4-phenethyl-piperazin-1 - yl)-ethanol;
6-[4-(2-dimethylamino-ethoxy)-2-methoxy-phenyl]-pyridin-2-ylamine; 6-[4-(2-dimethylamino-ethoxy)-2,3-dimethyl-phenyl]-pyridin-2-ylamine; 6-[4-(2-dimethylamino-ethoxy)-3-methoxy-phenyl]-pyridin-2-ylamine;
6-[4-(2-dimethylamino-ethoxy)-3-ethoxy-phenyI]-pyridin-2-ylamine; 6-[4-(2-dimethylamino-ethoxy)-2-isopropyl-phenyl]-pyridin-2-ylamine;
6-[2-cyclopropyl-4-(2-dimethylamino-ethoxy)-phenyl]-pyridin-2-ylamine;
6-[2-cyclobutyl-4-(2-dimethylamino-ethoxy)-phenyl]-pyridin-2-ylamine;
6-[2-cyclopentyl-4-(2-dimethylamino-ethoxy)-phenyl]-pyridin-2-ylamine; 6-[4-(2-dimethylamino-ethoxy)-2-methoxy-5-propyl-phenyl]-pyridinylamine;
6- [4-(1-methylazetin-3-yloxy)-2-methoxy-5-ethyl-phenyl]-pyridin-2-ylamine
2-(6-amino-pyridin-2-yl)-5-(2-dimethylamino-ethoxy)-phenol;
6-[4-(2-dimethylamino-ethoxy)-2-propoxy-phenyl]-pyridin-2-ylamine;
6-[4-(2-dimethylamino-ethoxy)-2-isopropoxy-phenyl]-pyridin-2-ylamine; 6-[4-(2-dimethylamino-ethoxy)-2-ethoxy-phenyl]-pyridin-2-ylamine;
6-[4-(2-dimethylamino-ethoxy)-2-methoxy-5-propyl-phenyl]-pyridin-2-ylamine;
6-[5-allyl-4-(2-dimethylamino-ethoxy)-2-methoxy-phenyl]-pyridin-2-ylamine;
6-[3-allyl-4-(2-dimethylamino-ethoxy)-2-methoxy-phenyl]-pyridin-2-ylamine;
6-[4-(2-dimethylamino-ethoxy)-2,6-dimethyl-phenyl]-pyridin-2-ylamine; 6-[4-(2-dimethylamino-ethoxy)-2-isopropyl-phenyl]-pyridin-2-ylamine;
6-[2-tert-butyl-4-(2-dimethylamino-ethoxy)-phenyl]-pyridin-2-ylamine;
4-(6-amino-pyridin-2-yl)-3-methoxyphenol;
6-[4-(2-pyrrolidinyl-ethoxy)-2,3-dimethyl-phenyl]-pyridin-2-ylamine;
6-[4-(4-(N-methyl)piperidinyloxy)-2,3-dimethyl-phenyl]-pyridin-2-ylamine; 6-[4-(2-pyrrolidinyl-ethoxy)-3-methoxy-phenyl]-pyridin-2-ylamine;
6-{4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-ethoxy]-3-methoxy-phenyl}- pyridin-2-ylamine;
6-{3-methoxy-4-[2-(4-phenethyl-piperazin-1-yl)-ethoxy]-phenyl}-pyridin-2-ylamine;
6-{3-methoxy-4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenyl}-pyridin-2-ylamine; 6-{4-[2-(4-dimethylamino-piperidin-1-yl)-ethoxy]-3-methoxy-phenyl}-pyridin-2-ylamine;
6-[4-(2-pyrrolidinyl-ethoxy)-3-ethoxy-phenyl]-pyridin-2-ylamine;
4-(6-amino-pyridin-yl)-3-cyclopropyl-phenol;
6-[2-cyclopropyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-ylamine;
3-[3-(6-amino-pyridin-2yl)-4-cyclopropyl-phenoxy] -pyrrolidine-1 -carboxylic acid tert- butyl ester;
6-[2-cyclopropyl-4-(1-methyl-pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
4-(6-amino-pyridin-2-yl)-3-cyclobutyl-phenol;
6-[2-cyclobutyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-ylamine;
6-[2-cyclobutyl-4-(1-methyl-pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine; 4-(6-amino-pyridin-2-yl)-3-cyclopentyl-phenol;
6-[2-cyclopentyl-4-(2-pyrrolidin-1yl-ethoxy)-phenyl]-pyridin-2-ylamine; 3-[4-(6-amino-pyridin-2yl)-3-methoxy-phenoxy]-pyrrolidine-1 -carboxylic acid tert butyl ester;
6-[4-(1-methyl-pyrrolidin-3-yloxy)-2-methoxy-phenyl]-pyridin-2-ylamine;
4-[4-(6-amino-pyridin-2yl)-3-methoxy-phenoxy]-piperidine-1 -carboxylic acid tert butyl ester;
6-[2-methoxy-4-(1-methyl-piperidin-4-yloxy)-phenyl]-pyridin-2-ylamine;
6-[4-(allyloxy)-2-methoxy-phenyl]-pyridin-2-ylamine;
4-(6-amino-pyridin-2-yl)-3-methoxy-6-allyl-phenol;
4-(6-amino-pyridin-2-yl)-3-methoxy-2-allyl-phenol; 4-(6-amino-pyridin-2-yl)-3-methoxy-6-propyl-phenol;
6-[2-isopropyl-4-(pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropyl-4-(piperidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropyl-4-(1-methyl-azetidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropyl-4-(1-methyl-piperidin-4-yloxy)-phenyl]-pyridin-2-ylamine; 6-[2-isopropyl-4-(1-methyl-pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropyl-4-(1-methyl-pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropyl-4-(2-methyl-2-aza-bicyclo[2.2.1]hept-5-yloxy)-phenyl]-pyridin-2- ylamine;
6-[4-(2-dimethylamino-ethoxy)-2-methoxy-phenyl]-pyridin-2-ylamine; 6-{4-[2-(benzyl-methyl-amino)-ethoxy]-2-methoxy-phenyl}-pyridin-2-ylamine;
6-[2-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-ylamine;
2-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-acetamide;
6-[4-(2-amino-ethoxy)-2-methoxy-phenyl]-pyridin-2-ylamine;
6-{4-[2-(3,4-dihydro-1h-isoquinolin-2-yl)-ethoxy]-2-methoxy-phenyl}-pyridin-2-ylamine; 2-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-ethanol;
6-{2-methoxy-4-[2-(2,2,6,6-tetramethyl-piperidin-1-yl)-ethoxy]-phenyl}-pyridin-2- ylamine;
6-{4-[2-(2,5-dimethyl-pyrrolidin-1-yl)-ethoxy]-2-methoxy-phenyl}-pyridin-2-ylamine;
6-{4-[2-(2,5-dimethyl-pyrrolidin-1-yl)-ethoxy]-2-methoxy-phenyl}-pyridin-2-ylamine; 2-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-1 -(2,2,6, 6-tetramethyl-piperidin-1-yl)- ethanone;
6-[2-methoxy-4-(1-methyl-pyrrolidin-2-ylmethoxy)-phenyl]-pyridin-2-ylamine;
6-{4-[2-(benzyl-methyl-amino)-ethoxy]-2-propoxy-phenyl}-pyridin-2-ylamine;
6-[4-(2-ethoxy-ethoxy)-2-methoxy-phenyl]-pyridin-2-ylamine; 6-[4-(2-ethoxy-ethoxy)-2-isopropoxy-phenyl]-pyridin-2-ylamine;
6-[2-methoxy-4-(3-methyl-butoxy)-phenyl]-pyridin-2-ylamine; 6-{4-[2-(benzyl-methyl-amino)-ethoxy]-2-ethoxy-phenyl}-pyridin-2-ylamine;
6-[2-ethoxy-4-(3-methyl-butoxy)-phenyl]-pyridin-2-ylamine;
1-(6-amino-3-aza-bicyclo[3.1.0]hex-3-yl)-2-[4-(6-amino-pyridin-2-yl)-3-ethoxy- phenoxyj-ethanone; 6-[2-ethoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-ylamine;
3-{2-[4-(6-amino-pyridin-2-yl)-3-ethoxy-phenoxy]-ethyl}-3-aza-bicyclo[3.1.0]hex-6- ylamine;
1 -(6-amino-3-aza-bicyclo[3.1.0]hex-3-y l)-2-[4-(6-amino-pyridin-2-y!)-3-methoxy- phenoxyj-ethanone; 3-{2-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-ethyl}-3-aza-bicyclo[3.1.0]hex-6- ylamine;
6-[2-isopropoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-ylamine;
6-{4-[2-(benzyl-methyl-amino)-ethoxy]-2-isopropoxy-phenyl}-pyridin-2-ylamine;
6-[5-allyl-2-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-ylamine; 6-[2-methoxy-4-(pyrrolidin-3-yloxy)-phenyl]-pyridin-2 -ylamine;
6-[2-methoxy-4-(1-methyl-pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-ethoxy-4-(pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropoxy-4-(pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-methoxy-4-(piperidin-4-yloxy)-phenyl]-pyridin-2-ylamine; 6-[2-methoxy-4-(2,2,6,6-tetramethyl-piperidin-4-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropoxy-4-(pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
3-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-azetidine-1 -carboxylic acid tert-butyl ester;
6-[4-(azetidin-3-yloxy)-2-methoxy-phenyl]-pyridin-2-ylamine; 6-[2-methoxy-4-(1-methyl-azetidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropoxy-4-(pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-isopropoxy-4-(pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-methoxy-4-(pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-methoxy-4-(1-methyl-pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine; 6-[2-methoxy-4-(1-methyl-pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-methoxy-4-(2-methyl-2-aza-bicyclo[2.2.1]hept-5-yloxy)-phenyl]-pyridin-2-ylamine;
6-[2-methoxy-4-(1-methyl-piperidin-4-yloxy)-phenyl]-pyridin-2-ylamine;
6-[4-(1-ethyl-piperidin-4-yloxy)-2-methoxy-phenyl]-pyridin-2-ylamine;
6-[5-allyl-2-methoxy-4-(1-methyl-pyrrolidin-3-yloxy)-phenyl]-pyridin-2-ylamine; 6-[2,6-dimethyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-pyridin-2-ylamine;
6-[2,6-dimethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-ylamine; 6-{2,6-dimethyl-4-[3-(4-methyl-piperazin-1-yl)-propoxy]-phenyl}-pyridin-2-ylamine;
6-[2,6-dimethyl-4-(2-morpholin-4-yl-ethoxy)-phenyl]-pyridin-2-ylamine;
6-{4-[2-(benzyl-methyl-amino)-ethoxy]-2,6-dimethyl-phenyl}-pyridin-2-ylamine;
2-[4-(6-amino-pyridin-2-yl)-3,5-dimethyl-phenoxy]-acetamide; 6-[4-(2-amino-ethoxy)-2,6-dimethyl-phenyl]-pyridin-2-ylamine;
6-[2-isopropyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-ylamine;
2-(2,5-dimethyl-pyrrolidin-1-yl)-6-[2-isopropyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]- pyridine;
6-{4-[2-(3,5-dimethyl-piperidin-1-yl)-ethoxy]-2-isopropyl-phenyl}-pyridin-2-ylamine; 6-[2-tert-butyl-4-(2-pyrrolidin-1 -yl-ethoxy)-phenyl]-pyridin-2-ylamine;
3-{2-[4'-(6-Amino-pyridin-2-yl)-biphenyl-4-yl]-ethyl}-3-aza-bicyclo[3.1.0]hex-6-ylamine;
6-[4'-(4-Phenethyl-piperazin-1-ylmethyl)-biphenyl-4-yl]-pyridin-2-ylamine;
3-[4'-(6-Amino-pyridin-2-yl)-biphenyl-4-ylmethyl]-3-aza-bicyclo[3.1.0]hex-6-ylamine;
3-[4'-(6-Amino-pyridin-2-yl)-biphenyl-3-ylmethyl]-3-aza-bicyclo[3.1.0]hex-6-ylamine; 2-Amino-N-[4'-(6-amino-pyridin-2-yl)-biphenyl-3-yl]-propionamide;
2-Amino-N-[4'-(6-amino-pyridin-2-yl)-biphenyl-3-yl]-3-phenyl-propionamide;
6-[4-(1-Benzyl-1 ,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-pyridin-2-yramine;
6-[4-(1-Benzyl-piperidin-3-yl)-phenyl]-pyridin-2-ylamine;
6-[4-(1-Benzyl-piperidin-2-ylmethyl)-phenyl]-pyridin-2-ylamine; 6-{4-[1-(2,2-Diphenyl-ethyl)-piperidin-2-ylmethyl]-phenyl}-pyridin-2-ylamine;
6-[3-(2-Dimethylamino-cyclopentylmethyl)-phenyl]-pyridin-2-ylamine;
6-[3-(2-(4-Methylpiperazin-1-yl)-cyclopentylmethyl)-phenyl]-pyridin-2-ylamine;
6-[4-(Piperidin-4-yl)-phenyl]-pyridin-2-ylamine;
6-[3-(2-(N-Cyclohexylamino)-cyclopentylmethyl)-phenyl]-pyridin-2-ylamine; 6-t3-(2-(N-Cyclohexylamino)-cyclopentylmethyl)-phenyl]-pyridin-2-ylamine;
6-[3-(2-(N-Phenethylamino)-cyclopentylmethyl)-phenyl]-pyridin-2-ylamine;
6-[3-(2-(N-Phenethylamino)-cyclopentylmethyl)-phenyl]-pyridin-2-ylamine;
6-[3-(2-(4-Methylpiperazin-1-yl)-cyclohexylmethyl)-phenyl]-pyridin-2-ylamine;
6-[3-(2-(N-benzylamino)-cyclohexylmethyl)-phenyl]-pyridin-2-ylamine; 6-{4-[2-(2-Ethoxy-ethylamino)-cyclohexylmethyl]-phenyl}-pyridin-2-ylamine;
6-[4-(2-(4-Benzylpiperazin-1-yl)-cyclohexylmethyl)-phenyl]-pyridin-2-ylamine;
6-[4-(2-(4-(N-lsopropylacetamido)piperazin-1-yl)-cyclohexylmethyl)-phenyl]-pyridin-2- ylamine;
6-[4-((2-(Phenethyl)-[2.2.1 ]bicyclohept-1 -yl)methyl)-phenyl]-pyridin-2-ylamine; 6-[4-((2-(3-aza-bicyclo[3.1.0]hex-6-ylaminoH2.2.1]bicyclohept-1-yl)methyl)-phenyl]- pyridin-2-ylamine; „ „ „
- 111 -
6-[2-(N-Phenethylamino)-5-phenyl-cyclohexylmethyl)methyl)-phenyl]-pyridin-2- ylamine;
6-[4-((2-(Phenethyl)-[2.2.1 ]bicyclohept-1 -yl)methyl)-phenyl]-pyridin-2-ylamine;
6-[((2-(3-aza-bicyclo[3.1.0]hex-6-ylamino)-5-phenyl-cyclohexylmethyl)methyl)-phenyl]- pyridin-2-ylamine;
N-Methyl-(2-aminopyrid-6-yl-benzylidene)-oxindole;
N-Methyl-(2-aminopyrid-6-yl-benzyl)-oxindole;
N-(2-Dimethylaminoethyl)-(2-aminopyrid-6-yl-benzylidene)-oxindole;
N-(2-Dimethylaminoethyl)-(2-aminopyrid-6-yl-benzyl)-oxindole; 6-[(N-5-lsoxazolylmethyl)-4-(piperidin-4-yl)-phenyl]-pyridin-2-ylamine;
6-[(N-Acetamido)-4-(piperidin-4-yl)-phenyl]-pyridin-2-ylamine;
6-[(N-Benzoylmethyl)-4-(piperidin-4-yl)-phenyl]-pyridin-2-ylamine;
6-[(N-(3,4-Dimethoxybenzyl))-4-(piperidin-4-yl)-phenyl]-pyridin-2-ylamine;
6-[(N-(3,4-Methylenedioxybenzyl))-4-(piperidin-4-yl)-phenyl]-pyridin-2-ylamine; 6-[(N-(2-Furyl)methyl)-4-(piperidin-4-yl)-phenyl]-pyridin-2-ylamine;
N-^'-te-Amino-pyridin^-ylJ-biphenyM-ylmethylj-S.e-dimethoxy-l , 2,3,4- tetrahydroisoquinoline;
6-[(N-(5-lsothiazolyl)methyl)-4-(piperidin-4-yl)-phenyl]-pyridin-2-ylamine;
6-[(N-(5-Thiazolyl)methyl)-4-(piperidin-4-yl)-phenyl]-pyridin-2-ylamine; 6-[(N-(2-Pyridyl)methyl)-4-(piperidin-4-yl)-phenyl]-pyridin-2-ylamine;
6-[(N-(3-Pyridyl)methyl)-4-(piperidin-4-yl)-phenyl]-pyridin-2-ylamine;
6-[(N-(2-lmidazolyl)methyl)-4-(piperidin-4-yl)-phenyl]-pyridin-2-ylamine;
6-[(N-(4-lmidazolyl)methyl)-4-(piperidin-4-yl)-phenyl]-pyridin-2-ylamine;
6-[(N-(4-Pyridyl)methyl)-4-(piperidin-4-yl)-phenyl]-pyridin-2-ylamine; 6-[(N-(2-Furyl)methyl)-4-(pyrroIidin-3-yl)-phenyl]-pyridin-2-ylamine;
6-[(N-(2-Methyl)propyl)-4-(pyrrolidin-3-yl)-phenyl]-pyridin-2-ylamine;
8-[4-(6-Amino-pyridin-2-yl)-phenyl]-3-isobutyl-3-aza-bicyclo[3.2.1]octan-8-ol;
8-[4-(6-Amino-pyridin-2-yl)-phenyl]-3-furan-2-ylmethyl-3-aza-bicyclo[3.2.1]octan-8-ol;
8-[4-(6-Amino-pyridin-2-yl)-phenyl]-3-benzyl-3-aza-bicyclo[3.2.1]octan-8-ol; 6-[8-(2-Dimethylamino-ethoxy)-1 ,2,3,4-tetrahydro-1 ,4-methano-naphthalen-5-yl]- pyridin-2-ylamine;
6-[8-(2-Pyrrolidin-1 -yl-ethoxy)-1 ,2,3,4-tetrahydro-1 ,4-methano-naphthalen-5-yl]- pyridin-2-ylamine;
6-[8-(2-Dimethylamino-ethoxy)-1 ,2,3,4-tetrahydro-1 ,4-ethano-naphthalen-5-yl]- pyridin-2-ylamine; Λ Λ„
- 112 -
6-[8-(2-Pyrrolidin-1 -yl-ethoxy)-1 ,2,3,4-tetrahydro-1 ,4-ethano-naphthalen-5-yl]- pyridin-2-ylamine;
6-[8-(2-(4-Dimethylamino-piperidin-1 -yl)-ethoxy)-1 ,2,3,4-tetrahydro-1 ,4-methano- naphthalen-5-yl]-pyridin-2-ylamine; 6-[8-(2-(6,7-Dimethoxy-teyrahydroisoquinol-2-yl)-ethoxy)-1 ,2,3,4-tetrahydro-1 ,4- methano-naphthalen-5-yl]-pyridin-2-ylamine; and
6-[8-(2-(4-Methylpiperazin-1 -yl)-ethoxy)-1 ,2,3,4-tetrahydro-1 ,4-methano- naphthalen-5-yl]-pyridin2-ylamine.
10. A method of treating a disorder or condition that can be treated by altering circadian rhythms in a mammal, comprising administering to said mammal a pharmaceutical composition according to any of claims 1, 2, 3 or 4.
11. A method of treating a disorder or condition selected from blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, REM sleep disorders, hypersomnia, parasomnias, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome in a mammal, comprising administering to said mammal a pharmaceutical composition according to any of claims 1, 2, 3 or 4.
12. A method of treating a disorder or condition selected from dysthymia, major depressive disorder, bipolar disorder, seasonal affective disorder and other mood disorders; anxiety disorders including generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social phobias, agoraphobia and other phobias; blindness, obesity, stroke, jet lag, sleep disorders such as circadian sleep rhythm disorders, narcolepsy, sleep apnea, REM sleep disorder, parasomnias, sleep-wake cycle disorders, sleep deprivation, insomnia, hypersomnia, and sleep disorders associated with advancing age, shift work or irregular work schedules; nocturnal enuresis, restless-legs syndrome and cognitive disorders such as dementias and memory disorders in a mammal, comprising administering to said mammal a pharmaceutical composition according to any of claims 2, 3 or 4.
PCT/IB2000/000295 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors Ceased WO2000071107A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
EP00907891A EP1178784A1 (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors
MXPA01011978A MXPA01011978A (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors.
PL00358538A PL358538A1 (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors
KR1020017014884A KR20020010916A (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors
JP2000619414A JP2003523941A (en) 1999-05-21 2000-03-16 Novel pharmaceutical combinations for NOS inhibitors
BR0010820-0A BR0010820A (en) 1999-05-21 2000-03-16 Pharmaceutical combinations for nos inhibitors
AU29353/00A AU2935300A (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors
APAP/P/2001/002326A AP2001002326A0 (en) 1999-05-21 2000-03-16 New pharmaceuticals combinations for nos inhibitors.
EEP200100611A EE200100611A (en) 1999-05-21 2000-03-16 New pharmaceutical combinations of NOS inhibitors
EA200101110A EA200101110A1 (en) 1999-05-21 2000-03-16 NEW PHARMACEUTICAL COMBINATIONS OF NOS INHIBITORS
HU0301287A HUP0301287A3 (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors
IL14595500A IL145955A0 (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors
SK1660-2001A SK16602001A3 (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for NOS inhibitors
CA002374668A CA2374668A1 (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors
HR20010862A HRP20010862A2 (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors
IS6126A IS6126A (en) 1999-05-21 2001-10-26 New pharmaceutical compositions for NOS lazy
NO20015651A NO20015651L (en) 1999-05-21 2001-11-20 New pharmaceutical combinations for NOS inhibitors
BG06208A BG106208A (en) 1999-05-21 2001-12-11 New pharmaceutical combinations for nos inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13552099P 1999-05-21 1999-05-21
US60/135,520 1999-05-21

Publications (2)

Publication Number Publication Date
WO2000071107A2 true WO2000071107A2 (en) 2000-11-30
WO2000071107A8 WO2000071107A8 (en) 2002-01-24

Family

ID=22468464

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000295 Ceased WO2000071107A2 (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors

Country Status (33)

Country Link
EP (1) EP1178784A1 (en)
JP (1) JP2003523941A (en)
KR (1) KR20020010916A (en)
CN (1) CN1617743A (en)
AP (1) AP2001002326A0 (en)
AR (1) AR022640A1 (en)
AU (1) AU2935300A (en)
BG (1) BG106208A (en)
BR (1) BR0010820A (en)
CA (1) CA2374668A1 (en)
CO (1) CO5160295A1 (en)
DZ (1) DZ3041A1 (en)
EA (1) EA200101110A1 (en)
EE (1) EE200100611A (en)
GT (1) GT200000071A (en)
HN (1) HN2000000045A (en)
HR (1) HRP20010862A2 (en)
HU (1) HUP0301287A3 (en)
IL (1) IL145955A0 (en)
IS (1) IS6126A (en)
MA (1) MA26732A1 (en)
MX (1) MXPA01011978A (en)
NO (1) NO20015651L (en)
OA (1) OA11943A (en)
PA (1) PA8494601A1 (en)
PE (1) PE20010157A1 (en)
PL (1) PL358538A1 (en)
SK (1) SK16602001A3 (en)
TN (1) TNSN00106A1 (en)
TR (1) TR200103351T2 (en)
UY (1) UY26148A1 (en)
WO (1) WO2000071107A2 (en)
ZA (1) ZA200109555B (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052854A1 (en) * 2000-01-18 2001-07-26 Boehringer Ingelheim Pharma Kg Nk1-receptor antagonists for treatment of restless legs syndrome
WO2002012187A1 (en) * 2000-08-04 2002-02-14 Astrazeneca Ab Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors
WO2003030993A1 (en) * 2001-10-10 2003-04-17 Pfizer Products Inc. 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors
EP1284141A3 (en) * 2001-08-15 2003-07-30 Pfizer Products Inc. Pharmaceutical combinations comprising neuronal nitric oxide synthase inhibitors for the treatment of neurodegenerative diseases
US6803470B2 (en) * 2001-10-10 2004-10-12 Pfizer Inc 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
EP1634598A1 (en) * 2004-09-07 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion
US7407970B2 (en) * 2003-06-24 2008-08-05 Neurosearch A/S 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US8633197B2 (en) 2007-06-08 2014-01-21 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8835437B2 (en) 2007-06-08 2014-09-16 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8946228B2 (en) 2007-06-08 2015-02-03 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8981094B2 (en) 2007-06-08 2015-03-17 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US9107946B2 (en) 2008-06-05 2015-08-18 Janssen Pharmaceutica Nv Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3983392A4 (en) * 2019-06-14 2023-12-06 SRX Cardio, LLC COMPOUNDS FOR MODULATING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889674B2 (en) 2009-03-05 2014-11-18 Shionogi & Co., Ltd. Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No Search *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052854A1 (en) * 2000-01-18 2001-07-26 Boehringer Ingelheim Pharma Kg Nk1-receptor antagonists for treatment of restless legs syndrome
WO2002012187A1 (en) * 2000-08-04 2002-02-14 Astrazeneca Ab Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors
EP1284141A3 (en) * 2001-08-15 2003-07-30 Pfizer Products Inc. Pharmaceutical combinations comprising neuronal nitric oxide synthase inhibitors for the treatment of neurodegenerative diseases
WO2003030993A1 (en) * 2001-10-10 2003-04-17 Pfizer Products Inc. 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors
US6803470B2 (en) * 2001-10-10 2004-10-12 Pfizer Inc 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
US7407970B2 (en) * 2003-06-24 2008-08-05 Neurosearch A/S 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7888358B2 (en) 2003-06-24 2011-02-15 Neurosearch A/S 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1634598A1 (en) * 2004-09-07 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion
WO2006027223A1 (en) * 2004-09-07 2006-03-16 Laboratorios Del Dr. Esteve, S.A. Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion
US8981094B2 (en) 2007-06-08 2015-03-17 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US9688696B2 (en) 2007-06-08 2017-06-27 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8946228B2 (en) 2007-06-08 2015-02-03 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8633197B2 (en) 2007-06-08 2014-01-21 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8835437B2 (en) 2007-06-08 2014-09-16 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US9120821B2 (en) 2007-06-08 2015-09-01 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US9227935B2 (en) 2007-06-08 2016-01-05 Janssen Pharmaceutical N.V. Piperidine/piperazine derivatives
US9499567B2 (en) 2007-06-08 2016-11-22 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US9107946B2 (en) 2008-06-05 2015-08-18 Janssen Pharmaceutica Nv Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
US9724418B2 (en) 2008-06-05 2017-08-08 Janssen Pharmaceutica Nv Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10624875B2 (en) 2012-11-14 2020-04-21 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3983392A4 (en) * 2019-06-14 2023-12-06 SRX Cardio, LLC COMPOUNDS FOR MODULATING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)

Also Published As

Publication number Publication date
GT200000071A (en) 2001-11-08
PE20010157A1 (en) 2001-02-16
MA26732A1 (en) 2004-12-20
KR20020010916A (en) 2002-02-06
WO2000071107A8 (en) 2002-01-24
HUP0301287A3 (en) 2005-03-29
BR0010820A (en) 2002-03-05
JP2003523941A (en) 2003-08-12
NO20015651L (en) 2002-01-18
HRP20010862A2 (en) 2003-06-30
HUP0301287A2 (en) 2003-08-28
NO20015651D0 (en) 2001-11-20
DZ3041A1 (en) 2004-03-27
CA2374668A1 (en) 2000-11-30
OA11943A (en) 2006-04-12
PL358538A1 (en) 2004-08-09
ZA200109555B (en) 2004-04-07
TR200103351T2 (en) 2002-06-21
AU2935300A (en) 2000-12-12
IS6126A (en) 2001-10-26
PA8494601A1 (en) 2002-08-29
CO5160295A1 (en) 2002-05-30
EA200101110A1 (en) 2002-08-29
EP1178784A1 (en) 2002-02-13
IL145955A0 (en) 2002-07-25
HN2000000045A (en) 2001-03-02
TNSN00106A1 (en) 2005-11-10
CN1617743A (en) 2005-05-18
AP2001002326A0 (en) 2001-12-31
EE200100611A (en) 2003-02-17
BG106208A (en) 2002-09-30
AR022640A1 (en) 2002-09-04
MXPA01011978A (en) 2002-05-06
SK16602001A3 (en) 2003-03-04
UY26148A1 (en) 2000-12-29

Similar Documents

Publication Publication Date Title
WO2000071107A2 (en) New pharmaceutical combinations for nos inhibitors
JP3604399B2 (en) 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors
CA2915561C (en) Novel substituted bicyclic compounds as bromodomain inhibitors
RU2441868C2 (en) Aza-ring bridged compound
EP1471055A1 (en) 6-phenylpyridyl-2-amine derivatives
CN101378807A (en) Combination of an H3 antagonist/inverse agonist and an appetite suppressant
AU2013365926A1 (en) Novel heterocyclic compounds as bromodomain inhibitors
JP2014122161A (en) Pyrazole compounds
CA3007168A1 (en) 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
CN100398103C (en) Treatment of affective disorders by combination action of nicotinic receptor agonists and monoaminergic substances
US20040229911A1 (en) New pharmaceutical combinations for NOS inhibitors
EP0978514B1 (en) Indazole derivatives as 5-HT1F agonists
KR20060121178A (en) Selective norepinephrine reuptake inhibitors for the treatment of personality changes due to hot flashes, impulse control disorders and general medical conditions
US6107307A (en) Inhibition of serotonin reuptake
US20020151572A1 (en) Pharmaceutical uses for nos inhibitors
KR100613050B1 (en) Aza tricyclic compound
CN102378630A (en) Compositions comprising 2,4,6-triamino-1,3,5-triazine derivatives for the treatment of schizophrenia
MXPA01001548A (en) New pharmaceutical uses for nos inhibitors
CN1386504A (en) Combined therapy for melancholia and anxiety

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00807878.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 514763

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000907891

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 29353/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 16602001

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2374668

Country of ref document: CA

Ref document number: 20010893

Country of ref document: UZ

Kind code of ref document: A

Ref document number: 2374668

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 619414

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20010862A

Country of ref document: HR

Ref document number: PV2001-4165

Country of ref document: CZ

Ref document number: 1200101133

Country of ref document: VN

Ref document number: P-825/01

Country of ref document: YU

Ref document number: 200101110

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011978

Country of ref document: MX

Ref document number: 1020017014884

Country of ref document: KR

Ref document number: 2001/03351

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 106208

Country of ref document: BG

Kind code of ref document: A

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

D17 Declaration under article 17(2)a
WWP Wipo information: published in national office

Ref document number: 1020017014884

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000907891

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-4165

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017014884

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2001-4165

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 2000907891

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000907891

Country of ref document: EP